Diabetes & Metabolism Journal

Review

Pharmacotherapy
Sodium-Glucose Cotransporter 2 Inhibitors as Emerging Anticancer Agents: Yun Kyung Cho, Chang Hee Jung; Diabetes Metab J. 2026;50(1):1-18. Published online January 1, 2026; DOI: https://doi.org/10.4093/dmj.2025.0964

3,455 View
307 Download

Abstract PDF PubReader ePub: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are established treatments for type 2 diabetes mellitus, heart failure, and chronic kidney disease, with well-documented metabolic and cardiorenal benefits. Emerging evidence indicates that these agents may also exert anticancer effects through mechanisms independent of glucose lowering. Preclinical studies have demonstrated functional SGLT2 expression in tumors such as prostate, pancreatic, breast, colorectal, and bone cancers. Inhibition of SGLT2 decreases tumor glucose uptake, disrupts mitochondrial respiration with subsequent adenosine monophosphate-activated protein kinase activation, and induces endoplasmic reticulum stress and autophagy. Immunomodulatory effects, including programmed death-ligand 1 (PD-L1) degradation and stimulator of interferon genes (STING)–interferon regulatory factor 3 (IRF3)–interferon-β (IFN-β) pathway activation, further illustrate their pleiotropic effects. Observational cohort studies, particularly from nationwide Korean databases, report reduced risks of pancreatic and prostate cancer among new users of SGLT2 inhibitors. In contrast, randomized controlled trials and meta-analyses focused on cardiovascular outcomes demonstrate neutral effects on overall cancer risk, providing reassurance regarding safety. Early translational studies suggest that combining SGLT2 inhibitors with chemotherapy is feasible and tolerable. In this review, we summarize the biological rationale and mechanistic insights underlying the anticancer effects of SGLT2 inhibitors, highlight preclinical and clinical evidence across different cancer types, and discuss challenges and future directions for their integration into oncology.

Original Articles

Pharmacotherapy
Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs: Jun Hwa Hong, Kyung Wan Min, Chang Beom Lee, Parinya Chamnan, Thanitha Sirirak, Kiran Sony, Sarinya Sattanon, Hae Jin Kim, Sang-Yong Kim, Younghee Kim, Jung A Heo, Jae Min Cho, Jae Jin Nah, Mi Hee Park, Jae Hyeon Kim; Received May 30, 2025 Accepted October 14, 2025 Published online December 15, 2025; DOI: https://doi.org/10.4093/dmj.2025.0477 [Epub ahead of print]

1,689 View
83 Download

Abstract PDF Supplementary Material PubReader ePub: Background
The study evaluated the efficacy and safety of enavogliflozin, a novel, promising selective sodium-glucose cotransporter 2 inhibitor, as an add-on in adults with type 2 diabetes mellitus (T2DM) inadequately controlled with insulin alone or combined with other antidiabetic drugs (OADs).
Methods
The double-blind, placebo-controlled, multicenter trial was conducted in South Korea and Thailand. Individuals with glycosylated hemoglobin (HbA1c) ≥7.5% after ≥8-week treatment with background insulin alone or combined with ≤2 OADs were randomized to receive enavogliflozin 0.3 mg or placebo (n=116 each) for 24 weeks. The primary outcome was a change in HbA1c at week 24. Secondary outcomes included, among others, changes in body weight, blood pressure, and other measures of glycemic control. Adverse events (AEs) were investigated throughout the study (Clinical trial registration number: NCT05466643).
Results
At week 24, the placebo-adjusted mean change in HbA1c from baseline in the enavogliflozin group was –0.9% (P<0.001). Also, placebo-adjusted mean changes in fasting plasma glucose (–32.4 mg/dL, P<0.001), body weight (–1.3 kg, P<0.001), and total daily dose of insulin (–1.3 units, P=0.010) at week 24 were statistically significant. In addition, a significant decrease in blood pressure and fasting C-peptide was observed in the enavogliflozin group, along with a significant increase in homeostasis model assessment of β-cell function, yet without a concomitant change in homeostasis model assessment of insulinresistance. No significant increase in treatment-related AEs was observed for enavogliflozin.
Conclusion
Enavogliflozin 0.3 mg/day is an efficacious and safe add-on treatment option in T2DM patients controlled inadequately with insulin alone or combined with OADs.

Pharmacotherapy
Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial: Jun Hwa Hong, Kyung Ah Han, You-Cheol Hwang, Eun-Gyoung Hong, Hae Jin Kim, Chang Beom Lee, Ho Chan Cho, Jong Chul Won, Hun-Sung Kim, Eui-Hyun Kim, Gwanpyo Koh, Kwang Hyun Ahn, Kyong Soo Park; Diabetes Metab J. 2026;50(2):320-330. Published online October 28, 2025; DOI: https://doi.org/10.4093/dmj.2024.0696

9,299 View
175 Download

Abstract PDF Supplementary Material PubReader ePub: Background
This study investigated the efficacy and safety of pioglitazone 30 mg/day add-on to inadequately controlled type 2 diabetes mellitus (T2DM) patients with treatment of dapagliflozin and metformin.
Methods
In this multicenter (34 sites), double-blind, randomized, phase 3 study, patients with T2DM with an inadequately controlled glycosylated hemoglobin (HbA1c) over 7.0% to treatment with dapagliflozin (10 mg/day) and metformin (≥1,000 mg/day) were randomized to receive additional pioglitazone 30 mg/day (n=124) or placebo (n=122) for 24 weeks. The primary outcome was the mean change of HbA1c from baseline to 24 weeks treatment. The efficacy and safety were evaluated with open label extension period, switching placebo to pioglitazone 30 mg/day at 48 weeks (ClinicalTrials.gov identifier: NCT05296044).
Results
The HbA1c after 24 weeks treatment reduced from 7.8%±0.8% to 7.0%±0.6% (P<0.0001). The proportions of patients who achieved HbA1c less than 7.0% at 24 weeks were significantly higher in pioglitazone add-on group (51.61% in pioglitazone vs. 22.95% in placebo, P<0.0001), or less than 6.5% at 24 weeks (21.77% in pioglitazone vs. 2.46% in placebo, P<0.0001). Body weight gain was 2.0 kg at 24 weeks with pioglitazone 30 mg/day and –0.6 kg at 24 weeks with placebo.
Conclusion
Addition of pioglitazone 30 mg/day to T2DM patients who did not reach the target HbA1c (≤7%) with treatment of dapagliflozin 10 mg/day and metformin over 1,000 mg/day showed effective glucose lowering efficacy without significant hypoglycemia and good tolerability with low prevalence of edema in spite of modest weight gain.

Cardiovascular Risk/Epidemiology
Prognostic Impact of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Coronary Ischemia: A Retrospective Cohort Study: Haochen Xuan, Yik-Ming Hung, Ran Guo, Qingwen Ren, Jiayi Huang, Jingnan Zhang, Wenli Gu, Ho-Leung Chan, Gaozhen Cao, Run Wang, Calvin Ka-Lam Leung, Tongda Xu, Kai-Hang Yiu; Received March 11, 2025 Accepted July 22, 2025 Published online October 24, 2025; DOI: https://doi.org/10.4093/dmj.2025.0200 [Epub ahead of print]

6,597 View
70 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Patients with type 2 diabetes mellitus (T2DM) and coronary ischemia face an exceptionally elevated risk, and the achievement of complete revascularization (CR) within this population could be challenging.
Methods
Patients with T2DM and coronary ischemia based on coronary angiography and retrospective angiographic fractional flow reserve analysis between 2014 and 2016 were included. The impact of the extent of revascularization on the improvement of endpoint events by sodium-glucose cotransporter 2 (SGLT2) inhibitors was analyzed. The primary study endpoint was major adverse cardiac events (MACE), while all-cause mortality served as secondary endpoints. Kaplan-Meier analysis and Cox proportional hazards regression model were adopted to assess the association between SGLT2 inhibitors and endpoint incidence.
Results
A total of 671 patients were identified. Among them, 206 (30.7%) were prescribed with SGLT2 inhibitors, while 484 (72.1%) achieved CR after the operation. During a mean 36-month follow-up, 100 MACE and 89 all-cause mortality were recorded. SGLT2 inhibitor users demonstrated lower rates of MACE (8.3% vs. 17.8%, P=0.002) and all-cause mortality (6.3% vs. 16.3%, P<0.001) compared to non-users. After adjusting for confounding factors in multivariable Cox analysis, the association between SGLT2 inhibitors and reduced MACE incidence remained consistent both in the CR and incomplete revascularization subgroups (hazard ratio [HR], 0.498; 95% confidence interval [CI], 0.246 to 0.938; P=0.040; and HR, 0.341; 95% CI, 0.123 to 0.805; P=0.023, respectively).
Conclusion
SGLT2 inhibitors were found to be associated with a reduced risk of 3-year MACE and all-cause mortality in patients with T2DM and coronary ischemia, regardless of extent of revascularization.

Pharmacotherapy
New Users of Sodium-Glucose Cotransporter 2 Inhibitors Are at Low Risk of Prostate Cancer: A Nationwide Cohort Study: Yun Kyung Cho, Sehee Kim, Myung Jin Kim, Woo Je Lee, Ye-Jee Kim, Chang Hee Jung; Diabetes Metab J. 2026;50(1):90-100. Published online July 22, 2025; DOI: https://doi.org/10.4093/dmj.2024.0693

3,380 View
86 Download
1 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Preclinical studies have reported anticancer properties of sodium-glucose cotransporter 2 inhibitors (SGLT2is). We aimed to elucidate the association between the use of SGLT2is and the risk of prostate cancer among male patients with type 2 diabetes mellitus (T2DM).
Methods
An active-comparator, new-user cohort design using a nationwide database between September 2014 and June 2020 was conducted on 45,601 new SGLT2i users and 205,395 new users of other glucose-lowering medications (oGLMs). In the following 1:1 propensity score matched (PSM) analysis, 35,371 SGLT2i users matched with an equivalent number of oGLM users were assessed. The hazard ratios (HRs) and 95% confidence intervals (CIs) for prostate cancer were calculated.
Results
Among the cohort, prostate cancer was diagnosed in 210 out of 45,601 SGLT2i users, corresponding to a cumulative incidence of 1.0%, in contrast to 1,880 cases among 205,395 users of oGLMs, with a cumulative incidence of 1.5%. The use of SGLT2is was significantly correlated with a reduced risk of prostate cancer based on a multivariable-adjusted HR of 0.83 (95% CI, 0.71 to 0.98). PSM analysis affirmed 18% reduction in prostate cancer risk associated with SGLT2i use (HR, 0.82; 95% CI, 0.67 to 0.99). Subgroup analyses revealed that body mass index (BMI) significantly influenced the effect of SGLT2i on prostate cancer risk, with a more pronounced reduction in the subgroup with a BMI <25 kg/m² (P=0.037).
Conclusion
The use of SGLT2is in Korean male patients with T2DM is associated with a lower risk of prostate cancer.

Citations

Citations to this article as recorded by

Sodium-Glucose Cotransporter 2 Inhibitors as Emerging Anticancer Agents
Yun Kyung Cho, Chang Hee Jung
Diabetes & Metabolism Journal.2026; 50(1): 1. CrossRef
Anti-diabetic Drugs and Cancer: Integrated Mechanisms of Tumor Suppression and Clinical Translation
Mahya Asadalizadeh, Mohammad Kazem Molavi Rahbar, Tabassom Mahmoudie, Mahshid Abbasi, Mitra Akbari, Davoud Shakiba, Aida Mohammadiun Shabestari, Meysam Ebrahimifar
Indian Journal of Clinical Biochemistry.2026;[Epub] CrossRef

Basic and Translational Research
Anti-Senescence Effect of Inhibiting Sodium-Glucose Cotransporter 2 and α-Glucosidase in a Type 2 Diabetes Mellitus Animal Model: Serin Hong, Byung Soo Kong, Hyunsuk Lee, Young Min Cho; Diabetes Metab J. 2025;49(6):1229-1241. Published online May 22, 2025; DOI: https://doi.org/10.4093/dmj.2024.0339

3,784 View
154 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The prevalence of type 2 diabetes mellitus (T2DM) increases with age, and cellular senescence of pancreatic β-cells plays a key role in T2DM pathogenesis. As canagliflozin and acarbose have been shown to increase lifespan in mice, we investigated the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitor, α-glucosidase inhibitor or both on the cellular senescence of β-cells in a T2DM mouse model.
Methods
Enavogliflozin (0.3 mg/kg), acarbose (10 mg/kg), or vehicle was orally administered daily to db/db mice for 6 weeks. The levels of senescence markers (p16, p21, and p53) in the pancreas and kidney were measured through real-time polymerase chain reaction (PCR), immunofluorescence staining, and Western blot. In an in vitro analysis, isolated pancreatic islets were exposed to H₂O₂ to induce cellular senescence, then treated with β-hydroxybutyrate (β-HB), and subsequently assessed for levels of senescent markers.
Results
Enavogliflozin alone or combined with acarbose effectively lowered blood glucose levels in db/db mice. The combined treatment resulted in the greatest increase in β-cell function calculated using insulinogenic index and homeostasis model assessment of β-cell function compared to the vehicle. Additionally, the combined treatment significantly reversed the increase in p16, with a similar trend observed in p21 and p53 in the islets. Treatment increased circulating β-HB and in vitro analysis suggested the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) by β-HB in reducing senescence in the islets.
Conclusion
The combined administration of enavogliflozin and acarbose significantly reduced blood glucose, improved β-cell function, and reduced senescent β-cells in db/db mice. This combination therapy holds potential as a senotherapeutic strategy for managing T2DM.

Citations

Citations to this article as recorded by

Microneedle strategies for diabetic wound management: A comprehensive review of materials, mechanisms, and therapeutic outcomes
Kaustubh Naik, Kanhaiya Singh
Materials Today Advances.2026; 29: 100684. CrossRef

Review

Pharmacotherapy
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application: Jae Hyun Bae; Diabetes Metab J. 2025;49(3):386-402. Published online May 1, 2025; DOI: https://doi.org/10.4093/dmj.2025.0220

26,853 View
1,620 Download
27 Web of Science
29 Crossref

Abstract PDF PubReader ePub

Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease and significantly increases cardiovascular risk and mortality. Despite conventional therapies, including renin-angiotensin-aldosterone system inhibitors, substantial residual risk remains. The emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists has reshaped DKD management. Beyond glycemic control, these agents provide distinct and complementary cardiorenal benefits through mechanisms such as hemodynamic modulation, anti-inflammatory effects, and metabolic adaptations. Landmark trials, including CREDENCE, DAPA-CKD, EMPA-KIDNEY, and FLOW, have demonstrated their efficacy in preserving kidney function and reducing adverse outcomes. SGLT2 inhibitors appear more effective in mitigating glomerular hyperfiltration and lowering heart failure risk, whereas GLP-1 receptor agonists are particularly beneficial in reducing albuminuria and atherosclerotic cardiovascular events. Although indirect comparisons suggest that SGLT2 inhibitors may offer greater protection against kidney function decline, direct head-to-head trials are lacking. Combination therapy holds promise, however further studies are needed to define optimal treatment strategies. This review synthesizes current evidence, evaluates comparative effectiveness, and outlines future directions in DKD management, emphasizing precision medicine approaches to enhance clinical outcomes. The integration of these therapies represents a paradigm shift in diabetes care, expanding treatment options for people with diabetes mellitus at risk of kidney failure.

Citations

Citations to this article as recorded by

Trends in nephrology: kidney metabolism as a therapeutic target
Jessica S Kleer, Markus M Rinschen
Nephrology Dialysis Transplantation.2026; 41(2): 193. CrossRef
Renoprotective effect of dulaglutide in L-NAME-induced hypertensive nephropathy in rats: insight into the roles of PPAR-gamma and VEGF
Nermeen Bastawy, Aliaa E. M. K. El-Mosallamy, Rabab Ahmed Rasheed, A. S. Sadek, R. T. Khattab, Esraa Ali, Randa A. Zaghloul, Wael B. A. Ghaly, Amy F. Boushra
Hypertension Research.2026; 49(3): 816. CrossRef
Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
Diabetes, Obesity and Metabolism.2026; 28(3): 1764. CrossRef
Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex
Changyuan Yang, Petra Denig, Lynne Chepulis, Ryan G. Paul, Jung‐Im Shin, Ron T. Gansevoort, Priya Vart
Diabetes, Obesity and Metabolism.2026; 28(3): 2265. CrossRef
Diabetic kidney disease: integrating multi-omics insights, artificial intelligence, and novel therapeutics for precision medicine
Tao Li, Kaili Chen, Yiting Sun, Linqi Zhang
Frontiers in Genetics.2026;[Epub] CrossRef
Nobiletin Ameliorated the Development of Diabetic Kidney Disease via Modulating Ferroptosis and Epithelial–Mesenchymal Transition Involving Gut–Kidney Axis
Tingting Zhao, Chuyun Zhao, Qian Xiang, Xi Zhang, Kin-Fong Hong, Peiyu Liu, Zhongyan Sun, Yadi Liu, Ruiting Huang, Yiran Li, Hio-Fai Cheong, Yuwei Wu, Yingqiu Mo, Yiduo Xu, Yingxi Zhao, Qiruo Huang, Ying Xie, Youhua Xu
The American Journal of Chinese Medicine.2026; 54(01): 303. CrossRef
Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists
Marios Spanakis, Agapi Fournaraki, Frantzeska Nimee, Christos Kontogiorgis, Emmanouil K. Symvoulakis
Pharmaceuticals.2026; 19(2): 271. CrossRef
Diabetic kidney disease in northwest Ethiopia: Prevalence and determinants among adults with type 2 diabetes
Workagegnehu Hailu, Tadesse Asmamaw Dejene, Markeshaw Tiruneh, Meseret Derbew Molla, Eshetie Melese Birru, Shitaye Alemu, Tadesse Awoke, Francesca D'Addio
PLOS One.2026; 21(2): e0343210. CrossRef
The Role of Non-Coding RNAs in the Pathogenesis and Progression of Diabetic Kidney Disease
Yinfeng Guo, Yonghao Feng, Henglan Wu, Huanqing Gao
International Journal of Molecular Sciences.2026; 27(5): 2352. CrossRef
Association between cardiovascular-kidney-metabolic syndrome stages and risk of all-cause mortality in U.S. adults: a cross-sectional survey based on NHANES
Yuanze Du, Wenxue Sun, Jiaqi Zhang, Jinfeng Wang, Kai Deng, Xiaowei Qiao, Jie Zhang, Xiaofang Zhang, Yueyuan Li, Xinyu Zhang, Xin Yang, Fangyu Cheng, Zongshuai Wang, Chunping Wang
BMC Cardiovascular Disorders.2026;[Epub] CrossRef
Integrated discovery of SBLR876: a potent RAGE inhibitor mitigating AGE–RAGE–NF-κB-mediated cytotoxicity and inflammation in diabetic kidney disease
Mesfer Mohammad AL Shahrani, Mohammad Abohassan, Ayed A. Dera, Sivakumar Vijayaraghavalu, Prasanna Rajagopalan
Biochemical and Biophysical Research Communications.2026; 811: 153540. CrossRef
Glucagon-like peptide-1 receptor agonist and lupus nephritis in systemic lupus erythematosus with type 2 diabetes
Muhammad Hanif, Jai S. Nagarajan, Ryan Murphy, Shiva P. Sah, Shuang Ye, Andras Perl, Cynthia C. Taub
The American Journal of Medicine.2026;[Epub] CrossRef
Impact of a structured nurse-delivered multi component SGLT2 inhibitor initiation and optimization pathway on kidney function and clinical outcomes in type 2 diabetes and chronic kidney disease: a real-world retrospective study
Liang Huang, Yi Muhui
BMC Nephrology.2026;[Epub] CrossRef
Інгібітори натрій-глюкозного котранспортера 2-го типу в контексті кардіоренально-метаболічної коморбідності. Частина 2: метаболомічні аспекти нефропротекції
Vira V. Zlatkina, Andriy O. Nesen, Nadiia V. Demikhova
Ukrainian Journal of Nephrology and Dialysis.2026; (1(89)): 94. CrossRef
Special Issue “Molecular Therapeutics for Diabetes and Related Complications”
Kota V. Ramana
International Journal of Molecular Sciences.2025; 26(12): 5585. CrossRef
Targeting ion channel networks in diabetic kidney disease: from molecular crosstalk to precision therapeutics and clinical innovation
Wenfeng Wang, Bi Ke, Chen Wang, Xiaojing Xiong, Xiuyuan Feng, Hua Yan
Frontiers in Medicine.2025;[Epub] CrossRef
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
Aryan Gajjar, Arvind Kumar Raju, Amani Gajjar, Mythili Menon, Syed Asfand Yar Shah, Sourbha Dani, Andrew Weinberg
Biomedicines.2025; 13(8): 1924. CrossRef
Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients—A systematic review and network meta‐analysis
Peter Bramlage, Anjaly Vijayan, Treesa P. Varghese, Deepthy Melepurakkal Sadanandan, Stefanie Lanzinger, Carmen Ferrero Rodriguez
Diabetes, Obesity and Metabolism.2025; 27(11): 6254. CrossRef
Type 2 Diabetes and the Multifaceted Gut-X Axes
Hezixian Guo, Liyi Pan, Qiuyi Wu, Linhao Wang, Zongjian Huang, Jie Wang, Li Wang, Xiang Fang, Sashuang Dong, Yanhua Zhu, Zhenlin Liao
Nutrients.2025; 17(16): 2708. CrossRef
Nutriomics and artificial intelligence nutrition obesity cohort (NAINOC): a design paper for a prospective cohort for nutrition and obesity research
Minyoung Lee, Sungha Park, Soo-Hyun Park, Ho-Young Park, Yu Ra Lee, Min-Sun Kim, Miso Nam, Jangho Lee, Hyein Seo, Yong-ho Lee, Chan Joo Lee, Jae-Ho Park, Hye Hyun Yoo, Hyun-Jin Kim, Kyong-Oh Shin, Yoshikazu Uchida, Kyungho Park
Clinical Hypertension.2025;[Epub] CrossRef
Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence
Atia Arif, Sanu Lama, Bhavna Singla, Shivam Singla, Sunita Kumawat, Anusha Tharwani, Muhammad Usman, Hamna Khalid, Venkata Madusudana Rao Kanukollu, Osatohanmwen Ekomwereren, Shabir Khan
Cureus.2025;[Epub] CrossRef
Integrating UHPLC-QE-MS and Bioinformatics with Experimental Validation Reveals MAPK/FOS-Mediated Podocyte Apoptosis as the Key Mechanism of Alpiniae oxyphyllae and Saposhnikovia divaricata in Treating Diabetic Kidney Disease
Xian Wang, Lin Zhang, Rongxin Tang, Wenlong Zhang, Yiqiang Xie, Kai Li
Pharmaceuticals.2025; 18(10): 1449. CrossRef
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Mark E. Cooper, Daniël H. van Raalte
Journal of Clinical Investigation.2025;[Epub] CrossRef
Short-Term Laboratory Outcomes of SGLT2 Inhibitor Use in Type 2 Diabetic Patients: A Retrospective Analysis
Hamood AlSudais, Turky AlSulaiman, Badi A. Alotaibi, Abdulrahman Alshalani, Abdulaziz M. Almuqrin, Rehab B. Albakr, Jehad A. Aldali
Journal of Clinical Medicine.2025; 14(22): 7985. CrossRef
Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i
Yixin Zhu, Chenxi Lv, Hanqi Yang, Qian Lu, XuChen Wang, Yueqi Zhang, Maojuan Guo, Bo Yang
Renal Failure.2025;[Epub] CrossRef
FGF4-FGFR1 signaling promotes podocyte survival and glomerular function to ameliorate diabetic kidney disease in male mice
Jie Zhou, Shuxin Wang, Jiaxin Lou, Beibin Pan, Min Zhao, Qian Li, Jing Zhou, Yali Du, Shuodan Ding, Meiling Yu, Jingjing Zhou, Xinwei Chen, Lingwei Jin, Xinyi Wang, Yepeng Hu, Zhe Wang, Xiaokun Li, Chao Zheng, Jian Sun, Zhifeng Huang
Nature Communications.2025;[Epub] CrossRef
Food‐Herb Dual‐Function in Astragali Radix‐Poria‐Rheum: Network Pharmacology and Database Mining for Diabetic Kidney Disease Mechanisms Exploration
Meizi Wang, Weizhong Li, Qiong Cheng, Jiayu Sun, Cheng Cheng, Nana Wang, Ping Zhou, Min Zha, Yufeng Yang
Food Science & Nutrition.2025;[Epub] CrossRef
Інгібітори натрій-глюкозного котранспортера 2-го типу в контексті кардіоренально-метаболічної коморбідності. Частина 1: основи патофізіології та ключові клінічні дослідження
Vira V. Zlatkina, Andriy O. Nesen, Nadiia V. Demikhova
Ukrainian Journal of Nephrology and Dialysis.2025; (4(88)): 88. CrossRef
GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications
Areesha Moiz, Tetiana Zolotarova, Kristian B Filion, Mark J Eisenberg
American Journal of Hypertension.2025;[Epub] CrossRef

Original Article

Pharmacotherapy
Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP): Nam Hoon Kim, Soo Lim, In-Kyung Jeong, Eun-Jung Rhee, Jun Sung Moon, Ohk-Hyun Ryu, Hyuk-Sang Kwon, Jong Chul Won, Sang Soo Kim, Sang Yong Kim, Bon Jeong Ku, Heung Yong Jin, Sin Gon Kim, Bong-Soo Cha, on Behalf of Investigators of ENVELOP Study; Diabetes Metab J. 2025;49(2):225-234. Published online January 6, 2025; DOI: https://doi.org/10.4093/dmj.2024.0238

8,074 View
292 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor enavogliflozin effectively lowers glycosylated hemoglobin levels and body weights without the increased risk of serious adverse events; however, the long-term clinical benefits of enavogliflozin in terms of cardiovascular and renal outcomes have not been investigated.
Methods
This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults (aged ≥19 years) with type 2 diabetes mellitus (T2DM) who have a history of, or are at risk of, cardiovascular disease. A total of 2,862 participants will be randomly assigned to receive either enavogliflozin or other SGLT2 inhibitors with proven cardiorenal benefits, such as dapagliflozin or empagliflozin. The primary endpoint is the time to the first occurrence of a composite of major adverse cardiovascular or renal events (Clinical Research Information Service registration number: KCT0009243).
Conclusion
This trial will determine whether enavogliflozin is non-inferior to dapagliflozin or empagliflozin in terms of cardiorenal outcomes in patients with T2DM and cardiovascular risk factors. This study will elucidate the role of enavogliflozin in preventing vascular complications in patients with T2DM.

Citations

Citations to this article as recorded by

Reverse translational approach to clarify the strong potency of enavogliflozin, a novel sodium-glucose cotransporter 2 inhibitor
Sun-Hwa Park, Hye-Young Ji, Ji-Soo Choi, Kyung Seok Oh, Jihoon Lee, Minyeong Pang, Im-Sook Song, Joon Seok Park
The Journal of Pharmacology and Experimental Therapeutics.2025; 392(8): 103650. CrossRef

Review

Drug/Regimen
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus: Ja Young Jeon, Dae Jung Kim; Diabetes Metab J. 2024;48(5):837-846. Published online September 1, 2024; DOI: https://doi.org/10.4093/dmj.2024.0317

15,285 View
732 Download
10 Web of Science
12 Crossref

Abstract PDF PubReader ePub

People with type 2 diabetes mellitus (T2DM) are at higher risk of developing cardiovascular disease, heart failure, chronic kidney disease, and premature death than people without diabetes. Therefore, treatment of diabetes aims to reduce these complications. Sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown beneficial effects on cardiorenal and metabolic health beyond glucose control, making them a promising class of drugs for achieving the ultimate goals of diabetes treatment. However, despite their proven benefits, the use of SGLT2 inhibitors in eligible patients with T2DM remains suboptimal due to reports of adverse events. The use of SGLT2 inhibitors is particularly limited in older patients with T2DM because of the lack of treatment experience and insufficient long-term safety data. This article comprehensively reviews the risk-benefit profile of SGLT2 inhibitors in older patients with T2DM, drawing on data from prospective randomized controlled trials of cardiorenal outcomes, original studies, subgroup analyses across different age groups, and observational cohort studies.

Citations

Citations to this article as recorded by

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial
Seung‐Hwan Lee, Kyung Ah Han, Eun‐Gyoung Hong, Jun Goo Kang, Choon Hee Chung, Jong Chul Won, Eon Ju Jeon, Jung‐Hwan Cho, Ho Chan Cho, Sin Gon Kim, Eun Seok Kang, So Hun Kim, Hae Jin Kim, In‐Kyung Jeong, Sung Wan Chun, Young Min Cho
Diabetes, Obesity and Metabolism.2026; 28(3): 2027. CrossRef
Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet
Phuc Thi Minh Pham, Giang Nguyen, So Young Park, Thuy Linh Lai, Dae-Hee Choi, Jeana Hong, Seon Mee Kang, Eun-Hee Cho
Diabetes & Metabolism Journal.2026; 50(1): 165. CrossRef
Cortex phellodendri Exerts Its Nephroprotective Effect via the Inhibition of the AGEs‐RAGE Pathway
Ao Li, Chao‐Fan Deng, Hua‐Ze Wu, Chen‐Yue Zeng, Yu‐Xin Gao, Zhi‐Quan Wang, Hong‐Yan Ma, Dan Tang
Chemistry & Biodiversity.2026;[Epub] CrossRef
Systemic effects of type 2 diabetes therapies: an integrated perspective on the cardio–renal– cerebral–metabolic axis
Lin Zhu, Chen Chen, Feng Lu, Bingying Li
Frontiers in Medicine.2026;[Epub] CrossRef
Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim
Journal of Diabetes Investigation.2025; 16(2): 215. CrossRef
Pharmacological management of diabetes in older adults
Junghyun Noh
Cardiovascular Prevention and Pharmacotherapy.2025; 7(1): 13. CrossRef
Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)—Special Interest Group in Diabetes
Virginia Boccardi, Gülistan Bahat, Cafer Balci, Isabelle Bourdel-Marchasson, Antoine Christiaens, Lorenzo Maria Donini, Sibel Cavdar, Stefania Maggi, Serdar Özkök, Tajana Pavic, Stany Perkisas, Stefano Volpato, Muhammad Shoaib Zaidi, Andrej Zeyfang, Alan
European Geriatric Medicine.2025; 16(4): 1231. CrossRef
Clinical Considerations for Safe Use of SGLT2 Inhibitors
Jae-Seung Yun, Eonju Jeon
The Journal of Korean Diabetes.2025; 26(2): 60. CrossRef
Effects of Blood-Glucose Lowering Therapies on Body Composition and Muscle Outcomes in Type 2 Diabetes: A Narrative Review
Ioana Bujdei-Tebeică, Doina Andrada Mihai, Anca Mihaela Pantea-Stoian, Simona Diana Ștefan, Claudiu Stoicescu, Cristian Serafinceanu
Medicina.2025; 61(8): 1399. CrossRef
Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis
Kirim Song, Jiwon Choi, Dayeon Jeong, Dongyun Shin, Young-Mi Ah, Ki Young Lee, Kyung Hee Choi
Frontiers in Endocrinology.2025;[Epub] CrossRef
Optimizing Physical Activity Strategies for Older Adults with Diabetes
Hyeon-Jin Yu, Doyoun Hong, Kyuho Kim, Ji Hye Heo, Dong-Hyeok Cho, Yoshitaka Hashimoto, Jae-Seung Yun
Diabetes & Metabolism Journal.2025; 49(6): 1178. CrossRef
Impact of preprocedural atrial fibrillation and body mass index on clinical outcomes after transcatheter aortic valve implantation
Hitoshi Umezaki, Hiroaki Yokoyama, Shun Hirosawa, Ken Yamazaki, Shun Shikanai, Misato Hamadate, Michiko Tsushima, Maiko Senoo, Noritomo Narita, Hiroaki Ichikawa, Shuji Shibutani, Kenji Hanada, Kenyu Murata, Yuki Imamura, Yoshiaki Saito, Masahito Minakawa,
Heart and Vessels.2025;[Epub] CrossRef

Brief Report

Complications
Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights: Han-Sang Baek, Chaiho Jeong, Yeoree Yang, Joonyub Lee, Jeongmin Lee, Seung-Hwan Lee, Jae Hyoung Cho, Tae-Seo Sohn, Hyun-Shik Son, Kun-Ho Yoon, Eun Young Lee; Diabetes Metab J. 2024;48(6):1169-1175. Published online June 10, 2024; DOI: https://doi.org/10.4093/dmj.2024.0036

15,994 View
462 Download
14 Web of Science
18 Crossref

Abstract PDF PubReader ePub

One of the notable adverse effects of sodium-glucose cotransporter 2 (SGLT2) inhibitor is diabetic ketoacidosis (DKA) often characterized by euglycemia. In this retrospective review of patients with DKA from 2015 to 2023, 21 cases of SGLT2 inhibitorassociated DKA were identified. Twelve (57.1%) exhibited euglycemic DKA (euDKA) while nine (42.9%) had hyperglycemic DKA (hyDKA). More than 90% of these cases were patients with type 2 diabetes mellitus. Despite similar age, sex, body mass index, and diabetes duration, individuals with hyDKA showed poorer glycemic control and lower C-peptide levels compared with euDKA. Renal impairment and acidosis were worse in the hyDKA group, requiring hemodialysis in two patients. Approximately one-half of hyDKA patients had concurrent hyperosmolar hyperglycemic state. Common symptoms included nausea, vomiting, general weakness, and dyspnea. Seizure was the initial manifestation of DKA in two cases. Infection and volume depletion were major contributors, while carbohydrate restriction and inadequate insulin treatment also contributed to SGLT2 inhibitor-associated DKA. Despite their beneficial effects, clinicians should be vigilant for SGLT2 inhibitor risk associated with DKA.

Citations

Citations to this article as recorded by

Fallbericht einer Euglykämischen Diabetischen Ketoacidose unter SGLT-2-Inhibition bei einer geriatrischen Patientin: „Sick-Day-Off Drug“
Laura Wassermann, Michael Denkinger
Zeitschrift für Gerontologie und Geriatrie.2026; 59(1): 74. CrossRef
The evolution of C-peptide's role in diabetes care
Laura Briggs, Alexander Read, Sarah Darch, Emma L. Williams, Wann Jia Loh, Julia S. Kenkre
Current Opinion in Endocrinology, Diabetes & Obesity.2026; 33(1): 16. CrossRef
Diabetic ketoacidosis is not a simple consequence of hyperglycemia, it is biochemical event driven by PDK4-mediated inhibition of PDC
Ayah Al-Qasrawi
Medical Hypotheses.2026; 208: 111898. CrossRef
Diabetic ketoacidosis in patients with type 2 diabetes: Risk factors for mortality and adverse outcomes
Vishnu Chandrabalan, Timothy Howcroft, Mohammed Khalid Alkhalifah, Noorulanne Younis, Ebrahim Aldhafiri, Joseph M Pappachan
World Journal of Experimental Medicine.2026;[Epub] CrossRef
Diabetes mellitus im Alter
Andrej Zeyfang, Jürgen Wernecke, Anke Bahrmann
Die Diabetologie.2026;[Epub] CrossRef
The Diabetes–Viral Respiratory Syndemic: Pathophysiological Insights and Precision Management: A Scoping Review
Ana Maria Mihai, Monica Marc, Florina Lucaciu, Alexandra Sima
Medicina.2026; 62(4): 770. CrossRef
Dapagliflozin/Empagliflozin/Ertugliflozin

Reactions Weekly.2025; 2042(1): 142. CrossRef
Diabetes Mellitus at an Elderly Age
Andrej Zeyfang, Jürgen Wernecke, Anke Bahrmann
Experimental and Clinical Endocrinology & Diabetes.2025; 133(04): 168. CrossRef
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
Jae Hyun Bae
Diabetes & Metabolism Journal.2025; 49(3): 386. CrossRef
Diabetes mellitus im Alter
Andrej Zeyfang, Jürgen Wernecke, Anke Bahrmann
Die Diabetologie.2025; 21(4): 503. CrossRef
Cardiorenal outcomes and safety of SGLT2 inhibitors in patients with diabetes secondary to disorders of the exocrine pancreas: a nationwide population-based study
Kyoung Hwa Ha, Minae Park, Yujin Lee, Dae Jung Kim, Seung Jin Han
Diabetes & Metabolism.2025; 51(5): 101668. CrossRef
SGLT2 Inhibitors: From Structure–Effect Relationship to Pharmacological Response
Teodora Mateoc, Andrei-Luca Dumitrascu, Corina Flangea, Daniela Puscasiu, Tania Vlad, Roxana Popescu, Cristina Marina, Daliborca-Cristina Vlad
International Journal of Molecular Sciences.2025; 26(14): 6937. CrossRef
Euglycaemic diabetic ketoacidosis and its risk factors in patients undergoing coronary artery bypass grafting surgery: a single-centre nested case-control study in China
Rui Hu, Congchao Lu, Yifan Liu, Mengli Yang, Hongya Xing, Kerui Dai, Jiyin Li, Hui Zheng, Xi Chen, Nai-Jun Tang
BMJ Open.2025; 15(8): e098758. CrossRef
Acute heart failure in non-cardiac surgery
Danielle M Gualandro, Josep Masip, Sigrun Halvorsen, Susanna Price, Xavier Rosselló, Ovidiu Chioncel, W Frank Peacock, Òscar Miró, Mucio Tavares Oliveira Junior, Alexandre Mebazaa, Elke Platz, Offer Amir, Hannah Schaubroeck, Johannes Grand, Alessandro Sio
European Heart Journal.2025; 46(40): 4042. CrossRef
Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report
Agnieszka Gandecka-Pempera, Dariusz Naskręt, Anna Adamska, Dorota Zozulińska-Ziółkiewicz
Frontiers in Endocrinology.2025;[Epub] CrossRef
Sodium-Glucose Cotransporter 2 Inhibitors-Induced Euglycemic Ketoacidosis Mimicking Myocardial Infarction in a Non-Diabetic Heart Failure Patient
KilYoon Pack, Kyung Eun Ha, Taeil Yang, Wook-Jin Chung
International Journal of Heart Failure.2025; 7(4): 257. CrossRef
Diabetes mellitus im Alter
Andrej Zeyfang, Jürgen Wernecke, Anke Bahrmann
Diabetologie und Stoffwechsel.2025; 20(S 02): S234. CrossRef
Diabetes mellitus im Alter
Andrej Zeyfang, Jürgen Wernecke, Anke Bahrmann
Diabetologie und Stoffwechsel.2024; 19(S 02): S226. CrossRef

Original Articles

Drug/Regimen
Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial: Ji Hye Heo, Kyung Ah Han, Jun Hwa Hong, Hyun-Ae Seo, Eun-Gyoung Hong, Jae Myung Yu, Hye Seung Jung, Bong-Soo Cha; Diabetes Metab J. 2024;48(5):937-948. Published online February 2, 2024; DOI: https://doi.org/10.4093/dmj.2023.0314

23,089 View
786 Download
11 Web of Science
14 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study assessed the efficacy and safety of triple therapy with pioglitazone 15 mg add-on versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and dapagliflozin.
Methods
In this multicenter, double-blind, randomized, phase 3 study, patients with T2DM with an inadequate response to treatment with metformin (≥1,000 mg/day) plus dapagliflozin (10 mg/day) were randomized to receive additional pioglitazone 15 mg/day (n=125) or placebo (n=125) for 24 weeks. The primary endpoint was the change in glycosylated hemoglobin (HbA1c) levels from baseline to week 24 (ClinicalTrials.gov identifier: NCT05101135).
Results
At week 24, the adjusted mean change from baseline in HbA1c level compared with placebo was significantly greater with pioglitazone treatment (–0.47%; 95% confidence interval, –0.61 to –0.33; P<0.0001). A greater proportion of patients achieved HbA1c <7% or <6.5% at week 24 with pioglitazone compared to placebo as add-on to 10 mg dapagliflozin and metformin (56.8% vs. 28% for HbA1c <7%, and 23.2% vs. 9.6% for HbA1c <6.5%; P<0.0001 for all). The addition of pioglitazone also significantly improved triglyceride, highdensity lipoprotein cholesterol levels, and homeostatic model assessment of insulin resistance levels, while placebo did not. The incidence of treatment-emergent adverse events was similar between the groups, and the incidence of fluid retention-related side effects by pioglitazone was low (1.5%).
Conclusion
Triple therapy with the addition of 15 mg/day of pioglitazone to dapagliflozin plus metformin was well tolerated and produced significant improvements in HbA1c in patients with T2DM inadequately controlled with dapagliflozin plus metformin.

Citations

Citations to this article as recorded by

Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial
Da Hea Seo, Kyung Wan Min, Ho Sang Sohn, Sang Yong Kim, In‐Kyung Jeong, Cheol‐Young Park, Kun‐Ho Yoon, So Hun Kim, Bong‐Soo Cha
Diabetes, Obesity and Metabolism.2026; 28(1): 728. CrossRef
Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
Diabetes, Obesity and Metabolism.2026; 28(3): 1764. CrossRef
Efficacy and safety of fixed-dose dapagliflozin–pioglitazone in Indian adults with type 2 diabetes: results from the randomized phase 3 PRO-1 trial
Awadhesh Kumar Singh, Krishna G Seshadri, A G Unnikrishnan, Jothydev Kesavadev, Sanjay Kalra, Shashank R Joshi, Kaushik Pandit, Rakesh K Sahay, Vijay K Panikar, Ambrish Mithal, Smriti Gadia, Thamburaj Anthuvan
Diabetology & Metabolic Syndrome.2026;[Epub] CrossRef
Lipid metabolism in homeostasis and disease
Zhenghao Li, Wende Deng, Lanxuan Yang, Changheng Tang, Jian-Min Yue, Olivia Monteiro, Daniel T. Baptista-Hon, Ting Li
Signal Transduction and Targeted Therapy.2026;[Epub] CrossRef
Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
Jun Hwa Hong, Kyung Ah Han, You-Cheol Hwang, Eun-Gyoung Hong, Hae Jin Kim, Chang Beom Lee, Ho Chan Cho, Jong Chul Won, Hun-Sung Kim, Eui-Hyun Kim, Gwanpyo Koh, Kwang Hyun Ahn, Kyong Soo Park
Diabetes & Metabolism Journal.2026; 50(2): 320. CrossRef
Cannabisin A and B from hemp seed hulls improve glucose homeostasis by re-engaging insulin, leptin, and AMPK pathways via selective PTP1B inhibition
Jang Hoon Kim, Sang Seop Lee, Sang Hoon Lee, Kyong Hwan Bang, Jin Yu, Yong Goo Kim, Sung Yeon Kim, Ik Soo Lee, Yung Choon Yoo
Phytomedicine.2026; 154: 158054. CrossRef
Efficacy and Safety of Pioglitazone Add‐On in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Ubaid Khan, Zuhair Majeed, Muhammad Haris Khan, Ahmed Bostamy Elsnhory, Ahmed Mazen Amin, Anum Nawaz, Ahmed Raza, Hafiz Muhammad Waqas Siddque, Mustafa Turkmani, Mohamed Abuelazm
Endocrinology, Diabetes & Metabolism.2025;[Epub] CrossRef
Pioglitazone as Add-On to Metformin and Dapagliflozin Yields Significant Enhancements in Glycemic Control in Poorly Controlled Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Sara Sabbagh, Ahmed Hegazy, Ahmed Adel, Abdullah Ali, Mohamed Alquddosy, Sara Khalid, Abdallah M Ibrahim, Ahmed Mohamed, Abdelrahman Mostafa, Ahmed Hassan, Ola Mohamed, Rawan Mesbah, Osama Osman, Mohamed Hamouda Elkasaby
Cureus.2025;[Epub] CrossRef
Triple oral therapy with metformin, DPP‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)
Miao Yu, Tong Wang, Chun Xu, Yan Bi, Ling Gao, Guang Wang, Guangda Xiang, Yaoming Xue, Tao Yang, Deying Kang, Zhiguang Zhou, Lixin Guo, Xinhua Xiao
Diabetes, Obesity and Metabolism.2025; 27(S9): 3. CrossRef
Thiazolidinediones for people with chronic kidney disease and diabetes
Patrizia Natale, Suetonia C Green, David J Tunnicliffe, Giovanni Pellegrino, Tadashi Toyama, Pantelis Sarafidis, Giovanni FM Strippoli
Cochrane Database of Systematic Reviews.2025;[Epub] CrossRef
Targeting adipose remodeling: Synergistic mechanisms of drugs and adipose-derived stem cells in obese type 2 diabetes mellitus
Cheng Luo, Xian-Mei Yu, Liang-Yan Hua, Mei-Qi Zeng, Hui Xu, Cheng-Zheng Duan, Shi-Yu Xu, Da Sun, Li-Ya Ye, Dong-Juan He
World Journal of Stem Cells.2025;[Epub] CrossRef
Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study
Kyuho Kim, Seung-Hyun Ko, Jae-Seung Yun, Kwan-Woo Lee, Eun Sook Kim, In-Kyung Jeong, Jae Hyeon Kim, Sang Yong Kim, Kyu Chang Won, Mikyung Kim, Bong-Soo Cha, Sungrae Kim, Sung Hee Choi, Eun-Jung Rhee, Sin Gon Kim, Bo Hyun Kim, Kang Seo Park, Young-Cheol Ju
Scientific Reports.2025;[Epub] CrossRef
Identification and validation of biomarkers related to mitochondria-associated endoplasmic reticulum membranes in type 2 diabetes mellitus using peripheral blood transcriptomics
Sufen Li, Yanqiong Yan, Qianjun Luo, Ruifei Tian, Jiahe Yan
European Journal of Medical Research.2025;[Epub] CrossRef
Ideal Combination of Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus
Hye Soon Kim
Diabetes & Metabolism Journal.2024; 48(5): 882. CrossRef

Drug/Regimen
Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis: Min-Hsiang Chuang, Yu-Shuo Tang, Jui-Yi Chen, Heng-Chih Pan, Hung-Wei Liao, Wen-Kai Chu, Chung-Yi Cheng, Vin-Cent Wu, Michael Heung; Diabetes Metab J. 2024;48(2):242-252. Published online January 26, 2024; DOI: https://doi.org/10.4093/dmj.2023.0201

10,946 View
519 Download
7 Web of Science
7 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2i) typically leads to a reversible initial dip in estimated glomerular filtration rate (eGFR). The implications of this phenomenon on clinical outcomes are not well-defined.
Methods
We searched MEDLINE, Embase, and Cochrane Library from inception to March 23, 2023 to identify randomized controlled trials and cohort studies comparing kidney and cardiovascular outcomes in patients with and without initial eGFR dip after initiating SGLT2i. Pooled estimates were calculated using random-effect meta-analysis.
Results
We included seven studies in our analysis, which revealed that an initial eGFR dip following the initiation of SGLT2i was associated with less annual eGFR decline (mean difference, 0.64; 95% confidence interval [CI], 0.437 to 0.843) regardless of baseline eGFR. The risk of major adverse kidney events was similar between the non-dipping and dipping groups but reduced in patients with a ≤10% eGFR dip (hazard ratio [HR], 0.915; 95% CI, 0.865 to 0.967). No significant differences were observed in the composite of hospitalized heart failure and cardiovascular death (HR, 0.824; 95% CI, 0.633 to 1.074), hospitalized heart failure (HR, 1.059; 95% CI, 0.574 to 1.952), or all-cause mortality (HR, 0.83; 95% CI, 0.589 to 1.170). The risk of serious adverse events (AEs), discontinuation of SGLT2i due to AEs, kidney-related AEs, and volume depletion were similar between the two groups. Patients with >10% eGFR dip had increased risk of hyperkalemia compared to the non-dipping group.
Conclusion
Initial eGFR dip after initiating SGLT2i might be associated with less annual eGFR decline. There were no significant disparities in the risks of adverse cardiovascular outcomes between the dipping and non-dipping groups.

Citations

Citations to this article as recorded by

Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy
Yan Miao, Pan He, Dan-Yu Wang, Lei Yan, Hui-Xia Cao, Feng-Min Shao
World Journal of Diabetes.2026;[Epub] CrossRef
Efficacy and Safety of Fixed‐Dose Combinations of Sitagliptin and Empagliflozin as Add‐On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Multi‐Centre, Placebo‐Controlled, Phase III Trial
Soo Lim, Tae Nyun Kim, Ji Oh Mok, Choon Hee Chung, You Cheol Hwang, Ho Chan Cho, Jong Chul Won, Eonju Jeon, Eun Seok Kang, Ki Young Lee, Chong Hwa Kim, Soo Heon Kwak, Cheol Young Park, Kang Seo Park, Sang Yong Kim, Jae Hyuk Lee, Soon Hee Lee, Dong Hyeok C
Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Pleiotropic Mechanisms and Translational Trajectory of SGLT2 Inhibitors in Sepsis-Induced Cardiomyopathy: Navigating the Evidence Hierarchy
Xinge Zhang, Liuyi Ren, Min Li, Xiangyu Li, Bimin Feng, Shurong Wang, Xuping Yang, Yilan Huang
European Journal of Pharmacology.2026; : 178858. CrossRef
Effect of Initial eGFR and Albuminuria Changes on Clinical Outcomes in People With Diabetes Receiving SGLT2 Inhibitors
Birdie Huang, Yi-Wei Kao, Kun-Chi Yen, Shao-Wei Chen, Tze-Fan Chao, Yi-Hsin Chan
The Journal of Clinical Endocrinology & Metabolism.2025; 110(12): e3505. CrossRef
The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention?
Sajjad Biglari, Harald Mischak, Joachim Beige, Agnieszka Latosinska, Justyna Siwy, Mirosław Banasik
Biomolecules.2025; 15(6): 809. CrossRef
Continuation Versus Discontinuation of Sodium‐Glucose Cotransporter‐2 Inhibitors and Cardiorenal Outcomes Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Cohort Study With a Target Trial Emulation Framework
Yaa‐Hui Dong, Chia‐Hsuin Chang, Li‐Chiu Wu, Sengwee Toh
Clinical and Translational Science.2025;[Epub] CrossRef
Association of neutrophil-to-lymphocyte ratio with the risk of kidney failure in critically ill patients with heart failure: a cohort study
Ning Li, Rui Wang, Ningpeng Liang, Huang Zhang, Yifei Dong
BMC Cardiovascular Disorders.2025;[Epub] CrossRef

Drug/Regimen
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients: Young-Hwan Park, Minji Sohn, So Yeon Lee, Soo Lim; Diabetes Metab J. 2024;48(2):253-264. Published online January 26, 2024; DOI: https://doi.org/10.4093/dmj.2023.0128

13,997 View
824 Download
9 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We investigated the long-term efficacy and safety of initial triple therapy using metformin, a dipeptidyl peptidase-4 inhibitor, and a sodium-glucose cotransporter-2 inhibitor, in patients with type 2 diabetes mellitus.
Methods
We enrolled 170 drug-naïve patients with glycosylated hemoglobin (HbA1c) level >7.5% who had started triple therapy (metformin, sitagliptin, and empagliflozin). Glycemic, metabolic, and urinary parameters were measured for 24 months.
Results
After 24 months, HbA1c level decreased significantly from 11.0%±1.8% to 7.0%±1.7%. At 12 and 24 months, the rates of achievement of the glycemic target goal (HbA1c <7.0%) were 72.5% and 61.7%, respectively, and homeostasis model assessment of β-cell function and insulin resistance indices improved. Whole-body fat percentage decreased by 1.08%, and whole-body muscle percentage increased by 0.97% after 24 months. Fatty liver indices and albuminuria improved significantly. The concentration of ketone bodies was elevated at the baseline but decreased after 24 months. There were no serious adverse events, including ketoacidosis.
Conclusion
Initial triple combination therapy with metformin, sitagliptin, and empagliflozin led to achievement of the glycemic target goal, which was maintained for 24 months without severe hypoglycemia but with improved metabolic function and albuminuria. This combination therapy may be a good strategy for drug-naïve patients with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Antidiabetic prescribing patterns, quality, and economic influence in resource-limited settings: evidence from a Pakistani tertiary care hospital using WHO/INRUD indicators
Amna Saeed, Iltaf Hussain, Ali Hassan Gillani, Farhan Ullah, Muhammad Ali, Muhammad Shafiq Khan, Ifra Maqbool, Asif Nawaz Khan, Yu Fang
BMC Health Services Research.2026;[Epub] CrossRef
Patterns and Clinical Outcomes of Sitagliptin/Metformin Extended-Release in Internal Medicine: A Real-World Multicenter Italian Study
Mariarosaria De Luca, Michele Arcopinto, Giosiana Bosco, Sebastiano Cicco, Francesco Di Giacomo Barbagallo, Chiara Giacinti, Marialuisa Sveva Marozzi, Maristella Salvatora Masala, Miriam Pinna, Giacomo Pucci, Andrea Salzano, Roberto Scicali, Alberto Maria
Journal of Clinical Medicine.2026; 15(3): 927. CrossRef
Long-term effectiveness on glycemic control of insulin compared to combined oral antidiabetic drugs for initial intensive treatment in newly diagnosed type 2 diabetes: A duplicated target trial
Tae Hyeon Kim, Yerin Hwang, Selin Woo, Kyeongmin Lee, Yejun Son, Seoyoung Park, Hyunjee Kim, Ju-Young Shin, YongHyun Cho, Dahye Shin, Dosang Cho, Kyung-Jae Lee, Sang Youl Rhee, Dong Keon Yon
Medicine.2026; 105(5): e47235. CrossRef
Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled Study
Brij Mohan, S. Vasanth Kumar, Prakash Harishchandra Kurmi, Sandeep Kumar Gupta, Neelaveni Kudugunti, Bharat Das, Kartikeya Parmar, Alok Kanungo, Sanjay Saran, Preetam Ahirrao Kashinath, Balamurugan Ramanathan, Micky Patel, Vivek Vedprakash Arya, Raisa Sha
Journal of Diabetes.2026;[Epub] CrossRef
Successful portosystemic shunt embolization resolves hepatic encephalopathy and enhances hepatic function and glycemic control in MASH-related cirrhosis: a case report
Yoshiaki Kobayashi, Takanobu Iwadare, Hiroyuki Kobayashi, Takefumi Kimura, Yoshiki Ozawa, Ryo Kodama, Masahiro Kurozumi, Yayoi Yamazaki, Yuki Yamashita, Takeji Umemura
Clinical Journal of Gastroenterology.2025; 18(1): 137. CrossRef
Efficacy and Safety of Triple Fixed Dose Combination of Dapagliflozin + Sitagliptin + Metformin IR in Indian Patients with Type 2 Diabetes Mellitus: A Randomized, Phase 3 Study in Comparison with Dual FDC Sitagliptin + Metformin IR
Mahendra Pal Singh, Sandeep Gupta, Manish Singh, C. Ambrish, Prakash Kurmi, Dinesh Kumar Gangwani, J. Naganna, Ravikumar Sethuraman, Vrindavani Dhumal, Sapan Behera, Piyush M. Patel, Dipak M. Patil, Lalit K. Lakhwani, Pravin S. Ghadge, Suyog C. Mehta, Sad
Advances in Therapy.2025; 42(10): 5187. CrossRef
Triple oral therapy with metformin, DPP‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)
Miao Yu, Tong Wang, Chun Xu, Yan Bi, Ling Gao, Guang Wang, Guangda Xiang, Yaoming Xue, Tao Yang, Deying Kang, Zhiguang Zhou, Lixin Guo, Xinhua Xiao
Diabetes, Obesity and Metabolism.2025; 27(S9): 3. CrossRef
Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy
Sachin Dhiman, Sanchit Dhankhar, Anjali Garg, Manni Rohilla, Monika Saini, Thakur Gurjeet Singh, Samrat Chauhan, Samy Selim, Soad K. Al Jaouni, Sabina Yasmin, Naseem Begum, Aziza Alshahrani, Mohammad Yousuf Ansari
Heliyon.2024; 10(21): e39996. CrossRef

Drug/Regimen
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: Tzu-Yi Lin, Eugene Yu-Chuan Kang, Shih-Chieh Shao, Edward Chia-Cheng Lai, Sunir J. Garg, Kuan-Jen Chen, Je-Ho Kang, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang; Diabetes Metab J. 2023;47(3):394-404. Published online March 6, 2023; DOI: https://doi.org/10.4093/dmj.2022.0221

14,631 View
459 Download
34 Web of Science
37 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To compare risk of diabetic retinopathy (DR) between patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2is) and those taking glucagon-like peptide-1 receptor agonists (GLP1-RAs) in routine care.
Methods
This retrospective cohort study emulating a target trial included patient data from the multi-institutional Chang Gung Research Database in Taiwan. Totally, 33,021 patients with type 2 diabetes mellitus using SGLT2is and GLP1-RAs between 2016 and 2019 were identified. 3,249 patients were excluded due to missing demographics, age <40 years, prior use of any study drug, a diagnosis of retinal disorders, a history of receiving vitreoretinal procedure, no baseline glycosylated hemoglobin, or no follow-up data. Baseline characteristics were balanced using inverse probability of treatment weighting with propensity scores. DR diagnoses and vitreoretinal interventions served as the primary outcomes. Occurrence of proliferative DR and DR receiving vitreoretinal interventions were regarded as vision-threatening DR.
Results
There were 21,491 SGLT2i and 1,887 GLP1-RA users included for the analysis. Patients receiving SGLT2is and GLP-1 RAs exhibited comparable rate of any DR (subdistribution hazard ratio [SHR], 0.90; 95% confidence interval [CI], 0.79 to 1.03), whereas the rate of proliferative DR (SHR, 0.53; 95% CI, 0.42 to 0.68) was significantly lower in the SGLT2i group. Also, SGLT2i users showed significantly reduced risk of composite surgical outcome (SHR, 0.58; 95% CI, 0.48 to 0.70).
Conclusion
Compared to those taking GLP1-RAs, patients receiving SGLT2is had a lower risk of proliferative DR and vitreoretinal interventions, although the rate of any DR was comparable between the SGLT2i and GLP1-RA groups. Thus, SGLT2is may be associated with a lower risk of vision-threatening DR but not DR development.

Citations

Citations to this article as recorded by

Sodium-glucose cotransporter 2 inhibitors and risk of diabetic retinopathy: systematic review and meta-analysis
Le Liang, Liping Yu, Yani He, Li Liu, Haohuan Yuan, Yating Hu, Jin Sun
Canadian Journal of Ophthalmology.2026; 61(2): 400. CrossRef
The influence of dapagliflozin on diabetic ocular complications: An observational cohort study
Jo-Hsin Chen, Fei-Hung Hung, Yu-Ting Wang, Jin-Hua Chen, Shu-Fen Liao, Chun-Mei Hsueh, Jong-Shiuan Yeh, Gregory Y.H. Lip
European Journal of Pharmaceutical Sciences.2026; 216: 107382. CrossRef
Diabetic retinopathy: why some eyes suffer more – a focus on retina-specific risk factors and metabolic memory
Shanshan Tang, Linlin Jiang, Wenjie Sun, Xuedong An, Xiaomin Kang, Xuefei Zhao, Qing Gao, Zehua Li, Chenran Liu, Hangyu Ji, Fengmei Lian
Journal of Translational Medicine.2026;[Epub] CrossRef
Design and Implementation of Observational Studies Emulating a Target Trial
Yan Ren, Yulong Jia, Lingyan Liu, Houchen Lyv, Liyuan Tao, Yuezhen Li, Peng Zhao, Yiquan Xiong, Guowei Li, Jiayue Xu, Chunrong Liu, Yongmei Lu, Kang Zou, Jing Tan, Xin Sun
JAMA Network Open.2026; 9(2): e2558262. CrossRef
Association between pentoxifylline use and diabetic retinopathy in patients with type 2 diabetes mellitus and chronic kidney disease: A multi-institutional cohort study
Tzu-Yi Lin, Eugene Yu-Chuan Kang, Nan-Kai Wang, Je-Ho Kang, Kuan-Jen Chen, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang
Biomedical Journal.2025; 48(3): 100771. CrossRef
Impact of glucagon‐like peptide‐1 receptor agonists on diabetic retinopathy: A meta‐analysis of clinical studies emphasising retinal changes as a primary outcome
Ishani Kapoor, Swara M. Sarvepalli, David A. D'Alessio, Majda Hadziahmetovic
Clinical & Experimental Ophthalmology.2025; 53(1): 67. CrossRef
SGLT2 inhibitors and diabetic retinopathy: Insights from the management of nephropathy
Maria S. Varughese, Lakshminarayanan Varadhan
Eye.2025; 39(2): 213. CrossRef
Impact of Obstructive Sleep Apnea on Diabetic Retinopathy Progression and Systemic Complications
Ehsan Rahimy, Euna B. Koo, Karen M. Wai, Cassie A. Ludwig, Andrea L. Kossler, Prithvi Mruthyunjaya
American Journal of Ophthalmology.2025; 270: 93. CrossRef
An update on ocular effects of antidiabetic medications
Elham Sadeghi, Elham Rahmanipour, Nicola Valsecchi, Saloni Kapoor, Maria Vittoria Cicinelli, Jay Chhablani
Survey of Ophthalmology.2025; 70(4): 704. CrossRef
Glucagon-like peptide-1 receptor agonists and the eye
David L. Zhang, Avni P. Finn
Current Opinion in Ophthalmology.2025; 36(5): 407. CrossRef
Ocular outcomes of the sodium-glucose cotransport inhibitors: A systematic review of cohort studies
Nathaniel Eraikhuemen, Bria George, Simon Leung, Shalonda Barnes Warren, Valerie Marcellus, Delany Santos Ferrer, Quovadis Epps
Journal of Clinical Ophthalmology and Research.2025; 13(2): 220. CrossRef
Linear and non-linear association of chronic kidney disease with retina and choroid vessel density in diabetes: a prospective study
Lijian Fang, Ruiheng Zhang, Suoqing Zhuang, Lei Wang, Qiuping Wang, Yong Huang, Mingli Wang, Yu Feng, Min Xiao, Chunyuan Zhou, Lili Wu, Sihan Zhang, Lili Xue, Tong Tian, Yuanyuan Li, Bing Cao, Huaiyu Hao
Photodiagnosis and Photodynamic Therapy.2025; 53: 104625. CrossRef
Comparison of Sodium‐Glucose Cotransporter 2 Inhibitors Versus Glucagon‐Like Peptide‐1 Receptor Agonists and Risks of Osteoarthritis and Arthroplasty in Patients With Type 2 Diabetes Mellitus: A Propensity Score‐Matched Cohorts Retrospective Study
Yu‐Chi Su, Pei‐Chun Hsieh, Edward Chia‐Cheng Lai, Yu‐Ching Lin
Diabetes/Metabolism Research and Reviews.2025;[Epub] CrossRef
New generation agents for glycemic control and diabetic retinopathy progression: what we need to know?
Stela Vujosevic, Caterina Toma, Anna Ferrulli, Stefano De Cillà, Paolo Nucci, Livio Luzi
Acta Diabetologica.2025; 62(10): 1573. CrossRef
Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial
Tomoaki Tatsumi, Yoko Takatsuna, Ryoichi Ishibashi, Masaya Koshizaka, Tomomi Kaiho, Toshiyuki Oshitari, Yuki Shiko, Noriko Asaumi, Shuichi Yamamoto, Koutaro Yokote, Takayuki Baba
Diabetes, Obesity and Metabolism.2025; 27(10): 5812. CrossRef
Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?
Kai Liu, Shu Liu, Dong Wang, Hong Qiao
Diabetes & Metabolism.2025; 51(6): 101696. CrossRef
Impact of SGLT2 inhibitors on the risk of age‐related ocular diseases in patients with type 2 diabetes mellitus: A target trial emulation study
Yueh‐Tsung Lee, Jheng‐Yan Wu, Tsung W. Chang, Cheng‐Hsien Hung
Diabetes, Obesity and Metabolism.2025; 27(12): 7299. CrossRef
SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysis
Saba Goodarzi, Faezah Soltani Abhari, Gelareh Azarinoush, Mohammd Ali Rafiei, Hessam Yousefian, Ehsan Heidari, Edris Ekramipour, Afshin Mirzaei, Kosar Namakin, Arman Shafiee
International Ophthalmology.2025;[Epub] CrossRef
Semaglutide and diabetic retinopathy: an OHDSI network study
Cindy Xinji Cai, Akihiko Nishimura, Sally Baxter, Kerry Goetz, Michelle Hribar, Brian Toy, Andrew Barkmeier, Sophia Wang, Swarup Swaminathan, Alexis Flowers, Eric Brown, Benjamin Xu, John Chen, Aiyin Chen, Theodore Leng, Michael Boland, Thamir Alshammari,
BMJ Open Diabetes Research & Care.2025; 13(6): e005424. CrossRef
Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) – a systematic review and meta-analysis
Hassan Alwafi, Sarah Saleh Al-Harbi, Ghada Ahmad Aladwani, Safaa M. Alsanosi, Tope Oyelade, Fahd Almalki, Husna Irfan Thalib, Abdallah Y. Naser, Manal Z. Alfahmi, Basil AlOtaibi, Samra Fuad, Mohammed Talha Mohammed Zubair, Abdulelah M. Aldhahir, Widya N.
Frontiers in Medicine.2025;[Epub] CrossRef
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Suraj Bala, Kevin C. Allan, Nicole L. Decker, Nadia J. Abbass, Julia H. Joo, Alison Zhao, Katherine E. Talcott, Aleksandra V. Rachitskaya
Survey of Ophthalmology.2025;[Epub] CrossRef
Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies
Samuel Igweokpala, Naheemot Olaoluwa Sule, Antonios Douros, Oriana H. Y. Yu, Kristian B. Filion
Diabetes, Obesity and Metabolism.2024; 26(2): 721. CrossRef
Association of sodium–glucose cotransporter‐2 inhibitors and the risk of retinal vascular occlusion: A real‐world retrospective cohort study in Taiwan
Tzu‐Yi Lin, Eugene Yu‐Chuan Kang, Shih‐Chieh Shao, Edward Chia‐Cheng Lai, Nan‐Kai Wang, Sunir J. Garg, Kuan‐Jen Chen, Je‐Ho Kang, Wei‐Chi Wu, Chi‐Chun Lai, Yih‐Shiou Hwang
Diabetes/Metabolism Research and Reviews.2024;[Epub] CrossRef
Risk of rotator cuff tear and rotator cuff repair surgery comparison between sodium-glucose cotransporter 2 inhibitors and glucagon like peptide-1 receptor agonists: A real-world study
Yu-Chi Su, Pei-Chun Hsieh, Edward Chia-Cheng Lai, Yu-Ching Lin
Diabetes & Metabolism.2024; 50(2): 101522. CrossRef
Optimising renal risk parameters in type 2 diabetes mellitus: Perspectives from a retinal viewpoint
Sarita Jacob, George I. Varughese
Clinical Medicine.2024; 24(2): 100031. CrossRef
Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database
Aikaterini Eleftheriadou, David Riley, Sizheng S. Zhao, Philip Austin, Gema Hernández, Gregory Y. H. Lip, Timothy L. Jackson, John P. H. Wilding, Uazman Alam
Diabetologia.2024; 67(7): 1271. CrossRef
Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study
Karen M. Wai, Kapil Mishra, Euna Koo, Cassie Ann Ludwig, Ravi Parikh, Prithvi Mruthyunjaya, Ehsan Rahimy
American Journal of Ophthalmology.2024; 265: 39. CrossRef
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy
Andrew J. Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, Yihong Deng, Eric C. Polley, Guillermo E. Umpierrez, Rodolfo J. Galindo, Joseph S. Ross, Mindy M. Mickelson, Rozalina G. McCoy
Ophthalmology Retina.2024; 8(10): 943. CrossRef
Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis
Bo Xu, Bo Kang, Fan Tang, Jiecan Zhou, Zunbo He
Expert Review of Clinical Pharmacology.2024; 17(10): 949. CrossRef
Comparison of the Risk of Diabetic Retinopathy Between Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus in Japan: A Retrospective Analysis of Real-World Data
Masaya Koshizaka, Tomoaki Tatsumi, Fumiko Kiyonaga, Yoshinori Kosakai, Yoko Yoshinaga, Mami Shintani-Tachi
Diabetes Therapy.2024; 15(11): 2401. CrossRef
NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY
Rithwick Rajagopal, Janet B. McGill
Retina.2024; 44(11): 1851. CrossRef
Mechanism and therapeutic targets of circulating immune cells in diabetic retinopathy
Bowen Zhao, Yin Zhao, Xufang Sun
Pharmacological Research.2024; 210: 107505. CrossRef
Diabetes Renders Photoreceptors Susceptible to Retinal Ischemia-Reperfusion Injury
David A. Antonetti, Cheng-Mao Lin, Sumathi Shanmugam, Heather Hager, Manjing Cao, Xuwen Liu, Alyssa Dreffs, Adam Habash, Steven F. Abcouwer
Investigative Ophthalmology & Visual Science.2024; 65(13): 46. CrossRef
Multi-omics in exploring the pathophysiology of diabetic retinopathy
Xinlu Li, XiaoJing Dong, Wen Zhang, Zhizhou Shi, Zhongjian Liu, Yalian Sa, Li Li, Ninghua Ni, Yan Mei
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
Tzu-Yi Lin, Eugene Yu-Chuan Kang, Shih-Chieh Shao, Edward Chia-Cheng Lai, Yih-Shiou Hwang
Diabetes & Metabolism Journal.2023; 47(4): 573. CrossRef
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
Jihee Ko, Sun Joon Moon
Diabetes & Metabolism Journal.2023; 47(4): 571. CrossRef
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes
Fu-Shun Yen, James Cheng-Chung Wei, Teng-Shun Yu, Yu-Tung Hung, Chih-Cheng Hsu, Chii-Min Hwu
JAMA Network Open.2023; 6(12): e2348431. CrossRef

Drug Regimen
Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial: Kyung Ah Han, Yong Hyun Kim, Doo Man Kim, Byung Wan Lee, Suk Chon, Tae Seo Sohn, In Kyung Jeong, Eun-Gyoung Hong, Jang Won Son, Jae Jin Nah, Hwa Rang Song, Seong In Cho, Seung-Ah Cho, Kun Ho Yoon; Diabetes Metab J. 2023;47(6):796-807. Published online February 9, 2023; DOI: https://doi.org/10.4093/dmj.2022.0315

52,064 View
859 Download
15 Web of Science
17 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Enavogliflozin is a novel sodium-glucose cotransporter-2 inhibitor currently under clinical development. This study evaluated the efficacy and safety of enavogliflozin as an add-on to metformin in Korean patients with type 2 diabetes mellitus (T2DM) against dapagliflozin.
Methods
In this multicenter, double-blind, randomized, phase 3 study, 200 patients were randomized to receive enavogliflozin 0.3 mg/day (n=101) or dapagliflozin 10 mg/day (n=99) in addition to ongoing metformin therapy for 24 weeks. The primary objective of the study was to prove the non-inferiority of enavogliflozin to dapagliflozin in glycosylated hemoglobin (HbA1c) change at week 24 (non-inferiority margin of 0.35%) (Clinical trial registration number: NCT04634500).
Results
Adjusted mean change of HbA1c at week 24 was –0.80% with enavogliflozin and –0.75% with dapagliflozin (difference, –0.04%; 95% confidence interval, –0.21% to 0.12%). Percentages of patients achieving HbA1c <7.0% were 61% and 62%, respectively. Adjusted mean change of fasting plasma glucose at week 24 was –32.53 and –29.14 mg/dL. An increase in urine glucose-creatinine ratio (60.48 vs. 44.94, P<0.0001) and decrease in homeostasis model assessment of insulin resistance (–1.85 vs. –1.31, P=0.0041) were significantly greater with enavogliflozin than dapagliflozin at week 24. Beneficial effects of enavogliflozin on body weight (–3.77 kg vs. –3.58 kg) and blood pressure (systolic/diastolic, –5.93/–5.41 mm Hg vs. –6.57/–4.26 mm Hg) were comparable with those of dapagliflozin, and both drugs were safe and well-tolerated.
Conclusion
Enavogliflozin added to metformin significantly improved glycemic control in patients with T2DM and was non-inferior to dapagliflozin 10 mg, suggesting enavogliflozin as a viable treatment option for patients with inadequate glycemic control on metformin alone.

Citations

Citations to this article as recorded by

Pharmacokinetic comparison between fixed-dose combination and loose combination of enavogliflozin 0.3 mg and metformin HCl 1000 mg in healthy subjects under fasting and fed conditions
Surim Meagan Kim, Wonsuk Shin, A.-Young Yang, Anhye Kim, Yil-Seob Lee, Jaejin Na, Jae Min Cho, Seoyeon Yoon, Hyounggyoon Yoo
Naunyn-Schmiedeberg's Archives of Pharmacology.2026;[Epub] CrossRef
Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP)
Nam Hoon Kim, Soo Lim, In-Kyung Jeong, Eun-Jung Rhee, Jun Sung Moon, Ohk-Hyun Ryu, Hyuk-Sang Kwon, Jong Chul Won, Sang Soo Kim, Sang Yong Kim, Bon Jeong Ku, Heung Yong Jin, Sin Gon Kim, Bong-Soo Cha
Diabetes & Metabolism Journal.2025; 49(2): 225. CrossRef
Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis
Leqing Xu, Yike Wu, Jiyifan Li, Yanan Ding, Junwei Chow, Longzhou Li, Haiyang Liu, Zihan Wang, Tingting Gong, Yue Li, Guo Ma
BMJ Open.2025; 15(2): e088687. CrossRef
Reverse translational approach to clarify the strong potency of enavogliflozin, a novel sodium-glucose cotransporter 2 inhibitor
Sun-Hwa Park, Hye-Young Ji, Ji-Soo Choi, Kyung Seok Oh, Jihoon Lee, Minyeong Pang, Im-Sook Song, Joon Seok Park
The Journal of Pharmacology and Experimental Therapeutics.2025; 392(8): 103650. CrossRef
Combined effects of Yupingfeng and metformin on blood glucose levels and intestinal tissue in high-fat diet-induced type 2 diabetic rats
Hui Liu, Yuan Guan, Like Xu, Ji Hu
Frontiers in Endocrinology.2025;[Epub] CrossRef
Comparison of safety profile of DPP4 inhibitors with SGLT2 inhibitors in type 2 diabetes mellitus: systematic review
Zeel R. Nimavat, Ankit N. Patel, Alpa P. Gor, Barna Ganguly
International Journal of Basic & Clinical Pharmacology.2025;[Epub] CrossRef
Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes
Young Sang Lyu, Hansol Lee, Kyung-Soo Kim, Sangmo Hong, Cheol-Young Park
Cardiovascular Diabetology.2025;[Epub] CrossRef
Pharmacokinetics and Safety of Fixed‐Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects
Young‐Sim Choi, JAEJIN NA, Seo Yeong Park, Jae Min Cho, Yoonhye Jeong, Jun Gi Hwang
Clinical and Translational Science.2025;[Epub] CrossRef
Inhibitors of sodium-glucose cotransporter: When wasting fuel is sought and beneficial to health
Francois Alhenc-Gelas
The Journal of Pharmacology and Experimental Therapeutics.2025; 392(11): 103742. CrossRef
Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials
Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol-Young Park
Cardiovascular Diabetology.2024;[Epub] CrossRef
A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
Tae Seo Sohn, Kyung‐Ah Han, Yonghyun Kim, Byung‐Wan Lee, Suk Chon, In‐Kyung Jeong, Eun‐Gyoung Hong, Jang Won Son, JaeJin Na, Jae Min Cho, Seong In Cho, Wan Huh, Kun‐Ho Yoon
Diabetes, Obesity and Metabolism.2024; 26(6): 2248. CrossRef
The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter‐2 inhibitor, in type 2 diabetes
Sae Im Jeong, Mu Seong Ban, Jun‐Gi Hwang, Min‐Kyu Park, Soo Lim, Sejoong Kim, Soon Kil Kwon, Yoonjin Kim, Jae Min Cho, Jae Jin Na, Wan Huh, Jae‐Yong Chung
Diabetes, Obesity and Metabolism.2024; 26(7): 2588. CrossRef
Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial
Soo Heon Kwak, Kyung Ah Han, Eun Sook Kim, Sung Hee Choi, Jong Chul Won, Jae Myung Yu, Seungjoon Oh, Hye Jin Yoo, Chong Hwa Kim, Kyung‐Soo Kim, SungWan Chun, Yong Hyun Kim, Seung Ah Cho, Da Hye Kim, Kyong Soo Park
Diabetes, Obesity and Metabolism.2024; 26(10): 4203. CrossRef
Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis
Deep Dutta, B.G. Harish, Beatrice Anne, Lakshmi Nagendra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(8): 102816. CrossRef
Characteristics of the Latest Therapeutic Agent for Diabetes
Nuri Yun
The Journal of Korean Diabetes.2023; 24(3): 148. CrossRef
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome.2023; (5): 8. CrossRef
Navigating the Future of Diabetes Treatment with New Drugs: Focusing on the Possibilities and Prospects of Enavogliflozin
Sang Youl Rhee
Diabetes & Metabolism Journal.2023; 47(6): 769. CrossRef

Review

Pathophysiology
Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics: Nam Hoon Kim, Nan Hee Kim; Diabetes Metab J. 2022;46(4):543-551. Published online July 27, 2022; DOI: https://doi.org/10.4093/dmj.2022.0209

28,254 View
1,531 Download
32 Web of Science
38 Crossref

Abstract PDF PubReader ePub

Diabetic kidney disease (DKD) is a prevalent renal complication of diabetes mellitus that ultimately develops into end-stage kidney disease (ESKD) when not managed appropriately. Substantial risk of ESKD remains even with intensive management of hyperglycemia and risk factors of DKD and timely use of renin-angiotensin-aldosterone inhibitors. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce hyperglycemia primarily by inhibiting glucose and sodium reabsorption in the renal proximal tubule. Currently, their effects expand to prevent or delay cardiovascular and renal adverse events, even in those without diabetes. In dedicated renal outcome trials, SGLT2 inhibitors significantly reduced the risk of composite renal adverse events, including the development of ESKD or renal replacement therapy, which led to the positioning of SGLT2 inhibitors as the mainstay of chronic kidney disease management. Multiple mechanisms of action of SGLT2 inhibitors, including hemodynamic, metabolic, and anti-inflammatory effects, have been proposed. Restoration of tubuloglomerular feedback is a plausible explanation for the alteration in renal hemodynamics induced by SGLT2 inhibition and for the associated renal benefit. This review discusses the clinical rationale and mechanism related to the protection SGLT2 inhibitors exert on the kidney, focusing on renal hemodynamic effects.

Citations

Citations to this article as recorded by

Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
Diabetes, Obesity and Metabolism.2026; 28(3): 1764. CrossRef
Glycemic control and renal function decline in patients with chronic coronary syndrome: A multicenter cohort study
An‐Yu Cheng, Chin‐Chou Huang, Hsin‐Bang Leu, Wei‐Hsian Yin, Wei‐Kung Tseng, Yen‐Wen Wu, Tsung‐Hsien Lin, Hung‐I Yeh, Kuan‐Cheng Chang, Ji‐Hung Wang, Chau‐Chung Wu, Jaw‐Wen Chen
Journal of Diabetes Investigation.2026;[Epub] CrossRef
Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors
Lorenzo Falsetti, Nicola Tarquinio, Luciano Mucci, Silvia Santini, Emanuele Guerrieri, Laura Giovenali, Giulia Pierdomenico, Vincenzo Zaccone, Giovanna Viticchi, Gianluca Moroncini
European Journal of Clinical Pharmacology.2026;[Epub] CrossRef
Unveiling the immune microenvironment in diabetic nephropathy: from mechanisms to therapeutics
Tao Jiang, Ran Chen, Jianying Chang, Jiajia Duan, Yanqiu Wang, Yuhan Sun, Xiaowan Chen, Yujin Ma, Liwen Zhang, Hongwei Jiang, Hetao Chen
Frontiers in Immunology.2026;[Epub] CrossRef
The Paradigm Shift in the Management of Diabetic Kidney Disease: A Comprehensive Review of the Four Pillars of Therapy
Y. J. Anupama
APIK Journal of Internal Medicine.2026; 14(2): 86. CrossRef
Real-world longitudinal trends in glycaemic control, renal function, and lipid profiles among Malaysian patients receiving sodium–glucose cotransporter 2 inhibitors
Abdullah Faiz Zaihan, Nurul Ameera Huda Mohamad Hafiz, Nur Irdina Athilah Khairul Hazamy, Aisyah Zahraa Termizy, Nurul Izzah Roslan, Perishithaa M Ganesan, Sze Hwe Choe, Chia Siang Kow
Asian Heart Journal.2026; 2(1): 33. CrossRef
Dapagliflozin in diabetic kidney disease patients with different filtration status
Yang Yang, Manna Li, Honghong Zou, Pingping Yang, Li Wang, Gaosi Xu
European Journal of Pharmaceutical Sciences.2025; 207: 107045. CrossRef
Prevalence, Incidence, and Metabolic Characteristics of Young Adults with Type 2 Diabetes Mellitus in South Korea (2010–2020)
Ji Yoon Kim, Jiyoon Lee, Joon Ho Moon, Se Eun Park, Seung-Hyun Ko, Sung Hee Choi, Nam Hoon Kim
Diabetes & Metabolism Journal.2025; 49(2): 172. CrossRef
Adverse kidney events with initiation of SGLT2 inhibitors versus DPP4 inhibitors in diabetic people with a history of acute kidney injury
Yi‐Wei Kao, Tze‐Fan Chao, Yu‐Wen Cheng, Shao‐Wei Chen, Yi‐Hsin Chan
European Journal of Clinical Investigation.2025;[Epub] CrossRef
The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats
Adel Albanna, Doa’a Ibrahim, Amani Shamsher, Mojahed Al-Shawia, Abdulsalam Halboup
Journal of Experimental Pharmacology.2025; Volume 17: 467. CrossRef
Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study
Sangmo Hong, Kyungdo Han, Kyung-Soo Kim, Cheol-Young Park
Cardiovascular Diabetology.2025;[Epub] CrossRef
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management
Raymond Rubianto Tjandrawinata, Dante Saksono Harbuwono, Sidartawan Soegondo, Nurpudji Astuti Taslim, Fahrul Nurkolis
Pharmaceuticals.2025; 18(8): 1101. CrossRef
Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs
Syed Arman Rabbani, Mohamed El-Tanani, Rakesh Kumar, Manita Saini, Yahia El-Tanani, Shrestha Sharma, Alaa A. A. Aljabali, Eman Hajeer, Manfredi Rizzo
Pharmaceuticals.2025; 18(8): 1130. CrossRef
Impact of SGLT2 Inhibitors Use on Risk of Postoperative Acute Kidney Injury Following Metabolic and Bariatric Surgery: A Retrospective Study
I-Wen Chen, Li-Chen Chang, Jheng-Yan Wu, Chun-Ning Ho, Ya-Wen Tsai, Ping-Hsin Liu, Kuo-Chuan Hung
Obesity Surgery.2025; 35(9): 3599. CrossRef
Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect
Alessio Mazzieri, Livia Maria Rita Marcon
Biomedicines.2025; 13(9): 2123. CrossRef
The effect of empagliflozin on renal outcomes compared to sitagliptin with type 2 diabetes: target trial emulation using electronic medical records
Min Ju Kang, Hyun Kyung Lee, Minoh Ko, Ha Young Jang, In-Wha Kim, Jung Mi Oh
International Journal of Clinical Pharmacy.2025; 48(2): 569. CrossRef
Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings from Anam Diabetes Observational Study
Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
Diabetes & Metabolism Journal.2025; 49(6): 1287. CrossRef
Mechanistic insights and clinical horizons of SGLT2 inhibitors in heart failure management
Samin Sadeghi Vahid, Marziyeh Salehi Jahromi, George V. Moukarbel, Jennifer W. Hill
Trends in Cardiovascular Medicine.2025;[Epub] CrossRef
Using intravoxel incoherent motion imaging to evaluate uric acid-induced renal injury and efficacy after treatment
Zhong-Yuan Cheng, Shang-Ao Gong, Ping-Kang Chen, Zong-Chao Yu, Chen Qiu, Ji-Xin Lin, Jia-Bin Mo, Long Qian, You-Zhen Feng, Xiang-Ran Cai
British Journal of Radiology.2024; 97(1153): 274. CrossRef
Rethinking eGFR Comparisons in SGLT2 Inhibitor Research
Yuzuru Ohshiro
Journal of the American College of Cardiology.2024; 83(9): e87. CrossRef
SGLT2 Inhibitors and Diabetes: Where Does It Come from and Where Does It Go?
Ji Yoon Kim, Sin Gon Kim
The Journal of Korean Diabetes.2024; 25(1): 9. CrossRef
Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history
Jin Hwa Kim, Young Sang Lyu, BongSeong Kim, Mee Kyung Kim, Sang Yong Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon
Diabetes, Obesity and Metabolism.2024; 26(7): 2567. CrossRef
Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease
Masatoshi Yoshimoto, Akinari Sekine, Tatsuya Suwabe, Yuki Oba, Hiroki Mizuno, Masayuki Yamanouchi, Yoshifumi Ubara, Junichi Hoshino, Noriko Inoue, Kiho Tanaka, Eiko Hasegawa, Naoki Sawa, Takehiko Wada
Clinical Kidney Journal.2024;[Epub] CrossRef
A new perspective on proteinuria and drug therapy for diabetic kidney disease
Ruimin Zhang, Qian Wang, Yaqing Li, Qihu Li, Xuefeng Zhou, Xiangmei Chen, Zheyi Dong
Frontiers in Pharmacology.2024;[Epub] CrossRef
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Hae Kyung Kim, Geert Jan Biessels, Min Heui Yu, Namki Hong, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Eun Jig Lee, Minyoung Lee
Neurology.2024;[Epub] CrossRef
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)
A. A. Avagimyan, M. Sheibani, A. I. Trofimenko, E. E. Lysov, F. M. Khamidova, A. Z. Aznauryan, L. M. Sukiasyan, K. T. Sahakyan, T. R. Gevorgyan, M. R. Tatoyan, G. L. Mkrtchyan, G. L. Meltonyan, A. R. Petrosyan, L. A. Martemyanova, R. R. Petrosyan, O. I. U
Innovative Medicine of Kuban.2024; (4): 126. CrossRef
Association of Succinate and Adenosine Nucleotide Metabolic Pathways with Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus
Inha Jung, Seungyoon Nam, Da Young Lee, So Young Park, Ji Hee Yu, Ji A Seo, Dae Ho Lee, Nan Hee Kim
Diabetes & Metabolism Journal.2024; 48(6): 1126. CrossRef
Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
Jin Hwa Kim, Junyeop Lee, Kyungdo Han, Jae-Taek Kim, Hyuk-Sang Kwon
Diabetes & Metabolism Journal.2024; 48(6): 1084. CrossRef
Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis
Yunke Ma, Chu Lin, Xiaoling Cai, Suiyuan Hu, Xingyun Zhu, Fang Lv, Wenjia Yang, Linong Ji
Acta Diabetologica.2023; 60(3): 435. CrossRef
Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials
Mengnan Li, Jian Zhang, Guimei Yang, Jiaxin Zhang, Minmin Han, Yi Zhang, Yunfeng Liu
European Journal of Clinical Pharmacology.2023; 79(6): 859. CrossRef
Age at Mortality in Patients with Type 2 Diabetes Who Underwent Kidney Transplantation: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
Sun Ok Song, Eugene Han, Kang Ju Son, Bong-Soo Cha, Byung-Wan Lee
Journal of Clinical Medicine.2023; 12(9): 3160. CrossRef
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
Sjoukje van der Hoek, Jeroen V. Koomen, Erik J. M. van Bommel, Charlotte M. Mosterd, Rosalie A. Scholtes, Anne C. Hesp, Jasper Stevens, Daniel H. van Raalte, Hiddo J. L. Heerspink
Journal of Personalized Medicine.2023; 13(5): 747. CrossRef
Osteopontin as a Biomarker in Chronic Kidney Disease
Satyesh K. Sinha, Michael Mellody, Maria Beatriz Carpio, Robert Damoiseaux, Susanne B. Nicholas
Biomedicines.2023; 11(5): 1356. CrossRef
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
Metabolism.2023; 145: 155612. CrossRef
Synthesis and biological profile of benzoxazolone derivatives
Parteek Prasher, Tanisqa Mall, Mousmee Sharma
Archiv der Pharmazie.2023;[Epub] CrossRef
SGLT2 inhibitors prevent LPS-induced M1 macrophage polarization and alleviate inflammatory bowel disease by downregulating NHE1 expression
Ye Jin Kim, Jonghwa Jin, Dong-Ho Kim, Daehoon Kim, You Mie Lee, Jun-Kyu Byun, Yeon-Kyung Choi, Keun-Gyu Park
Inflammation Research.2023; 72(10-11): 1981. CrossRef
Potential Antidiabetic Compounds from Anogeissus leiocarpus: Molecular Docking, Molecular Dynamic Simulation, and ADMET Studies
Mubarak Muhammad Dahiru, Neksumi Musa, AbdulAzeez Mumsiri Abaka, Maimuna Abdulrahman Abubakar
Borneo Journal of Pharmacy.2023; 6(3): 249. CrossRef
Reducing Oxygen Demand to Alleviate Acute Kidney Injury
Xiaoming Zhou
Frontiers in Bioscience-Landmark.2023;[Epub] CrossRef

Original Articles

Drug/Regimen
Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance: Jun Sung Moon, Nam Hoon Kim, Jin Oh Na, Jae Hyoung Cho, In-Kyung Jeong, Soon Hee Lee, Ji-Oh Mok, Nan Hee Kim, Dong Jin Chung, Jinhong Cho, Dong Woo Lee, Sun Woo Lee, Kyu Chang Won; Diabetes Metab J. 2023;47(1):82-91. Published online June 20, 2022; DOI: https://doi.org/10.4093/dmj.2021.0356

12,360 View
418 Download
5 Web of Science
6 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To evaluate the safety and effectiveness of empagliflozin in routine clinical settings, we collected and assessed the clinical profiles of Korean patients with type 2 diabetes mellitus.
Methods
This was a post-marketing surveillance study of empagliflozin 10 and 25 mg. Information on adverse events and adverse drug reactions (ADRs) was collected as safety data sets. Available effectiveness outcomes, including glycosylated hemoglobin (HbA1c) level, fasting plasma glucose, body weight, and blood pressure, were assessed.
Results
The incidence rate of ADRs was 5.14% in the safety dataset (n=3,231). Pollakiuria, pruritis genital, and weight loss were the most common ADRs. ADRs of special interest accounted for only 1.18%, and there were no serious events that led to mortality or hospitalization. In the effectiveness data set (n=2,567), empagliflozin significantly reduced the mean HbA1c level and body weight during the study period by –0.68%±1.39% and –1.91±3.37 kg (both P<0.0001), respectively. In addition, shorter disease duration, absence of dyslipidemia, and higher baseline HbA1c levels were identified as the clinical features characteristic of a “responder” to empagliflozin therapy.
Conclusion
Empagliflozin is a safe and potent glucose-lowering drug in routine use among Korean patients with type 2 diabetes mellitus. It is expected to have better glycemic efficacy in Korean patients with poorly controlled type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Impact of a structured nurse-delivered multi component SGLT2 inhibitor initiation and optimization pathway on kidney function and clinical outcomes in type 2 diabetes and chronic kidney disease: a real-world retrospective study
Liang Huang, Yi Muhui
BMC Nephrology.2026;[Epub] CrossRef
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
Jae Hyun Bae
Diabetes & Metabolism Journal.2025; 49(3): 386. CrossRef
Evaluation of Efficacy and Safety of Empagliflozin in Bangladeshi Patients with Type 2 Diabetes Mellitus (EFFISAEM Study)
Mohammad Saifuddin, Ajit K. Paul, Sultana M. Shefin, Md. Jahangir Alam, Shahjada Selim, Sunjida Islam, Tanjina Hossain, Sadiqa Tuqan, Nusrat Sultana, Marufa Mustari, Ramen C. Basak, Kazi A. Aftab, Indrajit Prasad, Mohammad R. Uddin, Shoma Sharker, Md. Abu
Indian Journal of Endocrinology and Metabolism.2024; 28(5): 500. CrossRef
Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trial
Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, Hisako Yoshida, Yosuke Okada, Toshinari Takamura, Isao Taguchi, Shigeru Toyoda, Hirofumi Tomiyama, Shinichiro Ueda, Yukihito Higashi, Koichi Node, Junya Ako, Hirohisa Amano, Itaru Hisauchi, Yumi Ikehara
Hypertension Research.2024; 47(9): 2295. CrossRef
Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
Xu Jiang, Sungyeun Bae, Deok Yong Yoon, Shin Jung Park, Jaeseong Oh, Joo-Youn Cho, Kyung-Sang Yu
Drug Design, Development and Therapy.2023; Volume 17: 2137. CrossRef
Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
Chun Xing Li, Li Yan Liu, Chen Xiao Zhang, Xu Hua Geng, Si Meng Gu, Yu Qiao Wang, Hua Liu, Qing Xie, Shuo Liang
Frontiers in Endocrinology.2023;[Epub] CrossRef

Drug/Regimen
Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: Jong Ha Baek, Ye Seul Yang, Seung-Hyun Ko, Kyung Do Han, Jae Hyeon Kim, Min Kyong Moon, Jong Suk Park, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Jong Han Choi, Kyu Yeon Hur, Committee of Clinical Practice Guidelines, Korean Diabetes Association; Diabetes Metab J. 2022;46(5):701-712. Published online June 3, 2022; DOI: https://doi.org/10.4093/dmj.2022.0002

9,773 View
386 Download
22 Web of Science
27 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background
To evaluate prescription trends and clinical factors of the sodium-glucose cotransporter 2 inhibitors (SGLT2i) use according to the presence of atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) in Korean patients with type 2 diabetes mellitus (T2DM).
Methods
Prescription patterns of SGLT2i use between 2015 and 2019 were determined using the Korean National Health Insurance Service database of claims.
Results
Of all patients with T2DM (n=4,736,493), the annual prescription rate of SGLT2i increased every year in patients with ASCVD (from 2.2% to 10.7%) or HF (from 2.0% to 11.1%). After the first hospitalization for ASCVD (n=518,572), 13.7% (n=71,259) of patients initiated SGLT2i with a median of 10.6 months. After hospitalization for HF (n=372,853), 11.2% (n=41,717) of patients initiated SGLT2i after a median of 8.8 months. In multivariate regression for hospitalization, older age (per 10 years, odds ratio [OR], 0.57; 95% confidence interval [CI], 0.56 to 0.57), lower household income (OR, 0.93; 95% CI, 0.92 to 0.95), rural residents (OR, 0.95; 95% CI, 0.93 to 0.97), and dipeptidyl peptidase-4 inhibitor (DPP-4i) users (OR, 0.82; 95% CI, 0.81 to 0.84) were associated with lesser initiation of SGLT2i in ASCVD. Additionally, female gender (OR, 0.97; 95% CI, 0.95 to 0.99) was associated with lesser initiation of SGLT2i in HF.
Conclusion
The prescription rate of SGLT2i increased gradually up to 2019 but was suboptimal in patients with ASCVD or HF. After the first hospitalization for ASCVD or HF, older age, female gender, low household income, rural residents, and DPP-4i users were less likely to initiate SGLT2i.

Citations

Citations to this article as recorded by

Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database
Kazuki Aoyama, Akira Okada, Hidehiro Kaneko, Tatsuhiko Azegami, Yuta Suzuki, Shu Meguro, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Koichi Node, Toshimasa Yamauchi, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi
Diabetes, Obesity and Metabolism.2026; 28(1): 701. CrossRef
Prescription Patterns and Associated Factors of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Use Among Patients Worldwide: A Systematic Review and Meta-Analysis of Real-World Studies
Man Xu, Quanzhi Li, Ning Chen, Xi Zhang, Wei Zhang
Journal of the American Medical Directors Association.2026; 27(2): 106036. CrossRef
Sex Differences in Antiarrhythmic Effects of Empagliflozin
Miyo Nakano, Yusuke Kondo, Shinya Fujiki, Yuki Shiko, Yohei Kawasaki, Yoshihisa Nakagawa, Kazuyoshi Takahashi, Masaaki Okabe, Kengo Kusano, Shingen Owada, Kenichi Tsujita, Yoshiaki Kubota, Hirofumi Tomita, Toshihisa Anzai, Kenichi Iijima, Takahiro Tanaka,
JACC: Asia.2026;[Epub] CrossRef
Association of Social Determinants of Health with Utilization of SGLT2 Inhibitors and GLP1 Receptor Agonists: A Systematic Review and Meta-Analysis
Nisarg Shah, Johann Alexandre Chafa Edjimbi, Melissa Daou, Alyssa A. Grimshaw, Craig Gunderson, Shaili Gupta
Journal of General Internal Medicine.2026;[Epub] CrossRef
Validation and Comparison of ASCVD Risk Score and SCORE2-Diabetes in Japanese Patients with Diabetes Mellitus
Yu Suresvar Singh, Yutaka Nakamura, Yuya Matsue, Hanako Inoue, Yuka Akama, Yudai Fujimoto, Taishi Dotare, Taisuke Nakade, Tadao Aikawa, Daichi Maeda, Hirohisa Endo, Akihiro Mochida, Mika Kurita, Fuki Ikeda, Hirotaka Watada, Tohru Minamino
International Heart Journal.2026; 67(2): 170. CrossRef
Maladie rénale du diabétique de type 2 : plutôt i-SGLT2 que AR-GLP1. Mais sont-ils suffisamment prescrits dans cette indication ?
Serge Halimi
Médecine des Maladies Métaboliques.2026;[Epub] CrossRef
Real-world prescription patterns of guideline-recommended therapies in heart failure across China
Yingming Zheng, Heng Guo, Wanqing Song, Xiao Luo, Hongge Yang, Zhenning Lu, Xingang Li, Dandan Li
Naunyn-Schmiedeberg's Archives of Pharmacology.2026;[Epub] CrossRef
Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Jin Komuro, Toshiyuki Ko, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Masaki Ieda, Koichi Node, Hideo Yasunaga, Masaomi Nangaku, Issei Komuro
Nephrology Dialysis Transplantation.2025; 40(3): 495. CrossRef
Evaluating the appropriateness and the factors associated with sodium-glucose co-transporter 2 inhibitors prescribing in a Middle Eastern country: a cross-sectional study
Nancy Zaghloul, Ahmed Awaisu, Ahmed Mahfouz, Zainab Ali, Sumaya Alyafei, Hazem Elewa
International Journal of Clinical Pharmacy.2025; 47(2): 314. CrossRef
Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim
Journal of Diabetes Investigation.2025; 16(2): 215. CrossRef
Prescribing patterns of SGLT-2 inhibitors and their association with heart failure readmissions: a single-center cross-sectional study from a low- and middle-income country
Abrar Ali Chhachhar, Saadia Sattar, Farhala Baloch, Umair Javed, Maria Wajid, Salva Shariq, Muhammad Qamar Masood
Hospital Practice.2025;[Epub] CrossRef
Assessing the application of American Heart Association (AHA) guidelines in the management of heart failure with reduced ejection fraction
Sima Sobhani Shahri, Zahra Pirayesh, Azar Zare Noughabi, Marzieh Heshmati, Saeede Khosravi Bizhaem, Shima Jafari, Toba Kazemi
The Egyptian Heart Journal.2025;[Epub] CrossRef
Optimisation of care among patients with diabetes mellitus and acute coronary syndrome through a specialised cardiodiabetes service—A registry study
Muhammad Usman Shah, Alun Roebuck, Bala Srinivasan, Paul Edward Squires, Claire Elizabeth Hills, Maxime Inghels, Kelvin Lee
Diabetic Medicine.2025;[Epub] CrossRef
A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial
Sangyong Jo, Kyungil Park, Jae Hyuk Choi, Chang‐Bae Sohn, Jeonghwan Kim, Yong‐Seop Kwon, Su Hong Kim, Tae‐ho Park
Journal of the American Heart Association.2025;[Epub] CrossRef
Prescribing Patterns of SGLT2 Inhibitors and GLP‐1 Receptor Agonists in Patients With T2DM and ASCVD in South Korea
Yeong Rok Eom, Hajung Joo, Seung Eun Chae, Nam Kyung Je
Pharmacoepidemiology and Drug Safety.2025;[Epub] CrossRef
Effectiveness and safety of sodium–glucose cotransporter 2 inhibitors in Asian populations
Kyoung Hwa Ha, Dae Jung Kim
Journal of Diabetes Investigation.2024; 15(3): 285. CrossRef
Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study
Ye Seul Yang, Nam Hoon Kim, Jong Ha Baek, Seung-Hyun Ko, Jang Won Son, Seung-Hwan Lee, Sang Youl Rhee, Soo-Kyung Kim, Tae Seo Sohn, Ji Eun Jun, In-Kyung Jeong, Chong Hwa Kim, Keeho Song, Eun-Jung Rhee, Junghyun Noh, Kyu Yeon Hur
Diabetes & Metabolism Journal.2024; 48(2): 279. CrossRef
Hospital Readmissions for Fluid Overload among Individuals with Diabetes and Diabetic Kidney Disease: Risk Factors and Multivariable Prediction Models
Jiashen Cai, Dorothy Huang, Hanis Binte Abdul Kadir, Zhihua Huang, Li Choo Ng, Andrew Ang, Ngiap Chuan Tan, Yong Mong Bee, Wei Yi Tay, Chieh Suai Tan, Cynthia C. Lim
Nephron.2024; 148(8): 523. CrossRef
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Ja Young Jeon, Dae Jung Kim
Diabetes & Metabolism Journal.2024; 48(5): 837. CrossRef
Impact of Chronic Kidney Disease and Gout on End-Stage Renal Disease in Type 2 Diabetes: Population-Based Cohort Study
Inha Jung, Da Young Lee, Seung Min Chung, So Young Park, Ji Hee Yu, Jun Sung Moon, Ji A Seo, Kyungdo Han, Nan Hee Kim
Endocrinology and Metabolism.2024; 39(5): 748. CrossRef
Income-Related Disparities in Mortality Among Young Adults With Type 2 Diabetes
Ji Yoon Kim, Sojeong Park, Minae Park, Nam Hoon Kim, Sin Gon Kim
JAMA Network Open.2024; 7(11): e2443918. CrossRef
Association of Succinate and Adenosine Nucleotide Metabolic Pathways with Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus
Inha Jung, Seungyoon Nam, Da Young Lee, So Young Park, Ji Hee Yu, Ji A Seo, Dae Ho Lee, Nan Hee Kim
Diabetes & Metabolism Journal.2024; 48(6): 1126. CrossRef
Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis
Teja Chakrala, Roshni O. Prakash, Justin Kim, Hanzhi Gao, Umar Ghaffar, Jaymin Patel, Alex Parker, Bhagwan Dass
American Heart Journal Plus: Cardiology Research and Practice.2023; 28: 100286. CrossRef
Risk of developing chronic kidney disease in young-onset Type 2 diabetes in Korea
Joonyub Lee, Seung-Hwan Lee, Kun-Ho Yoon, Jae Hyoung Cho, Kyungdo Han, Yeoree Yang
Scientific Reports.2023;[Epub] CrossRef
Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
Young Sang Lyu, Seok Oh, Jin Hwa Kim, Sang Yong Kim, Myung Ho Jeong
Cardiovascular Diabetology.2023;[Epub] CrossRef
Severe hypoglycemia as a risk factor for cardiovascular outcomes in patients with type 2 diabetes: is it preventable?
Seung-Hyun Ko
Cardiovascular Prevention and Pharmacotherapy.2022; 4(3): 106. CrossRef
Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis
Seung Min Chung, Ji-In Lee, Eugene Han, Hyun-Ae Seo, Eonju Jeon, Hye Soon Kim, Ji Sung Yoon
Endocrinology and Metabolism.2022; 37(5): 759. CrossRef

Cardiovascular Risk/Epidemiology
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus: Seung Eun Lee, Hyewon Nam, Han Seok Choi, Hoseob Kim, Dae-Sung Kyoung, Kyoung-Ah Kim; Diabetes Metab J. 2022;46(4):567-577. Published online February 8, 2022; DOI: https://doi.org/10.4093/dmj.2021.0160

11,049 View
421 Download
11 Web of Science
11 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Although cardiovascular outcome trials using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) showed a reduction in risk of 3-point major adverse cardiovascular events (MACE), they did not demonstrate beneficial effects on stroke risk. Additionally, meta-analysis showed SGLT-2i potentially had an adverse effect on stroke risk. Contrarily, pioglitazone, a type of thiazolidinedione (TZD), has been shown to reduce recurrent stroke risk. Thus, we aimed to compare the effect of SGLT-2i and TZD on the risk of stroke in type 2 diabetes mellitus (T2DM) patients.
Methods
Using the Korean National Health Insurance Service data, we compared a 1:1 propensity score-matched cohort of patients who used SGLT-2i or TZD from January 2014 to December 2018. The primary outcome was stroke. The secondary outcomes were myocardial infarction (MI), cardiovascular death, 3-point MACE, and heart failure (HF).
Results
After propensity-matching, each group included 56,794 patients. Baseline characteristics were well balanced. During the follow-up, 862 patients were newly hospitalized for stroke. The incidence rate of stroke was 4.11 and 4.22 per 1,000 person-years for the TZD and SGLT-2i groups respectively. The hazard ratio (HR) of stroke was 1.054 (95% confidence interval [CI], 0.904 to 1.229) in the SGLT-2i group compared to the TZD group. There was no difference in the risk of MI, cardiovascular death, 3-point MACE between groups. Hospitalization for HF was significantly decreased in SGLT-2i-treated patients (HR, 0.645; 95% CI, 0.466 to 0.893). Results were consistent regardless of prior cardiovascular disease.
Conclusion
In this real-world data, the risk of stroke was comparable in T2DM patients treated with SGLT-2i or TZD.

Citations

Citations to this article as recorded by

SGLT2 Inhibitors and Prevention of Cardiovascular Events in Diabetes Patients with and Without Hypertension: A Nationwide Cohort Study
Fu-Shun Yen, James Cheng-Chung Wei, Yao-Min Hung, Pei-Yun Li, Chih-Cheng Hsu, Chii-Min Hwu
Journal of General Internal Medicine.2026; 41(1): 143. CrossRef
The possible therapeutic role of advanced glycation end-product inhibitors in ischemic stroke
Nada H. Aljarba, Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Mustafa M. Shokr, Marios Papadakis, Athanasios Alexiou, Mubarak Alruwaili, Mohammed Alrouji, Mohammed S. Alshammari, Gaber El-Saber Batiha
Brain Research Bulletin.2025; 222: 111236. CrossRef
Comparative Effectiveness of Sodium-Glucose Co-transporter 2 Inhibitors and Thiazolidinediones in Reducing Adverse Cardiovascular Events in Type 2 Diabetes
Arshad Ali, Uzair Sohail, Talha Rao, Faryal Tariq, Abdul Moeed Baig, Syeda Ambreen Fatima
Cureus.2025;[Epub] CrossRef
Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
André J. Scheen
Diabetes Epidemiology and Management.2024; 13: 100179. CrossRef
Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
Inês Henriques Vieira, Tânia Santos Carvalho, Joana Saraiva, Leonor Gomes, Isabel Paiva
Biomedicines.2024; 12(5): 1102. CrossRef
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk
Thomas Nyström
Diabetes, Obesity and Metabolism.2024; 26(S5): 35. CrossRef
Comparison of Statin With Ezetimibe Combination Therapy Versus Statin Monotherapy for Primary Prevention in Middle-Aged Adults
Jung-Joon Cha, Soon Jun Hong, Subin Lim, Ju Hyeon Kim, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu, Do-Sun Lim, Jang Young Kim, Jin-Ok Jeong, Jeong-Hun Shin, Chi Young Shim, Jong-Young Lee, Young-Hyo Lim, Sung Ha Park, Eun Joo Cho, Hasung Kim, Jungkuk
Korean Circulation Journal.2024; 54(9): 534. CrossRef
A Green Approach: Optimization of the UPLC Method Using DoE Software for Concurrent Quantification of Pioglitazone and Dapagliflozin in a SNEDDS Formulation for the Treatment of Diabetes
Ehab M. Elzayat, Abdelrahman Y. Sherif, Mohamed W. Attwa, Mohammad A. Altamimi
ACS Omega.2024; 9(45): 45011. CrossRef
Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
Jin Hwa Kim, Junyeop Lee, Kyungdo Han, Jae-Taek Kim, Hyuk-Sang Kwon
Diabetes & Metabolism Journal.2024; 48(6): 1084. CrossRef
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
Cardiovascular Diabetology.2023;[Epub] CrossRef
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André J. Scheen
Diabetes & Metabolism.2023; 49(5): 101474. CrossRef

Short Communication

Drug/Regimen
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study: Hwi Seung Kim, Taekwan Yoon, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee; Diabetes Metab J. 2022;46(4):658-662. Published online November 8, 2021; DOI: https://doi.org/10.4093/dmj.2021.0232

65,804 View
455 Download
10 Web of Science
12 Crossref

Abstract PDF Supplementary Material PubReader ePub

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) are novel anti-diabetic drugs whose glucose-lowering effect and cardiovascular and renal benefits were evidenced in clinical trials. We investigated the real-world efficacy and safety of the combination of SGLT2i and GLP-1RA in patients with type 2 diabetes mellitus in Korea. The medical records of 104 patients who maintained the combination for at least 1 year were retrospectively reviewed. The change in glycosylated hemoglobin (HbA1c) after 6 months and 1 year of treatment was evaluated. The mean age was 51 years, and 41% were female. The mean baseline HbA1c, body mass index, and duration of diabetes were 9.0%, 28.8 kg/m², and 11.7 years, respectively. Compared with baseline, the HbA1c decreased by 1.5% (95% confidence interval [CI], 1.27 to 1.74; P<0.001) after 6 months and by 1.4% (95% CI, 1.19 to 1.70; P<0.001) after 1 year. Over 1 year, the bodyweight change was −2.8 kg (95% CI, −4.21 to −1.47; P<0.001). The combination of SGLT2i and GLP-1RA is effective and tolerable in type 2 diabetes mellitus patients in real-world practice.

Citations

Citations to this article as recorded by

Comparative Analysis of Clinical Outcomes in Patients With Type 2 Diabetes Mellitus on Monotherapy Versus Combination Therapy
Hariballav Mahapatra, Piyush Kumar Gupta, Ajo Paul, Amit Nampalliwar, Manju Bansal, Baijnath Das, K. Parameswaran Namboothiri
Cureus.2026;[Epub] CrossRef
Real-world longitudinal trends in glycaemic control, renal function, and lipid profiles among Malaysian patients receiving sodium–glucose cotransporter 2 inhibitors
Abdullah Faiz Zaihan, Nurul Ameera Huda Mohamad Hafiz, Nur Irdina Athilah Khairul Hazamy, Aisyah Zahraa Termizy, Nurul Izzah Roslan, Perishithaa M Ganesan, Sze Hwe Choe, Chia Siang Kow
Asian Heart Journal.2026; 2(1): 33. CrossRef
Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique
Carlos A. Yepes-Cortés, Isabel C. Cardenas-Moreno, Rodrigo Daza-Arnedo, Karen M. Feriz-Bonelo, Erica Yama-Mosquera, Alex H. Ramirez-Rincón, Gilberto A. Castillo-Barrios, Andres F. Suarez-Rodriguez, Johanna Carreño-Jiménez, Carlos E. Builes-Montaño
Diabetes Therapy.2025; 16(5): 813. CrossRef
Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
Aftab Ahmad, Hani Sabbour
Cardiovascular Diabetology.2024;[Epub] CrossRef
Sodium–Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome
Fernando Cortés-Camacho, Oscar René Zambrano-Vásquez, Elena Aréchaga-Ocampo, Jorge Ismael Castañeda-Sánchez, José Guillermo Gonzaga-Sánchez, José Luis Sánchez-Gloria, Laura Gabriela Sánchez-Lozada, Horacio Osorio-Alonso
Antioxidants.2024; 13(7): 768. CrossRef
SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation
António Cabral Lopes, Olga Lourenço, Manuel Morgado
Expert Review of Clinical Pharmacology.2024; 17(11): 1081. CrossRef
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Eun Roh, Kyung Mook Choi
International Journal of Molecular Sciences.2023; 24(4): 3384. CrossRef
All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
David R. Riley, Hani Essa, Philip Austin, Frank Preston, Isatu Kargbo, Gema Hernández Ibarburu, Ramandeep Ghuman, Daniel J. Cuthbertson, Gregory Y. H. Lip, Uazman Alam
Diabetes, Obesity and Metabolism.2023; 25(10): 2897. CrossRef
The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Chen Li, Jie Luo, Mingyan Jiang, Keke Wang
Frontiers in Pharmacology.2022;[Epub] CrossRef
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Hwi Seung Kim, Woo Je Lee
Diabetes & Metabolism Journal.2022; 46(4): 665. CrossRef
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Tomoyuki Kawada
Diabetes & Metabolism Journal.2022; 46(4): 663. CrossRef
Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
Hwi Seung Kim, Yun Kyung Cho, Myung Jin Kim, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Frontiers in Endocrinology.2022;[Epub] CrossRef

Original Articles

Basic Research
Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway: Ji-Yeon Lee, Minyoung Lee, Ji Young Lee, Jaehyun Bae, Eugene Shin, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha; Diabetes Metab J. 2021;45(6):921-932. Published online February 22, 2021; DOI: https://doi.org/10.4093/dmj.2020.0187

14,018 View
464 Download
37 Web of Science
40 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs that exhibit multiple extraglycemic effects. However, there are conflicting results regarding the effects of SGLT2 inhibition on energy expenditure and thermogenesis. Therefore, we investigated the effect of ipragliflozin (a selective SGLT2 inhibitor) on energy metabolism.
Methods
Six-week-old male 129S6/Sv mice with a high propensity for adipose tissue browning were randomly assigned to three groups: normal chow control, 60% high-fat diet (HFD)-fed control, and 60% HFD-fed ipragliflozin-treated groups. The administration of diet and medication was continued for 16 weeks.
Results
The HFD-fed mice became obese and developed hepatic steatosis and adipose tissue hypertrophy, but their random glucose levels were within the normal ranges; these features are similar to the metabolic features of a prediabetic condition. Ipragliflozin treatment markedly attenuated HFD-induced hepatic steatosis and reduced the size of hypertrophied adipocytes to that of smaller adipocytes. In the ipragliflozin treatment group, uncoupling protein 1 (Ucp1) and other thermogenesis-related genes were significantly upregulated in the visceral and subcutaneous adipose tissue, and fatty acid oxidation was increased in the brown adipose tissue. These effects were associated with a significant reduction in the insulin-to-glucagon ratio and the activation of the AMP-activated protein kinase (AMPK)/sirtuin 1 (SIRT1) pathway in the liver and adipose tissue.
Conclusion
SGLT2 inhibition by ipragliflozin showed beneficial metabolic effects in 129S6/Sv mice with HFD-induced obesity that mimics prediabetic conditions. Our data suggest that SGLT2 inhibitors, through their upregulation of energy expenditure, may have therapeutic potential in prediabetic obesity.

Citations

Citations to this article as recorded by

Limited Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Appetite and Body Weight: Evidence From Clinical and Rodent Studies
Joonyub Lee, Sohee Park, Evonne Kim, Ji-Yeon Park, Marie Rhee, Jing W. Hughes, Seung-Hyun Ko, Obin Kwon, Eun Young Lee
Journal of Korean Medical Science.2026;[Epub] CrossRef
Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet
Phuc Thi Minh Pham, Giang Nguyen, So Young Park, Thuy Linh Lai, Dae-Hee Choi, Jeana Hong, Seon Mee Kang, Eun-Hee Cho
Diabetes & Metabolism Journal.2026; 50(1): 165. CrossRef
GraphBAN-based identification of active ingredients and key gene targets in compound Chinese herbal medicines for polycystic ovary syndrome
Shiyang Wei, Ting Qin, Ying Li, Daguo Zhang, Limin Liu, Liying Wei, Renfeng Zhao
Naunyn-Schmiedeberg's Archives of Pharmacology.2026;[Epub] CrossRef
Empagliflozin Alleviates Arsenic Trioxide–Induced Nephrotoxicity by Activating the SIRT1/Akt/Nrf2 Pathway
Chunrong Pang, Wenlei Zhang, Chenli Yue, Haoxuan Li, Jinyan Li, Xinru Wang, Xinsheng Duan, Longyu Li, Zengliang Gao, Xin Hai, Phuping sucharitakul
Journal of Toxicology.2026;[Epub] CrossRef
SGLT2 inhibitors and AMPK crosstalk in diabetes mellitus: mechanistic insights and therapeutic applications
Kiavash Hushmandi, Navvabeh Salarizadeh, Behzad Einollahi, Morteza Izadi, Pardis Doosti, Mohammad Javad Behzadnia, William C. Cho, Tooba Yousefi, Seyedeh Mahdieh Khoshnazar, Mina Alimohammadi, Najma Farahani
Journal of Diabetes & Metabolic Disorders.2026;[Epub] CrossRef
AMPK is dispensable for physiological podocyte and glomerular functions but prevents glomerular fibrosis in experimental diabetes
Swayam Prakash Srivastava, Olivia Kopasz-Gemmen, Abhiram Kunamneni, Aaron Thurman, Shota Yoshida, Eden Ozkan, Vinamra Swaroop, Rahul Nanwani, Ajan Arora, Arya Joshi, Om Khuperkar, Mariam Hamed, Mihir Suresh Bharadwaj, Niloy Islam, Adesh Urval, Junying Wan
Cell Death Discovery.2026;[Epub] CrossRef
Unlocking the therapeutic potential of canagliflozin in NAFLD: Insights into AMPK/SIRT1-mediated lipophagy
Nahla E. El-Ashmawy, Ghada M. Al-Ashmawy, Asmaa A. Kamel, Eman G. Khedr
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(3): 167666. CrossRef
Lactucin and lactucopicrin ameliorate obesity in high-fat diet fed mice by promoting white adipose tissue browning through the activation of the AMPK/SIRT1/PGC-1α pathway
Yewei Zhong, Junlin Yan, Yi Lei, Rui Zhang, Adalaiti Abudurexiti, Shuwen Qi, Wenhui Hou, Xiaoli Ma
The Journal of Nutritional Biochemistry.2025; 139: 109851. CrossRef
Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes
Francesco Piccirillo, Matteo Lanciotti, Annunziata Nusca, Lorenzo Frau, Agostino Spanò, Paola Liporace, Gian Paolo Ussia, Francesco Grigioni
International Journal of Molecular Sciences.2025; 26(5): 2103. CrossRef
Effect of Empagliflozin on Serum Levels of Thyroid Hormones Among Prediabetic and Diabetic Patients
Mojgan Sanjari, Narges Sadeghi, Ladan Amirkhosravi, Mohammad Hadavizadeh, Ahmad Naghibzadeh-Tahami, Zohreh Safi, Suraiya Saleem
International Journal of Endocrinology.2025;[Epub] CrossRef
SGLT2 Inhibition by Enavogliflozin Significantly Reduces Aβ Pathology and Restores Cognitive Function via Upregulation of Microglial AMPK Signaling in 5XFAD Mouse Model of Alzheimer's Disease
Jihui Han, Jaehoon Song, Eun Sun Jung, Ji Won Choi, Hye Young Ji, Inhee Mook‐Jung
Aging Cell.2025;[Epub] CrossRef
Physiological Conditions, Bioactive Ingredients, and Drugs Stimulating Non-Shivering Thermogenesis as a Promising Treatment Against Diabesity
Diego Salagre, Ciskey V. Ayala-Mosqueda, Samira Aouichat, Ahmad Agil
Pharmaceuticals.2025; 18(9): 1247. CrossRef
The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Milton Packer
JACC.2025; 86(16): 1269. CrossRef
Beyond the Cardio–Renal–Metabolic Axis: Emerging Therapeutic Targets and Novel Mechanisms of Action of Flozins
Wojciech Matuszewski, Lena Tomaszek, Michał Szklarz, Jan Marek Górny, Bernard Kordas, Joanna Rutkowska, Judyta Juranek
Journal of Clinical Medicine.2025; 14(18): 6348. CrossRef
Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?
Milton Packer, Carolyn S.P. Lam, Javed Butler, Faiez Zannad, Muthiah Vaduganathan, Barry A. Borlaug
JACC.2025; 86(20): 1917. CrossRef
Rationale and design of the Adipose Dysfunction, Imaging, Physiology, and Outcomes with sodium-glucose cotransporter − 2 inhibitors for Sleep Apnea (ADIPOSA) study
Ehimen Aneni, Isaac Karim, Joe Rutter, Opemipo Olaseni, Iouri Kreinin, Sui Tsang, Zuoheng Wang, Kingman P. Strohl, H. Klar Yaggi, Ian J. Neeland
Contemporary Clinical Trials.2025; 159: 108134. CrossRef
Extracellular vesicle miR-425-5p promotes visceral fat reduction via DACT1 suppression in SGLT2i-treated diabetes
Jae-Hyung Park, Thi Nhi Nguyen, Hye Min Shim, Yun-Ui Bae, Gyeong Im Yu, Junho Kang, Eun Yeong Ha, Hochan Cho
Frontiers in Endocrinology.2025;[Epub] CrossRef
SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration
Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh
Endocrinology and Metabolism.2025; 40(6): 851. CrossRef
SGLT2 inhibitors and AMPK: The road to cellular housekeeping?
Nasser Safaie, Shahab Masoumi, Shaban Alizadeh, Pourya Mirzajanzadeh, Hamid Reza Nejabati, Mobasher Hajiabbasi, Vahid Alivirdiloo, Neda Chobdari Basmenji, Aysan Derakhshi Radvar, Ziba Majidi, Yousef Faridvand
Cell Biochemistry and Function.2024;[Epub] CrossRef
Proximal tubule hypertrophy and hyperfunction: a novel pathophysiological feature in disease states
Mehmet Kanbay, Sidar Copur, Mustafa Guldan, Lasin Ozbek, Alper Hatipoglu, Adrian Covic, Francesca Mallamaci, Carmine Zoccali
Clinical Kidney Journal.2024;[Epub] CrossRef
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Yafei Xie, Yujie Wei, Dan Li, Jie Pu, Hong Ding, Xiaowei Zhang
Journal of Cardiovascular Pharmacology.2023; 81(1): 4. CrossRef
Current Treatment Options, Including Diet, Exercise, and Medications
Mazen Noureddin, Manal F. Abdelmalek
Clinics in Liver Disease.2023; 27(2): 397. CrossRef
SGLT2 Inhibitors and Kidney Diseases: A Clinical Perspective
Panagiotis Theofilis, Rigas G. Kalaitzidis
Current Medicinal Chemistry.2023; 30(23): 2595. CrossRef
Treatment of obesity-related diabetes: significance of thermogenic adipose tissue and targetable receptors
Ruping Pan, Jiadai Liu, Yong Chen
Frontiers in Pharmacology.2023;[Epub] CrossRef
Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Ema Schönberger, Vjera Mihaljević, Kristina Steiner, Sandra Šarić, Tomislav Kurevija, Ljiljana Trtica Majnarić, Ines Bilić Ćurčić, Silvija Canecki-Varžić
International Journal of Environmental Research and Public Health.2023; 20(17): 6671. CrossRef
SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model
Manal Moustafa Mahmoud, Laila Ahmed Rashed, Somia Abdulatif Soliman, Safaa Mostafa Sayed, Omneya Kamel, Samaa Samir Kamar, Rania El Sayed Hussien
Physiological Reports.2023;[Epub] CrossRef
Resting energy expenditure based on equation estimation can predict renal outcomes in patients with type 2 diabetes mellitus and biopsy-proven diabetic kidney disease
Xiang Xiao, Shuming Ji, Junlin Zhang, Deying Kang, Fang Liu
Renal Failure.2023;[Epub] CrossRef
Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial Hypertrophy
Zhicheng Gao, Jiaqi Bao, Yilan Hu, Junjie Tu, Lifang Ye, Lihong Wang
Current Drug Targets.2023; 24(13): 1009. CrossRef
SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1
Weijie Wang, Yilan Li, Yanxiu Zhang, Tao Ye, Kui Wang, Shuijie Li, Yao Zhang
Cardiovascular Diabetology.2023;[Epub] CrossRef
Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling
Ke Lin, Na Yang, Wu Luo, Jin-fu Qian, Wei-wei Zhu, Shi-ju Ye, Chen-xin Yuan, Di-yun Xu, Guang Liang, Wei-jian Huang, Pei-ren Shan
Acta Pharmacologica Sinica.2022; 43(10): 2624. CrossRef
Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes
Panagiotis Theofilis, Marios Sagris, Evangelos Oikonomou, Alexios S. Antonopoulos, Gerasimos Siasos, Kostas Tsioufis, Dimitris Tousoulis
Diabetes Research and Clinical Practice.2022; 188: 109927. CrossRef
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
Sandra Feijóo-Bandín, Alana Aragón-Herrera, Manuel Otero-Santiago, Laura Anido-Varela, Sandra Moraña-Fernández, Estefanía Tarazón, Esther Roselló-Lletí, Manuel Portolés, Oreste Gualillo, José Ramón González-Juanatey, Francisca Lago
International Journal of Molecular Sciences.2022; 23(10): 5634. CrossRef
Potential molecular mechanism of action of sodium-glucose co-transporter 2 inhibitors in the prevention and management of diabetic retinopathy
Lia Meuthia Zaini, Arief S Kartasasmita, Tjahjono D Gondhowiardjo, Maimun Syukri, Ronny Lesmana
Expert Review of Ophthalmology.2022; 17(3): 199. CrossRef
New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
Juexing Li, Lei Zhou, Hui Gong
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Milton Packer
Circulation.2022; 146(18): 1383. CrossRef
Nutraceutical activation of Sirt1: a review
James J DiNicolantonio, Mark F McCarty, James H O'Keefe
Open Heart.2022; 9(2): e002171. CrossRef
Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells
Jing Xu, Munehiro Kitada, Yoshio Ogura, Haijie Liu, Daisuke Koya
Cells.2021; 10(6): 1457. CrossRef
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations
Dimitrios A. Vrachatis, Konstantinos A. Papathanasiou, Konstantinos E. Iliodromitis, Sotiria G. Giotaki, Charalampos Kossyvakis, Konstantinos Raisakis, Andreas Kaoukis, Vaia Lambadiari, Dimitrios Avramides, Bernhard Reimers, Giulio G. Stefanini, Michael C
Drugs.2021; 81(12): 1381. CrossRef
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes
Milton Packer
JACC: Heart Failure.2021; 9(8): 535. CrossRef
Ketone bodies: from enemy to friend and guardian angel
Hubert Kolb, Kerstin Kempf, Martin Röhling, Martina Lenzen-Schulte, Nanette C. Schloot, Stephan Martin
BMC Medicine.2021;[Epub] CrossRef

Drug/Regimen
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus: Ja Young Jeon, Kyoung Hwa Ha, Dae Jung Kim; Diabetes Metab J. 2021;45(4):505-514. Published online October 30, 2020; DOI: https://doi.org/10.4093/dmj.2020.0057

13,581 View
417 Download
12 Web of Science
13 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background
Using real-world data, cardiovascular safety was investigated in metformin users newly starting sodium glucose cotransporter 2 (SGLT2) inhibitors compared with other glucose-lowering drugs in Korea.
Methods
This was a retrospective observational study using the National Health Insurance Service claims database in Korea. The study period was from September 2014 to December 2016. The study included subjects who were newly prescribed SGLT2 inhibitors or other glucose-lowering drugs while on metformin monotherapy; cohort 1 was composed of new users of SGLT2 inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and cohort 2 included new users of SGLT2 inhibitors versus sulfonylureas. To balance the patient characteristics, propensity score matching was performed at a 1:1 ratio. Cardiovascular outcomes included hospitalization for heart failure (HHF), all-cause mortality, HHF plus all-cause mortality, myocardial infarction (MI), stroke, and modified major adverse cardiovascular events (MACEs).
Results
After propensity score matching, each cohort group was well balanced at baseline (21,688 pairs in cohort 1 and 20,120 pairs in cohort 2). As the second-line treatment, use of SGLT2 inhibitors was associated with a lower risk of HHF and HHF plus all-cause mortality compared with DPP-4 inhibitors. In addition, use of SGLT2 inhibitors versus sulfonylurea as add-on therapy to metformin was associated with decreased risks of HHF, all-cause mortality, HHF plus all-cause mortality, MI, stroke, and modified MACEs.
Conclusion
SGLT2 inhibitors can be a good second-line drug to reduce the incidence of cardiovascular diseases compared with DPP-4 inhibitors or sulfonylureas in people with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

The effect of empagliflozin and sitagliptin as an add-on therapy to metformin in blood pressure reduction in diabetic patients in primary health care settings in Riyadh, Saudi Arabia
Mayada Ahmed, Mohammed Altoyan, Raghad Hijazi, Joud AlJebreen, Mohammed H. Alshalan, Reema Aldhalaan, Lama Altarifi
Journal of Family Medicine and Primary Care.2025; 14(3): 1116. CrossRef
Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and cerebrovascular diseases: a meta-analysis of controlled clinical trials
Fei Wang, Chunyu Li, Lili Cui, Shuo Gu, Junyu Zhao, Haipeng Wang
Frontiers in Endocrinology.2024;[Epub] CrossRef
Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
International Journal of Heart Failure.2023; 5(1): 1. CrossRef
Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
Diabetes & Metabolism Journal.2023; 47(1): 10. CrossRef
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Jingqian Su, Yingsheng Luo, Shan Hu, Lu Tang, Songying Ouyang
International Journal of Molecular Sciences.2023; 24(17): 13381. CrossRef
Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes
Jui Wang, Hon-Yen Wu, Kuo-Liong Chien
Diabetes & Metabolism.2022; 48(3): 101299. CrossRef
Cardiovascular disease in patients with type 2 diabetes
Ja Young Jeon, Dae Jung Kim
Journal of Diabetes Investigation.2022; 13(4): 614. CrossRef
The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients
Israel Mazin, Fernando Chernomordik, Paul Fefer, Shlomi Matetzky, Roy Beigel
Journal of Clinical Medicine.2022; 11(7): 1904. CrossRef
Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation
Chang Hee Kwon, Ye-Jee Kim, Min-Ju Kim, Myung-Jin Cha, Min Soo Cho, Gi-Byoung Nam, Kee-Joon Choi, Jun Kim
The American Journal of Cardiology.2022; 178: 35. CrossRef
Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
Ha Young Jang, In-Wha Kim, Jung Mi Oh
Frontiers in Pharmacology.2022;[Epub] CrossRef
Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
Kyuho Kim, Sung Hee Choi
Diabetes & Metabolism Journal.2021; 45(4): 502. CrossRef
The effect of sodium‐glucose transport protein 2 inhibitors on mortality and heart failure in randomized trials versus observational studies
Jesper Krogh, Carsten Hjorthøj, Søren L. Kristensen, Christian Selmer, Steen B. Haugaard
Diabetic Medicine.2021;[Epub] CrossRef
Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies
Enrico Longato, Benedetta Maria Bonora, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini
Diabetes Research and Clinical Practice.2021; 179: 109024. CrossRef

Review

Guideline/Fact Sheet
Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement: Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon, The Committee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Society of Nephrology; Diabetes Metab J. 2020;44(4):489-497. Published online August 21, 2020; DOI: https://doi.org/10.4093/dmj.2020.0172

12,872 View
201 Download
5 Web of Science
7 Crossref

Abstract PDF Supplementary Material PubReader ePub

Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of renal dysfunction is an important treatment goal in the management of diabetes. The data of landmark cardiovascular outcome trials of sodium-glucose cotransporter-2 (SGLT2) inhibitor showed profound reno-protective effects. The Korean Diabetes Association and the Korean Society of Nephrology reviewed clinical trials and performed meta-analysis to assess the effects of SGLT2 inhibitors on the preservation of estimated glomerular filtration rate (eGFR). We limited the data of SGLT2 inhibitors which can be prescribed in Korea. Both eGFR value and its change from the baseline were significantly more preserved in the SGLT2 inhibitor treatment group compared to the control group after 156 weeks. However, some known adverse events were increased in SGLT2 inhibitor treatment, such as genital infection, diabetic ketoacidosis, and volume depletion. We recommend the long-term use SGLT2 inhibitor in patients with type 2 diabetes mellitus (T2DM) for attenuation of renal function decline. However, we cannot generalize our recommendation due to lack of long-term clinical trials testing reno-protective effects of every SGLT2 inhibitor in a broad range of patients with T2DM. This recommendation can be revised and updated after publication of several large-scale renal outcome trials.

Citations

Citations to this article as recorded by

2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association
Shinae Kang, Seon Mee Kang, Jong Han Choi, Seung-Hyun Ko, Bo Kyung Koo, Hyuk-Sang Kwon, Mi Kyung Kim, Sang Yong Kim, Soo-Kyung Kim, Young-eun Kim, Eun Sook Kim, Jae Hyeon Kim, Chong Hwa Kim, Ji Min Kim, Hae Jin Kim, Min Kyong Moon, Sun Joon Moon, Jun Sung
Diabetes & Metabolism Journal.2025; 49(4): 582. CrossRef
Clinical Considerations for Safe Use of SGLT2 Inhibitors
Jae-Seung Yun, Eonju Jeon
The Journal of Korean Diabetes.2025; 26(2): 60. CrossRef
Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study
Ye Seul Yang, Nam Hoon Kim, Jong Ha Baek, Seung-Hyun Ko, Jang Won Son, Seung-Hwan Lee, Sang Youl Rhee, Soo-Kyung Kim, Tae Seo Sohn, Ji Eun Jun, In-Kyung Jeong, Chong Hwa Kim, Keeho Song, Eun-Jung Rhee, Junghyun Noh, Kyu Yeon Hur
Diabetes & Metabolism Journal.2024; 48(2): 279. CrossRef
2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, Yoon Ju Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang
Diabetes & Metabolism Journal.2024; 48(4): 546. CrossRef
Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
Jin Hwa Kim, Junyeop Lee, Kyungdo Han, Jae-Taek Kim, Hyuk-Sang Kwon
Diabetes & Metabolism Journal.2024; 48(6): 1084. CrossRef
Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
Nam Hoon Kim, Nan Hee Kim
Diabetes & Metabolism Journal.2022; 46(4): 543. CrossRef
Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease
Jong Ha Baek, Ye Seul Yang, Seung-Hyun Ko, Kyung Do Han, Jae Hyeon Kim, Min Kyong Moon, Jong Suk Park, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Jong Han Choi, Kyu Yeon Hur
Diabetes & Metabolism Journal.2022; 46(5): 701. CrossRef

Original Article

Drug/Regimen
Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study: Seung-Hwan Lee, Kyung-Wan Min, Byung-Wan Lee, In-Kyung Jeong, Soon-Jib Yoo, Hyuk-Sang Kwon, Yoon-Hee Choi, Kun-Ho Yoon; Diabetes Metab J. 2021;45(3):339-348. Published online May 28, 2020; DOI: https://doi.org/10.4093/dmj.2019.0203

14,592 View
404 Download
19 Web of Science
23 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background

Glycemic variability is associated with the development of diabetic complications and hypoglycemia. However, the effect of sodium-glucose transporter 2 (SGLT2) inhibitors on glycemic variability is controversial. We aimed to examine the effect of dapagliflozin as an add-on therapy to insulin on the glycemic variability assessed using continuous glucose monitoring (CGM) in subjects with type 2 diabetes mellitus.

Methods

In this multicenter, placebo-controlled, double-blind, randomized study, 84 subjects received 10 mg of dapagliflozin (n=41) or the placebo (n=43) for 12 weeks. CGM was performed before and after treatment to compare the changes in glycemic variability measures (standard deviation [SD], mean amplitude of glycemic excursions [MAGEs]).

Results

At week 12, significant reductions in glycosylated hemoglobin (−0.74%±0.66% vs. 0.01%±0.65%, P<0.001), glycated albumin (−3.94%±2.55% vs. −0.67%±2.48%, P<0.001), and CGM-derived mean glucose (−41.6±39.2 mg/dL vs. 1.1±46.2 mg/dL, P<0.001) levels were observed in the dapagliflozin group compared with the placebo group. SD and MAGE were significantly decreased in the dapagliflozin group, but not in the placebo group. However, the difference in ΔSD and ΔMAGE failed to reach statistical significance between two groups. No significant differences in the incidence of safety endpoints were observed between the two groups.

Conclusion

Dapagliflozin effectively decreased glucose levels, but not glucose variability, after 12 weeks of treatment in participants with type 2 diabetes mellitus receiving insulin treatment. The role of SGLT2 inhibitors in glycemic variability warrants further investigations.

Citations

Citations to this article as recorded by

Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-naïve type 2 diabetes: The EMPA-FIT study
Soo Lim, Cheol Young Park, In Kyung Jeong, Ji Sung Yoon, Sang Yong Kim, Eun Seok Kang, Junghyun Noh, Kyu Yeon Hur, Sungrae Kim
Journal of Diabetes and its Complications.2026; 40(1): 109214. CrossRef
Comparative Study of Efficacy and Safety of Dapagliflozin vs Basal Insulin in Stabilizing Glycemic Variability in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Triple Drug Combination Therapy
Deepak S Bhosle, Bhakti Chandekar, Satish Shelke
Journal of The Association of Physicians of India.2025; 73(4): 29. CrossRef
Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis
Shiwen Yang, Qiaozhi Hu, Kexin Liu, Binjie Xiao, Bofei Zhang, Na Su
Frontiers in Pharmacology.2025;[Epub] CrossRef
Glycemic variability and iatrogenic hypoglycemia: how to resolve
Louis Monnier, Claude Colette, Eric Renard, Pierre-Yves Benhamou, Safa Aouinti, Nicolas Molinari, David Owens
Diabetes Research and Clinical Practice.2025; 226: 112360. CrossRef
Effects of sodium-glucose cotransporter-2 inhibitors on serum urate levels and gout in patients with and without type 2 diabetes: a systematic review and network meta-analysis
Qiaozhi Hu, Shiwen Yang, Bofei Zhang, Na Su
International Journal of Clinical Pharmacy.2025; 47(5): 1162. CrossRef
Proteomic Signatures and Blood Adenosine Triphosphate Levels as Markers of Empagliflozin Efficacy in Type 2 Diabetes Mellitus and Heart Failure
Uulkan Omurzakova, Matthias Breidert, Markus Donner, Nurgul Toktogulova, Maria Moldobaeva, Angélique Quartier, Pierre Eftekhari
Hormone and Metabolic Research.2025; 57(11): 653. CrossRef
Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis
Yuanyuan Luo, Ruojing Bai, Wei Zhang, Guijun Qin
Frontiers in Endocrinology.2024;[Epub] CrossRef
Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine
Donald C Simonson, Marcia A Testa, Ella Ekholm, Maxwell Su, Tina Vilsbøll, Serge A Jabbour, Marcus Lind
The Journal of Clinical Endocrinology & Metabolism.2024; 109(12): e2261. CrossRef
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis
Khawaja M. Talha, Jennifer Green, Gerasimos Filippatos, Stuart Pocock, Faiez Zannad, Martina Brueckmann, Elke Schueler, Anne Pernille Ofstad, João Pedro Ferreira, Stefan D. Anker, Javed Butler, Julio Rosenstock, Milton Packer
Diabetes, Obesity and Metabolism.2024; 26(7): 2578. CrossRef
Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety
Pei-Ling Yu, You Yu, Shuang Li, Bai-Chen Mu, Ming-Hua Nan, Min Pang
World Journal of Diabetes.2024; 15(7): 1518. CrossRef
Glycemic Variability in Pancreatogenic Diabetes Mellitus: characteristics, Risks, Potential Mechanisms, and Treatment Possibilities
Yuyan Sun, Bing Lu, Yuanwen Hu, Yingqi Lv, Shao Zhong
International Journal of General Medicine.2024; Volume 17: 4297. CrossRef
Risk of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Zhigui Zheng, Dongyuan He, Jianguo Chen, Xiaohui Xie, Yunan Lu, Binbin Wu, Xinxin Jiang
Clinical Drug Investigation.2023; 43(4): 209. CrossRef
Effect of SGLT2 Inhibitors and Metformin on Inflammatory and Prognostic Biomarkers in Type 2 Diabetes Patients
Yang Cao, Ning Liang, Ting Liu, Jingai Fang, Xiaodong Zhang
Endocrine, Metabolic & Immune Disorders - Drug Targets.2023; 23(4): 530. CrossRef
What is Glycaemic Variability and which Pharmacological Treatment Options are Effective? A Narrative Review
Juan Miguel Huertas Cañas, Maria Alejandra Gomez Gutierrez, Andres Bedoya Ossa
European Endocrinology.2023; 19(2): 4. CrossRef
La variabilité glycémique : un facteur de risque singulier à conjuguer au pluriel
Louis Monnier, Claude Colette, Fabrice Bonnet, David Owens
Médecine des Maladies Métaboliques.2022; 16(1): 15. CrossRef
Association between Variability of Metabolic Risk Factors and Cardiometabolic Outcomes
Min Jeong Park, Kyung Mook Choi
Diabetes & Metabolism Journal.2022; 46(1): 49. CrossRef
Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials
Alicia Swee Yan Yip, Shariel Leong, Yao Hao Teo, Yao Neng Teo, Nicholas L. X. Syn, Ray Meng See, Caitlin Fern Wee, Elliot Yeung Chong, Chi-Hang Lee, Mark Y. Chan, Tiong-Cheng Yeo, Raymond C. C. Wong, Ping Chai, Ching-Hui Sia
Therapeutic Advances in Chronic Disease.2022;[Epub] CrossRef
Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis
SuA Oh, Sujata Purja, Hocheol Shin, Minji Kim, Eunyoung Kim
Diabetes and Vascular Disease Research.2022;[Epub] CrossRef
The Clinical Effect of Dapagliflozin in Patients with Angiographically Confirmed Coronary Artery Disease and Concomitant Type 2 Diabetes Mellitus
Yana Yu. Dzhun, Yevhen Yu. Marushko, Yanina A. Saienko, Nadiya M. Rudenko, Borys M. Mankovsky
Ukrainian Journal of Cardiovascular Surgery.2022; 30(3): 35. CrossRef
Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives
Alessandro Bellis, Ciro Mauro, Emanuele Barbato, Antonio Ceriello, Antonio Cittadini, Carmine Morisco
International Journal of Molecular Sciences.2021; 22(2): 775. CrossRef
Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
Heeyoung Lee, Se-eun Park, Eun-Young Kim
Journal of Clinical Medicine.2021; 10(18): 4078. CrossRef
Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs
Menghui Luo, Xiaocen Kong, Huiying Wang, Xiaofang Zhai, Tingting Cai, Bo Ding, Yun Hu, Ting Jing, Xiaofei Su, Huiqin Li, Jianhua Ma, Yoshifumi Saisho
Journal of Diabetes Research.2020; 2020: 1. CrossRef
Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control
Jee Hee Yoo, Jae Hyeon Kim
Diabetes & Metabolism Journal.2020; 44(6): 828. CrossRef

Review

Drug/Regimen
Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations: Wayne Huey-Herng Sheu, Siew Pheng Chan, Bien J. Matawaran, Chaicharn Deerochanawong, Ambrish Mithal, Juliana Chan, Ketut Suastika, Chin Meng Khoo, Huu Man Nguyen, Ji Linong, Andrea Luk, Kun-Ho Yoon; Diabetes Metab J. 2020;44(1):11-32. Published online February 21, 2020; DOI: https://doi.org/10.4093/dmj.2019.0208

20,504 View
300 Download
45 Web of Science
43 Crossref

Abstract PDF PubReader ePub

The prevalence of obesity in Asia is of epidemic proportions, with an estimated 1 billion overweight/obese individuals in the region. The majority of patients with type 2 diabetes mellitus (T2DM) are overweight/obese, which increases the risk of cardiorenal outcomes in these patients; hence, sustained reductions in body weight and visceral adiposity are important management goals. However, most of the glucose-lowering therapies such as insulin, sulfonylureas, glinides, and thiazolidinediones induce weight gain, which makes the management of overweight/obese T2DM patients challenging. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are the only oral glucose-lowering agents that have been shown to reduce body weight and visceral adiposity. In addition, SGLT-2 inhibitors therapy reduces ectopic fat deposition and improves adipose tissue function and weight-related quality of life. In this article, we aim to consolidate the existing literature on the effects of SGLT-2 inhibitors in Asian patients with T2DM and to produce clinical recommendations on their use in overweight or obese patients with T2DM. Recommendations from international and regional guidelines, as well as published data from clinical trials in Asian populations and cardiovascular outcomes trials are reviewed. Based on the available data, SGLT-2 inhibitors represent an evidence-based therapeutic option for the management of overweight/obese patients with T2DM.

Citations

Citations to this article as recorded by

Risk of depression with GLP‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study
Yu Chang, Ming‐Hong Hsieh, Po‐Chung Ju, Cheng‐Chen Chang
Diabetes, Obesity and Metabolism.2026; 28(1): 197. CrossRef
Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
Jun Hwa Hong, Kyung Ah Han, You-Cheol Hwang, Eun-Gyoung Hong, Hae Jin Kim, Chang Beom Lee, Ho Chan Cho, Jong Chul Won, Hun-Sung Kim, Eui-Hyun Kim, Gwanpyo Koh, Kwang Hyun Ahn, Kyong Soo Park
Diabetes & Metabolism Journal.2026; 50(2): 320. CrossRef
Hypothesis: Nutrient Off-Loading and Ectopic Fat Reduction Reverse Insulin Resistance and Improve Cardiovascular Outcomes in Type 2 Diabetes—A Narrative Review
Joseph A. M. J. L. Janssen
International Journal of Molecular Sciences.2026; 27(5): 2150. CrossRef
SGLT-2i—A Useful Tool for Real-Life Metabolic and Body Weight Control in Type 2 Diabetes Mellitus Patients
Mihaela-Simona Popoviciu, Teodor Salmen, Delia Reurean-Pintilei, Vlad Voiculescu, Anca Pantea Stoian
Medicina.2025; 61(3): 548. CrossRef
Discrepancies in Dapagliflozin Response in Terms of Glycemic Control and Body Weight Reduction
Ji Eun Jun, Kyoung-Ah Kim, Nan-Hee Kim, Kwan-Woo Lee, In-Kyung Jeong
Endocrinology and Metabolism.2025; 40(2): 278. CrossRef
Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP‐4 inhibitors: A multicentre, phase 4 randomized controlled trial
Yun Kyung Cho, Jae‐Hyoung Cho, Sang‐Mo Hong, Jung Hwan Park, Byung‐Wan Lee, Jee Hee Yoo, Jae Hyeon Kim, Sung Wan Chun, You‐Cheol Hwang, Kee‐Ho Song, Woo Je Lee
Diabetes, Obesity and Metabolism.2025; 27(11): 6375. CrossRef
Indian Clinicians’ Perspectives on Utilizing Dapagliflozin-Based Combination Therapy for the Management of Obesity in Patients With Type 2 Diabetes Mellitus
Mayur Agrawal, Abhay Ahluwalia, Raman Boddula, Arjun Baidya, Hiteswar Saikia, Anu Mathew, Prem Naryanan, Arjun R, Modhugu N Reddy, Rohan N Kesarkar, Abhijit Pednekar
Cureus.2025;[Epub] CrossRef
New approach to optimize therapy in type 2 diabetes mellitus: the importance of subclassification
María José Reyes-Medina, Vanesa Cantón-Habas, Francisco Javier Sánchez-Jiménez, Enrique Molina-Hurtado, María del Pilar Carrera-González
Frontiers in Endocrinology.2025;[Epub] CrossRef
Comparative efficacy of multiple drugs for non-alcoholic fatty liver disease: a Bayesian network meta-analysis
Zhile Xiao, Xiaonan Li, Jiahong Gong, Feng Zhou
European Journal of Medical Research.2025;[Epub] CrossRef
Extracellular vesicle miR-425-5p promotes visceral fat reduction via DACT1 suppression in SGLT2i-treated diabetes
Jae-Hyung Park, Thi Nhi Nguyen, Hye Min Shim, Yun-Ui Bae, Gyeong Im Yu, Junho Kang, Eun Yeong Ha, Hochan Cho
Frontiers in Endocrinology.2025;[Epub] CrossRef
The interaction between non-coding RNAs and SGLT2: A review
Joanna Jarosz-Popek, Ceren Eyileten, Gloria M. Gager, Anna Nowak, Piotr Szwed, Zofia Wicik, Jeff Palatini, Dirk von Lewinski, Harald Sourij, Jolanta M. Siller-Matula, Marek Postula
International Journal of Cardiology.2024; 398: 131419. CrossRef
A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
Tae Seo Sohn, Kyung‐Ah Han, Yonghyun Kim, Byung‐Wan Lee, Suk Chon, In‐Kyung Jeong, Eun‐Gyoung Hong, Jang Won Son, JaeJin Na, Jae Min Cho, Seong In Cho, Wan Huh, Kun‐Ho Yoon
Diabetes, Obesity and Metabolism.2024; 26(6): 2248. CrossRef
Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus
Seyed Saman Talebi, Shabnam Rezaie, Minoo Sadat Hajmiri, Maryam Zamanirafe, Akram Ranjbar, Heresh Moridi, Mahtabalsadat Mirjalili, Maryam Mehrpooya
Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(11): 9149. CrossRef
Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial
Soo Heon Kwak, Kyung Ah Han, Eun Sook Kim, Sung Hee Choi, Jong Chul Won, Jae Myung Yu, Seungjoon Oh, Hye Jin Yoo, Chong Hwa Kim, Kyung‐Soo Kim, SungWan Chun, Yong Hyun Kim, Seung Ah Cho, Da Hye Kim, Kyong Soo Park
Diabetes, Obesity and Metabolism.2024; 26(10): 4203. CrossRef
Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
Basavana Goudra, Geno J. Merli, Michael Green
Pharmaceuticals.2024; 18(1): 4. CrossRef
The effect of combining nutrient intake and physical activity levels on central obesity, sarcopenia, and sarcopenic obesity: a population-based cross-sectional study in South Korea
Jong Eun Park, Seulgi Lee, Kirang Kim
BMC Geriatrics.2023;[Epub] CrossRef
Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database
Minyoung Lee, Kyeongseob Jeong, Yu Rang Park, Yumie Rhee
Metabolism.2023; 138: 155311. CrossRef
Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Leili Gao, Zhifeng Cheng, Benli Su, Xiuhai Su, Weihong Song, Yushan Guo, Lin Liao, Xiaowen Chen, Jiarui Li, Xingrong Tan, Fangjiang Xu, Shuguang Pang, Kun Wang, Jun Ye, Yuan Wang, Lili Chen, Jingfang Sun, Linong Ji
Diabetes, Obesity and Metabolism.2023; 25(3): 785. CrossRef
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
Bains Jasleen, Gupta K Vishal, Malepati Sameera, Molla Fahad, O'Brien Brendan, Santander Deion, Sudhakar Pemminati
Cureus.2023;[Epub] CrossRef
Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
Jun Sung Moon, Nam Hoon Kim, Jin Oh Na, Jae Hyoung Cho, In-Kyung Jeong, Soon Hee Lee, Ji-Oh Mok, Nan Hee Kim, Dong Jin Chung, Jinhong Cho, Dong Woo Lee, Sun Woo Lee, Kyu Chang Won
Diabetes & Metabolism Journal.2023; 47(1): 82. CrossRef
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
Linong Ji, Jie Liu, Zhi Jin Xu, Zhiqi Wei, Ruya Zhang, Seema Malkani, Nilo B. Cater, Robert Frederich
Diabetes Therapy.2023; 14(2): 319. CrossRef
Research Progress of Dapagliflozin in Treatment of Acute Myocardial Infarction Complicated with Type 2 Diabetes Mellitus
鸿王
Advances in Clinical Medicine.2023; 13(02): 1667. CrossRef
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
Metabolism.2023; 145: 155612. CrossRef
Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial
Kyung Ah Han, Yong Hyun Kim, Doo Man Kim, Byung Wan Lee, Suk Chon, Tae Seo Sohn, In Kyung Jeong, Eun-Gyoung Hong, Jang Won Son, Jae Jin Nah, Hwa Rang Song, Seong In Cho, Seung-Ah Cho, Kun Ho Yoon
Diabetes & Metabolism Journal.2023; 47(6): 796. CrossRef
Renoprotection with sodium‐glucose cotransporter‐2 inhibitors in children: Knowns and unknowns
Buchun Jiang, Zhiwen Cheng, Fei Liu, Qiuyu Li, Haidong Fu, Jianhua Mao
Nephrology.2022; 27(2): 126. CrossRef
Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
Angelo Cignarelli, Valentina Annamaria Genchi, Giulia Le Grazie, Irene Caruso, Nicola Marrano, Giuseppina Biondi, Rossella D’Oria, Gian Pio Sorice, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino
Frontiers in Endocrinology.2022;[Epub] CrossRef
Sodium–glucose cotransporter 2 inhibitors do not increase the risk of fractures in real‐world clinical practice in Korea: A national observational cohort study
Kyoung Hwa Ha, Dae Jung Kim, Yong Jun Choi
Journal of Diabetes Investigation.2022; 13(6): 986. CrossRef
Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells
Li-Li Shi, Ming Hao, Zhou-Yun Jin, Gui-Fang Peng, Ying-Ying Tang, Hong-Yu Kuang, Yaoyao Bian
Disease Markers.2022; 2022: 1. CrossRef
Relationship Between Four Non-Insulin-Based Indexes of Insulin Resistance and Serum Uric Acid in Patients with Type 2 Diabetes: A Cross-Sectional Study
Rongfeng Han, Yang Zhang, Xia Jiang
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1461. CrossRef
The dual role of empagliflozin: Cardio renal protection in T2DM patients
Aimen Shafiq, Eman Mahboob, Muhammad Ammar Samad, Mohammad Hassam Ur Rehman, Zoaib Habib Tharwani
Annals of Medicine & Surgery.2022;[Epub] CrossRef
Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
Katarzyna Wołos-Kłosowicz, Wojciech Matuszewski, Joanna Rutkowska, Katarzyna Krankowska, Elżbieta Bandurska-Stankiewicz
Journal of Clinical Medicine.2022; 11(20): 6183. CrossRef
Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development
Ernest A. Adeghate, Huba Kalász, Saeeda Al Jaberi, Jennifer Adeghate, Kornelia Tekes
Expert Opinion on Investigational Drugs.2021; 30(2): 85. CrossRef
Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Jianping Weng, Longyi Zeng, Yuwei Zhang, Shen Qu, Xueying Wang, Ping Li, Liujun Fu, Boqing Ma, Shandong Ye, Jiao Sun, Weiping Lu, Zhiwen Liu, Daoxiong Chen, Zhifeng Cheng, Haiyan Liu, Tao Zhang, Jianjun Zou
Diabetes, Obesity and Metabolism.2021; 23(8): 1754. CrossRef
How do you treat obesity in the elderly pharmacologically?
Claudio Daniel González, Guillermo Di Girolamo
Expert Opinion on Pharmacotherapy.2021; 22(13): 1639. CrossRef
Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
Ayako Nagayama, Kenji Ashida, Miki Watanabe, Kanoko Moritaka, Aya Sonezaki, Yoichiro Kitajima, Hirokazu Takahashi, Satoko Yoshinobu, Shimpei Iwata, Junichi Yasuda, Nao Hasuzawa, Shuichi Ozono, Seiichi Motomura, Masatoshi Nomura
Frontiers in Endocrinology.2021;[Epub] CrossRef
New Pandemic: Obesity and Associated Nephropathy
Isha Sharma, Yingjun Liao, Xiaoping Zheng, Yashpal S. Kanwar
Frontiers in Medicine.2021;[Epub] CrossRef
Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective
Hayato Tanabe, Hiroaki Masuzaki, Michio Shimabukuro
Diabetes Research and Clinical Practice.2021; 180: 109067. CrossRef
The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
Mariana Tilinca, Robert Tiuca, Ioan Tilea, Andreea Varga
Journal of Personalized Medicine.2021; 11(12): 1249. CrossRef
The ‘diamond’ approach to personalized drug treatment of heart failure with reduced ejection fraction
Hongbo Gan, Heng Tang, Yujie Huang, Dan Wang, Peng Pu, Zhong Zuo
Reviews in Cardiovascular Medicine.2021;[Epub] CrossRef
Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
Wayne H‐H Sheu
Journal of Diabetes Investigation.2020; 11(5): 1115. CrossRef
SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

André J Scheen
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 2765. CrossRef
SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Yoshifumi Saisho
Diseases.2020; 8(2): 14. CrossRef
Roles of Epicardial Adipose Tissue in the Pathogenesis of Coronary Atherosclerosis　― An Update on Recent Findings ―
Kimie Tanaka, Daiju Fukuda, Masataka Sata
Circulation Journal.2020; 85(1): 2. CrossRef

Original Article

Clinical Diabetes & Therapeutics
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors: Ji-Yeon Lee, Yongin Cho, Minyoung Lee, You Jin Kim, Yong-ho Lee, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang; Diabetes Metab J. 2019;43(2):158-173. Published online January 25, 2019; DOI: https://doi.org/10.4093/dmj.2018.0057

10,810 View
210 Download
18 Web of Science
17 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

We investigated the predictive markers for the therapeutic efficacy and the best combination of sodium-glucose co-transporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and ipragliflozin) therapy in patients with type 2 diabetes mellitus (T2DM).

Methods

A total of 804 patients with T2DM who had taken SGLT2 inhibitor as monotherapy or an add-on therapy were analyzed. Multivariate regression analyses were performed to identify the predictors of SGLT2 inhibitor response including the classes of baseline anti-diabetic medications.

Results

After adjusting for age, sex, baseline body mass index (BMI), diabetes duration, duration of SGLT2 inhibitor use, initial glycosylated hemoglobin (HbA1c) level, estimated glomerular filtration rate (eGFR), and other anti-diabetic agent usage, multivariate analysis revealed that shorter diabetes duration, higher initial HbA1c and eGFR were associated with better glycemic response. However, baseline BMI was inversely correlated with glycemic status; lean subjects with well-controlled diabetes and obese subjects with inadequately controlled diabetes received more benefit from SGLT2 inhibitor treatment. In addition, dipeptidyl peptidase 4 (DPP4) inhibitor use was related to a greater reduction in HbA1c in patients with higher baseline HbA1c ≥7%. Sulfonylurea users experienced a larger change from baseline HbA1c but the significance was lost after adjustment for covariates and metformin and thiazolidinedione use did not affect the glycemic outcome.

Conclusion

A better response to SGLT2 inhibitors is expected in Korean T2DM patients who have higher baseline HbA1c and eGFR with a shorter diabetes duration. Moreover, the add-on of an SGLT2 inhibitor to a DPP4 inhibitor is likely to show the greatest glycemic response.

Citations

Citations to this article as recorded by

A machine learning model for optimizing treatment of patients with poorly controlled type 2 diabetes
Juan Shi, Cong Liu, Jiahang Hu, Yuancheng Dai, Ying Peng, Fengmei Xu, Haonan Shi, Yunsong Li, Jun Li, Zunhai Zhou, Chunfang Wen, Shan Huang, Yi Shu, Xiaolin Ye, Aifang Wang, Hongxia Zhao, Ping Feng, Shengli Wu, Dandan Wang, Ping Liu, Yi Shi, Shuhui Yang,
Communications Medicine.2026;[Epub] CrossRef
Exploring the value of ChatGPT in selecting antidiabetic agents for type 2 diabetes
Seol A. Jang, Su Jin Kwon, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
Diabetes, Obesity and Metabolism.2025; 27(10): 5761. CrossRef
Predictors of efficacy of Sodium‐GLucose Transporter‐2 inhibitors and Glucagon‐Like Peptide 1 receptor agonists: A retrospective cohort study
Daniele Scoccimarro, Giacomo Cipani, Ilaria Dicembrini, Edoardo Mannucci
Diabetes/Metabolism Research and Reviews.2024;[Epub] CrossRef
Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study
M. L. Morieri, I. Raz, A. Consoli, M. Rigato, A. Lapolla, F. Broglio, E. Bonora, A. Avogaro, G. P. Fadini, Federica Ginestra, Gloria Formoso, Agostino Consoli, Francesco Andreozzi, Giorgio Sesti, Salvatore Turco, Luigi Lucibelli, Adriano Gatti, Raffaella
Journal of Endocrinological Investigation.2023; 46(7): 1429. CrossRef
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review
Katherine G. Young, Eram Haider McInnes, Robert J. Massey, Anna R. Kahkoska, Scott J. Pilla, Sridharan Raghavan, Maggie A. Stanislawski, Deirdre K. Tobias, Andrew P. McGovern, Adem Y. Dawed, Angus G. Jones, Ewan R. Pearson, John M. Dennis, Deirdre K. Tobi
Communications Medicine.2023;[Epub] CrossRef
Predictors of HbA1c treatment response to add-on medication following metformin monotherapy: a population-based cohort study
Wei Ying Tan, Wynne Hsu, Mong Li Lee, Ngiap Chuan Tan
Scientific Reports.2023;[Epub] CrossRef
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extensio
Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon
Diabetes & Metabolism Journal.2023; 47(6): 808. CrossRef
Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
Seung-Hwan Lee, Kyung-Wan Min, Byung-Wan Lee, In-Kyung Jeong, Soon-Jib Yoo, Hyuk-Sang Kwon, Yoon-Hee Choi, Kun-Ho Yoon
Diabetes & Metabolism Journal.2021; 45(3): 339. CrossRef
Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice
Kana N. Miyata, Chao-Sheng Lo, Shuiling Zhao, Min-Chun Liao, Yuchao Pang, Shiao-Ying Chang, Junzheng Peng, Matthias Kretzler, Janos G. Filep, Julie R. Ingelfinger, Shao-Ling Zhang, John S.D. Chan
Clinical Science.2021; 135(7): 943. CrossRef
Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
Diabetes & Metabolism Journal.2020; 44(4): 489. CrossRef
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure
Francesco Giorgino, Irene Caruso, Julia Moellmann, Michael Lehrke
Metabolism.2020; 104: 154045. CrossRef
Clinical Predictors of the Hypoglycemic Effect of Sodium–Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study
Toshinori Hirai, Yuya Kawagoe, Motoki Kei, Ryuichi Ogawa, Toshimasa Itoh
Biological and Pharmaceutical Bulletin.2020; 43(5): 782. CrossRef
Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
Kidney Research and Clinical Practice.2020; 39(3): 269. CrossRef
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
Ildiko Lingvay, Matthew S Capehorn, Andrei-Mircea Catarig, Pierre Johansen, Jack Lawson, Anna Sandberg, Robert Shaw, Abby Paine
The Journal of Clinical Endocrinology & Metabolism.2020; 105(12): e4593. CrossRef
Letter: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
Kyung-Soo Kim
Diabetes & Metabolism Journal.2019; 43(3): 377. CrossRef
Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
Ji-Yeon Lee, Eun Seok Kang
Diabetes & Metabolism Journal.2019; 43(3): 379. CrossRef
An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
Ji A Seo
Diabetes & Metabolism Journal.2019; 43(5): 578. CrossRef

Review

Complications
Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet: Vincenza Spallone; Diabetes Metab J. 2019;43(1):3-30. Published online November 2, 2018; DOI: https://doi.org/10.4093/dmj.2018.0259

43,347 View
682 Download
213 Web of Science
227 Crossref

Abstract PDF PubReader ePub

The burden of diabetic cardiovascular autonomic neuropathy (CAN) is expected to increase due to the diabetes epidemic and its early and widespread appearance. CAN has a definite prognostic role for mortality and cardiovascular morbidity. Putative mechanisms for this are tachycardia, QT interval prolongation, orthostatic hypotension, reverse dipping, and impaired heart rate variability, while emerging mechanisms like inflammation support the pervasiveness of autonomic dysfunction. Efforts to overcome CAN under-diagnosis are on the table: by promoting screening for symptoms and signs; by simplifying cardiovascular reflex tests; and by selecting the candidates for screening. CAN assessment allows for treatment of its manifestations, cardiovascular risk stratification, and tailoring therapeutic targets. Risk factors for CAN are mainly glycaemic control in type 1 diabetes mellitus (T1DM) and, in addition, hypertension, dyslipidaemia, and obesity in type 2 diabetes mellitus (T2DM), while preliminary data regard glycaemic variability, vitamin B12 and D changes, oxidative stress, inflammation, and genetic biomarkers. Glycaemic control prevents CAN in T1DM, whereas multifactorial intervention might be effective in T2DM. Lifestyle intervention improves autonomic function mostly in pre-diabetes. While there is no conclusive evidence for a disease-modifying therapy, treatment of CAN manifestations is available. The modulation of autonomic function by SGLT2i represents a promising research field with possible clinical relevance.

Citations

Citations to this article as recorded by

Impact of cardiovascular autonomic neuropathy on cardiopulmonary, sympathoadrenal and metabolic responses to physical exercise in adults with type 1 diabetes
Olivia M. McCarthy, Rasmus B. Brødsgaard, Sandra Tawfik, Sissel Banner Lundemose, Emilie B. Lindkvist, Sara H. Naaman, Christian Stevns Hansen, Richard M. Bracken, Kirsten Nørgaard
Diabetologia.2026; 69(3): 618. CrossRef
Echocardiographic insights into cardiovascular autonomic dysfunction in Parkinson's disease
Zihao Li, Xiaohong Li, Wenlin Huang, Ziqi Gao, Piao Zhang, Chentao He, Siming Rong, Mengfei Cai, Zhenzhen Chen, Yan Li, Ruixue Xu, Lijuan Wang, Zhichao Zheng, Hongwen Fei, Yuhu Zhang
Journal of Parkinson’s Disease.2026; 16(1): 146. CrossRef
Recent Advances in the Study of Diabetic Cardiac Autonomic Neuropathy
Nan Wang, Jie Zhang
Reviews in Cardiovascular Medicine.2026;[Epub] CrossRef
Cutoffs, sensitivity and specificity of the Ewing battery in evaluating autonomic nervous system disorders: a systematic review
Theodora R. Barkoula, Christiana Ioannou, Martina Rekatsina, Kassiani Theodoraki, Panagiotis Zis
Clinical Autonomic Research.2026; 36(2): 155. CrossRef
Association between metabolic dysfunction-associated fatty liver disease and cardiovascular autonomic neuropathy in type 2 diabetes
Rong Peng, Yaoyun Ao, Enni Cen, Junnian Chen, Zeshan Huang, Xiaoying Fu, Jian Kuang, Shuiqing Lai, Shuting Zhang
Frontiers in Endocrinology.2026;[Epub] CrossRef
SDNN predicts 90-day disability after intravenous thrombolysis: autonomic dysfunction as a novel predictors in acute ischemic stroke
Xiaoyan Wu, Jianping Wang, Liumeng Jian, Li Shi, Jie Li, Jianqiang Zhong, Guoyou Peng, Jianjun Guo
Frontiers in Neurology.2026;[Epub] CrossRef
Catestatin and Diabetic Retinopathy in Type 2 Diabetes Mellitus
Karla Katić, Josip Katić, Marko Kumrić, Joško Božić, Daniela Šupe Domić, Ivan Aranza, Šime Kabić, Ivana Barun, Kajo Bućan
Biomedicines.2026; 14(3): 648. CrossRef
Circulating Neopterin Is Independently Associated with Autonomic Neuropathy in Type 2 Diabetes, but Not with Other Microvascular Complications
Diana Nikolova, Zdravko Kamenov, Julieta Hristova, Antoaneta Trifonova Gateva
Medical Sciences.2026; 14(2): 166. CrossRef
Metabolic inflexibility mediates the association between type 2 diabetes and impaired post-exercise heart rate recovery: a mediation analysis
Yutao Liu, Jiahui Wu, Nan Li, Suhui Zhang, Yan Feng, Ying Zhang, Yong Shao
Nutrition & Metabolism.2026;[Epub] CrossRef
Heart Rate Variability in Newborns From Diabetic Mothers: Clinical Application and Significance
Virginia Beretta, Laura Cannavò, Sebastiano Ravenda, Chiara Petrolini, Vincenzo Raitano, Sabrina Moretti, Valentina Dell'Orto, Serafina Perrone
Annals of Noninvasive Electrocardiology.2026;[Epub] CrossRef
Advancing entropy analysis for heart rate variability: clinical insights for aging and diabetes
Shanglin Yang, Hsientsai Wu, Xuwei Liao, Yuyang Lin, Juin J. Liou
Frontiers in Physiology.2026;[Epub] CrossRef
Laser-Evoked Potentials in the Early Diagnosis of Diabetic Neuropathy and Their Association with Cardiovascular Autonomic Reflex Tests: A Retrospective Observational Study in Patients with Type 2 Diabetes
Giovanni Umberto Borin, Marta Aventaggiato, Cristina Bittante, Vittorio Cacciatori, Alessia Segatti, Elisa Concon, Grazia Devigili, Enzo Bonora, Giacomo Zoppini, Giovanna Maddalena Squintani
Brain Sciences.2026; 16(4): 390. CrossRef
Normative data on measures of cardiovascular autonomic neuropathy and the effect of pretest conditions in a large Danish non-diabetic CVD-free population from the Lolland-Falster Health Study
Christian S. Hansen, Marie Mathilde Bjerg Christensen, Dorte Vistisen, Randi Jepsen, Christina Ellervik, Marit Eika Jørgensen, Jesper Fleischer
Clinical Autonomic Research.2025; 35(1): 101. CrossRef
Comparative study of autonomic function in diabetics and yoga practitioners using Ewing’s battery
Tasneem Amadawala, Charushila Rukadikar, Dileep Deshpande
Journal of Family Medicine and Primary Care.2025; 14(1): 121. CrossRef
A call to action for peripheral neuropathy research funding—Time to consolidate funding under one NIH initiative?
Stéphanie A. Eid, Kristy L. Townsend, Vincenza Spallone, Daniela M. Menichella, Emily J. Koubek, Eva L. Feldman
Journal of the Peripheral Nervous System.2025;[Epub] CrossRef
Electrodiagnostic assessment of autonomic nervous system in diabetic autonomic neuropathy: Case series in 72 diabetes patients
Suchitra Dube, Sandip M. Hulke, Santosh L. Wakode, Sagar Khadanga
Journal of Family Medicine and Primary Care.2025; 14(1): 452. CrossRef
Disorders of circadian rhythms of heart rate variability in diabetic cardiac autonomic neuropathy: mechanisms and consequences
V.A. Serhiyenko, M.I. Dolynay, V.B. Sehin, Y.V. Lazur, A.A. Serhiyenko
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 20(8): 549. CrossRef
Cardiac Autonomic Neuropathy in Diabetes Mellitus: Pathogenesis, Epidemiology, Diagnosis and Clinical Implications: A Narrative Review
Alexandra Gogan, Ovidiu Potre, Vlad-Florian Avram, Minodora Andor, Florina Caruntu, Bogdan Timar
Journal of Clinical Medicine.2025; 14(3): 671. CrossRef
Cardiovascular autonomic neuropathy is associated with SLEDAI in patients with systemic lupus erythematosus
Simin Guo, Yujiao Wang, Lingyun Sun
Clinical Rheumatology.2025; 44(3): 1103. CrossRef
Correlation between Sirtuin 1 downregulation and reduced vitamin D receptor expression in patients with diabetic neuropathy
Andrea Latini, Giada De Benedittis, Chiara Morgante, Beatrice Gasperini, Ilenia D’Ippolito, Davide Lauro, Giuseppe Novelli, Cinzia Ciccacci, Vincenza Spallone, Paola Borgiani
Acta Diabetologica.2025; 62(9): 1395. CrossRef
Obesity Class and Severity of Metabolic Emergencies: A Single-Center Retrospective Five-Year Study
Iulia Najette Crintea, Alexandru Cristian Cindrea, Teodor Florin Fulga, Cosmin Iosif Trebuian, Adina Maria Marza, Alina Petrica, Ovidiu Alexandru Mederle, Romulus Timar
Healthcare.2025; 13(6): 617. CrossRef
Sequential classification approach for enhancing the assessment of cardiac autonomic neuropathy
Moustafa Abdelwanis, Karim Moawad, Shahmir Mohammed, Ammar Hummieda, Shayaan Syed, Maher Maalouf, Herbert F. Jelinek
Computers in Biology and Medicine.2025; 190: 109999. CrossRef
Pooled prevalence and associated factors of ECG abnormality among type 2 diabetic patients in the last ten years: Systematic review and meta-analysis
Mihret Getnet, Habtu Kifle Negash, Hailu Aragie, Hiwot Tezera Endale, Tseganesh Asefa, Winta Tesfaye, Yibeltal Yismaw Gela, Gaetano Santulli
PLOS ONE.2025; 20(3): e0319173. CrossRef
Resident Macrophages in the Cervical Sympathetic Ganglia Participate in P2Y12 Receptor Mediated Diabetic Cardiac Autonomic Neuropathy
Junpei Du, Yuxin Yang, Jingan Rao, Xiaoqian Ma, Shanshan Tang, Jian Liu, Yeqing Liu, Shipan Liu, Guodong Li, Shangdong Liang, Yun Gao
Molecular Neurobiology.2025; 62(8): 9744. CrossRef
Heart Rate Variability, Microvascular Dysfunction, and Inflammation: Exploring the Potential of taVNS in Managing Heart Failure in Type 2 Diabetes Mellitus
Serge C. Thal, Sergey Shityakov, Ellaine Salvador, Carola Y. Förster
Biomolecules.2025; 15(4): 499. CrossRef
Corneal confocal microscopy identifies early and definite diabetic cardiac autonomic neuropathy
Shazli Azmi, Maryam Ferdousi, Alise Kalteniece, Ioannis N Petropoulos, Uazman Alam, Georgios Ponirakis, Omar Asghar, Andrew Marshall, Andrew JM Boulton, Nathan Efron, Rayaz A Malik
Diabetes Research and Clinical Practice.2025; 224: 112172. CrossRef
Diabetic neuropathy: cutting-edge research and future directions
Yang Yang, Bing Zhao, Yuanzhe Wang, Hongli Lan, Xinyu Liu, Yue Hu, Peng Cao
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
External validation of a clinical risk score for the presence of cardiovascular autonomic neuropathy in type 1 diabetes
Pietro Pertile, Ilenia D'Ippolito, Beatrice De Santis, Aikaterini Andreadi, Davide Lauro, Vincenza Spallone
Journal of Diabetes and its Complications.2025; 39(7): 109066. CrossRef
ВПЛИВ ВИМУШЕНОГО ПЕРЕСЕЛЕННЯ НА СТАН ХРОНІЧНОГО ЗАПАЛЕННЯ ТА ІНСУЛІНОВОЇ РЕЗИСТЕНТНОСТІ ПРИ ДІАБЕТИЧНІЙ КАРДІАЛЬНІЙ АВТОНОМНІЙ НЕЙРОПАТІЇ
Вікторія Сергієнко, Володимир Сегін, Олександр Сергієнко
PROBLEMS OF ENDOCRINE PATHOLOGY.2025; 82(1): 33. CrossRef
Features of short-term heart rate variability in internally displaced people with type 2 diabetes mellitus
V.A. Serhiyenko, V.B. Sehin, V.I. Pankiv, A.A. Serhiyenko
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 21(3): 243. CrossRef
Autonomic function and hemodynamic changes in type 2 diabetes: insights into sympathetic activation and vascular stiffness
Larissa Morete Caieiro da Costa, Tatiana Palotta Minari, Luciana Pellegrini Pisani, Tatiane de Azevedo Rubio, Louise Bounalume Tácito Yugar, Luis Gustavo Sedenho-Prado, Milene Ribeiro, Lúcia Helena Bonalume Tacito, Luciana Neves Cosenso-Martin, Antônio Ca
Diabetes Research and Clinical Practice.2025; 225: 112266. CrossRef
NerveCheck master to screen patients with type 1 or type 2 diabetes for peripheral and cardiac autonomic neuropathy
Raffaele Galiero, Amel Rezki, Vittorio Simeon, Domenico Beccia, Maria Alfano, Alfredo Caturano, Ferdinando Carlo Sasso, Paul Valensi
Journal of Diabetes and its Complications.2025; 39(9): 109107. CrossRef
High Diagnostic Performance of the Indicator Plaster Neuropad for the Detection of Established Diabetic Autonomic Neuropathy
Ioanna Zografou, Panagiotis Doukelis, Theocharis Koufakis, Evangelia Kotzakioulafi, Polykarpos Evripidou, Zisis Kontoninas, Christos Savopoulos, Michael Doumas, Triantafyllos Didangelos, Konstantinos Kantartzis
Diabetology.2025; 6(6): 55. CrossRef
2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association
Shinae Kang, Seon Mee Kang, Jong Han Choi, Seung-Hyun Ko, Bo Kyung Koo, Hyuk-Sang Kwon, Mi Kyung Kim, Sang Yong Kim, Soo-Kyung Kim, Young-eun Kim, Eun Sook Kim, Jae Hyeon Kim, Chong Hwa Kim, Ji Min Kim, Hae Jin Kim, Min Kyong Moon, Sun Joon Moon, Jun Sung
Diabetes & Metabolism Journal.2025; 49(4): 582. CrossRef
Cross-cultural adaptation and validation of the Ukrainian version of the Type 2 Diabetes Distress Assessment System
V.A. Serhiyenkо, V.B. Sehin, S.Y. Holovach, A.A. Serhiyenko
INTERNATIONAL NEUROLOGICAL JOURNAL.2025; 21(4): 266. CrossRef
Diabetic distress, low-grade chronic inflammation, and cardiac autonomic neuropathy in internally displaced people (literature review and own observations)
V.A. Serhiyenkо
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 21(4): 381. CrossRef
Initial Evaluation of Patients with Diabetes Mellitus according to Clinical Guidelines
Dughyun Choi
The Journal of Korean Diabetes.2025; 26(2): 69. CrossRef
Long-term prediction of mortality by heart rate turbulence in hemodialysis patients and the impact of diabetes mellitus–a longitudinal observational study
Nora Hannane, Christopher C. Mayer, Julia Matschkal, Felix Bormann, Axel Krieter, Jürgen R. Braun, Claudius Küchle, Lutz Renders, Roman Günthner, Georg Schmidt, Alexander Müller, Siegfried Wassertheurer, Uwe Heemann, Bernhard Haller, Marek Malik, Christop
Journal of Nephrology.2025; 38(8): 2261. CrossRef
Assessing the impact of supervised interval training on cardiovascular autonomic neuropathy in type 2 diabetes patients
Laura Stirane, Karlis Stirans, Leonora Pahirko, Janis Mednieks, Karina Ostrovska, Aija Kļavina, Leo Selavo, Jelizaveta Sokolovska
Physiological Reports.2025;[Epub] CrossRef
Glycaemic control, low levels of high-density lipoprotein, and high cardiovascular risk are associated with cardiovascular autonomic neuropathy
Tina Okdahl, Anne-Marie Wegeberg, Marie Møller Jensen, Jonas Salling Quist, Christina Brock
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Obstructive Sleep Apnea and Type 2 Diabetes: An Update
Sandro Gentile, Vincenzo Maria Monda, Giuseppina Guarino, Ersilia Satta, Maria Chiarello, Giuseppe Caccavale, Edi Mattera, Raffaele Marfella, Felice Strollo
Journal of Clinical Medicine.2025; 14(15): 5574. CrossRef
Comparison of Diabetic Polyneuropathy and Cardiac Autonomic Neuropathy in Type 1 and Type 2 Diabetes Mellitus
Laura Šiaulienė, Ieva Sereikė, Juozas Rimantas Lazutka, Joana Semigrejeviene, Žydrūnė Visockienė
Diabetology.2025; 6(8): 74. CrossRef
Bioprospecting the antidiabetic potential of aqueous seed extract of Allanblackia floribunda Oliv. (Clusiaceae)
John Alake, Wisdom Ahlidja, Isaac Tabiri Henneh, Augustine Kwabil, Kwabena Darko Adu, Samuel Ansong Asiamah, Du-Bois Asante, Francis Ackah Armah
Food Chemistry Advances.2025; 8: 101071. CrossRef
Diabetes mellitus and postural hypotension in prehospital care
William Young
Journal of Paramedic Practice.2025; 17(9): 1. CrossRef
The prevalence of diabetic neuropathy in Greenland and its association with Inuit genetic ancestry – a cross-sectional study
Marie Mathilde Bjerg Christensen, Christian Stevns Hansen, Jesper Fleischer, Ninna Senftleber, Frederik Filip Stæger, Torben Hansen, Daniel R. Witte, Marit Eika Jørgensen
Journal of Diabetes and its Complications.2025; 39(11): 109179. CrossRef
Cardiac Autonomic Neuropathy and Its Impact on Progression of Diabetic Kidney Disease in Type 1 and Type 2 Diabetes
Kywe Kywe Soe, Dinesh Selvarajah
Kidney Medicine.2025; 7(12): 101149. CrossRef
SPARC-modified mesenchymal stem cells promote recovery of β-cells and insulin secretion by calcium ion homeostasis
Jiaqi Gao, Balun Li, Hongkai Tian, Chenchen Li, Nikita Merzlikin, Dongyao Han, Zixi Ling, Zengyu Zhang, Wenlong zhu, Jianqi Dai, Lydmila Gerunova, Changrong Lv, Na Li, Jinlian Hua
Stem Cell Research & Therapy.2025;[Epub] CrossRef
Association between physical activity propensity and cardiovascular autonomic neuropathy in type 1 diabetes: evidence from a single-centre study
Simona Zaccaria, Laura Giurato, Isabella Nardone, Sium Wolde Sellasie, Innocenza Tripicchio, Marco Meloni, Pasquale Di Perna, Luigi Uccioli
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Physical Exercise Before Long‐Term Electrocardiogram May Enhance the Assessment of Nocturnal Heart Rate Variability in Young Individuals With Type 1 Diabetes Melltius
Cecilia Fridolfsson, Peter Blomstrand, Jan Engvall, Johanna Thegerström
Annals of Noninvasive Electrocardiology.2025;[Epub] CrossRef
Rectal sensitivity correlated with gastrointestinal‐mediated glucose disposal, but not the incretin effect
Sondre Meling, Erling Tjora, Heike Eichele, Rasmus B. Nedergaard, Filip K. Knop, Niels Ejskjaer, Siri Carlsen, Pål R. Njølstad, Christina Brock, Eirik Søfteland
Endocrinology, Diabetes & Metabolism.2024;[Epub] CrossRef
Glucose metabolism and autonomic function in healthy individuals and patients with type 2 diabetes mellitus at rest and during exercise
Takuto Hamaoka, Urs A. Leuenberger, Rachel C. Drew, Matthew Murray, Cheryl Blaha, Jonathan Carter Luck, Lawrence I. Sinoway, Jian Cui
Experimental Physiology.2024; 109(2): 214. CrossRef
Quantification of lipoproteins by proton nuclear magnetic resonance spectroscopy (1H-NMRS) improves the prediction of cardiac autonomic dysfunction in patients with type 1 diabetes
L. Nattero-Chávez, M. Insenser, N. Amigó, S. Samino, N. Martínez-Micaelo, B. Dorado Avendaño, A. Quintero Tobar, H. F. Escobar-Morreale, M. Luque-Ramírez
Journal of Endocrinological Investigation.2024; 47(8): 2075. CrossRef
Predictors of pacemaker requirement in patients with implantable loop recorder and unexplained syncope: A systematic review and meta‐analysis
Moein Zangiabadian, Kiarash Soltani, Yasaman Gholinejad, Reyhane Yahya, Shayan Bastami, Mohammad Ali Akbarzadeh, Mohammad Sharifian Ardestani, Azadeh Aletaha
Clinical Cardiology.2024;[Epub] CrossRef
Impaired Cardiovagal Activity as a Link Between Hyperglycemia and Arterial Stiffness in Adults With Type 2 Diabetes Mellitus Among an Eastern Indian Population: A Cross-sectional Study
Nibedita Priyadarsini, Devineni Likhitha, Madumathy Ramachandran, Kishore Kumar Behera
Canadian Journal of Diabetes.2024; 48(3): 147. CrossRef
No clear evidence of neuropathy among patients with high risk for the development of prediabetes/diabetes—a pilot study
Anna E. Körei, Magdolna Békeffy, Adrienn Menyhárt, Karola Osgyán, Ildikó Istenes, Viktor J. Horváth, Péter Kempler
Frontiers in Endocrinology.2024;[Epub] CrossRef
Effects of Physical Cues on Stem Cell-Derived Extracellular Vesicles toward Neuropathy Applications
Danyale Berry, Justice Ene, Aakash Nathani, Mandip Singh, Yan Li, Changchun Zeng
Biomedicines.2024; 12(3): 489. CrossRef
Oxidative Stress, Endothelial Dysfunction, and N -Acetylcysteine in Type 2 Diabetes Mellitus
Xin Li, Junyong Zou, Aiping Lin, Jingshu Chi, Hong Hao, Hong Chen, Zhenguo Liu
Antioxidants & Redox Signaling.2024; 40(16-18): 968. CrossRef
High dose cholecalciferol supplementation causing morning blood pressure reduction in patients with type 1 diabetes mellitus and cardiovascular autonomic neuropathy
João Felício, Lorena Moraes, Gabriela Lemos, Ícaro Souza, Giovana Vieira, Lilian Silva, Natércia Queiroz, Ana Carolina Souza, Franciane Melo, João Felício Abrahão Neto, Hana Britto, Manuela Lemos, Márcia Santos, Priscila Figueiredo, Ana Regina Motta, Meli
Scientific Reports.2024;[Epub] CrossRef
Transcutaneous vagal nerve stimulation for treating gastrointestinal symptoms in individuals with diabetes: a randomised, double-blind, sham-controlled, multicentre trial
Ditte S. Kornum, Davide Bertoli, Huda Kufaishi, Anne-Marie Wegeberg, Tina Okdahl, Esben B. Mark, Katrine L. Høyer, Jens B. Frøkjær, Birgitte Brock, Klaus Krogh, Christian S. Hansen, Filip K. Knop, Christina Brock, Asbjørn M. Drewes
Diabetologia.2024; 67(6): 1122. CrossRef
Independent and interactive associations of heart rate and obesity with type 2 diabetes mellites: A population‐based study
Tianxin Zhu, Qingyu Chen, Hongxing Chen, Lili You, Dan Liu, Xiaoyun Zhang, Feng Li, Hongshi Wu, Juying Tang, Diaozhu Lin, Kan Sun, Li Yan, Meng Ren
Journal of Diabetes.2024;[Epub] CrossRef
Bladder dysfunction in adolescents with type 1 diabetes
Vinni Faber Rasmussen, Mathilde Thrysøe, Páll Karlsson, Mette Madsen, Esben Thyssen Vestergaard, Jens Randel Nyengaard, Astrid Juhl Terkelsen, Konstantinos Kamperis, Kurt Kristensen
Journal of Pediatric Urology.2024; 20(4): 564.e1. CrossRef
Genetic markers of cardiac autonomic neuropathy in the Kazakh population
Nazira Bekenova, Ainur Sibagatova, Alisher Aitkaliyev, Tamara Vochshenkova, Balzhan Kassiyeva, Valeriy Benberin
BMC Cardiovascular Disorders.2024;[Epub] CrossRef
Acompanhamento e rastreamento de pacientes com Diabetes Mellitus Tipo 2 em uma unidade de saúde: prevenção de complicações macro e microvasculares
Maria Helena Cordeiro de Oliveira, Milena Nunes Alves de Sousa
Cuadernos de Educación y Desarrollo.2024; 16(5): e4145. CrossRef
POST-TRAUMATIC STRESS DISORDER, INSOMNIA, HEART RATE VARIABILITY AND METABOLIC SYNDROME (NARRATIVE REVIEW)
Alexandr Serhiyenko, Myroslav Baitsar, Volodymyr Sehin, Ludmila Serhiyenko, Vitaliy Kuznets, Victoria Serhiyenko
Proceeding of the Shevchenko Scientific Society. Medical Sciences.2024;[Epub] CrossRef
Determinants of Orthostatic Hypotension in Type 2 Diabetes: Is Cardiac Autonomic Neuropathy the Main Factor?
Ilenia D'Ippolito, Myriam Angelica Carlucci, Cinzia D'Amato, Davide Lauro, Vincenza Spallone
Endocrine Practice.2024; 30(9): 802. CrossRef
New Diabetic Treatment by Alleviation of Autonomic Nervous System Dysfunction Measured as Periosteal Pressure Sensitivity at Sternum Improves Empowerment, Treatment Satisfaction, and Self-Reported Health of People with Type 2 Diabetes: A Randomized Trial
Sofie Hecquet, Søren Ballegaard, Ebbe Eldrup, Christian Hansen, Tine Hansen, Gitte Harboe, Peter Rossing, Caroline Pichat, Torquil Watt, Finn Gyntelberg, Nanna Ørsted, Jens Faber
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 2519. CrossRef
Exploring heart rate variability in polycystic ovary syndrome: implications for cardiovascular health: a systematic review and meta-analysis
Seyedeh Tarlan Mirzohreh, Padideh Panahi, Fariba Heidari
Systematic Reviews.2024;[Epub] CrossRef
Predicting the dynamics of heart rate variability in patients with type 1 diabetes against improving glycemic control
N.O. Pertseva, K.I. Moshenets
Medicni perspektivi.2024; 29(2): 87. CrossRef
Neurophysiological assessment of peripheral neuropathy through whole plantar nerve conduction in type 2 diabetes mellitus and healthy control subjects
Dario Ricciardi, Raffaele Galiero, Vincenzo Todisco, Gioacchino Tedeschi, Giuseppe Loffredo, Alfredo Caturano, Luca Rinaldi, Giovanni Cirillo, Ferdinando Carlo Sasso
Metabolism and Target Organ Damage.2024;[Epub] CrossRef
Glycemic variability and diabetic cardiac autonomic neuropathy
A.A. Serhiyenko, T.V. Tsaryk, Y.I. Pavlovskiy, V.A. Serhiyenko
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(4): 225. CrossRef
2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, Yoon Ju Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang
Diabetes & Metabolism Journal.2024; 48(4): 546. CrossRef
Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management
Aikaterini Eleftheriadou, Vincenza Spallone, Abd A. Tahrani, Uazman Alam
Diabetologia.2024; 67(12): 2611. CrossRef
Prevalence of cardiovascular autonomic neuropathy in an admixed population of patients with type 1 diabetes. Lessons from a pioneer multicentre study in Brazil
Lucianne Righeti Monteiro Tannus, Hermelinda Cordeiro Pedrosa, Cejana Hamu Aguiar, Karla Guerra Drummond, André Pinheiro, Franz Schubert Leal, Carlos Antonio Negrato, Marilia Brito Gomes
Primary Care Diabetes.2024; 18(5): 539. CrossRef
Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy
Triantafyllos Didangelos, Eleni Karlafti, Evangelia Kotzakioulafi, Parthena Giannoulaki, Zisis Kontoninas, Anastasia Kontana, Polykarpos Evripidou, Christos Savopoulos, Andreas L. Birkenfeld, Konstantinos Kantartzis
Nutrients.2024; 16(18): 3045. CrossRef
Cardiovascular Autonomic Dysfunction Before and After Chemotherapy in Cancer Patients
So Young Yoon, Jeeyoung Oh
Journal of Clinical Neurology.2024; 20(6): 551. CrossRef
Remodeling of the Intracardiac Ganglia During the Development of Cardiovascular Autonomic Dysfunction in Type 2 Diabetes: Molecular Mechanisms and Therapeutics
Anthony J. Evans, Yu-Long Li
International Journal of Molecular Sciences.2024; 25(22): 12464. CrossRef
Prevalence and Risk Factors of Cardiovascular Autonomic Neuropathy in Individuals with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Xin Huang, Yun Bao, Jie Wang, Limin Tian
Reviews in Cardiovascular Medicine.2024;[Epub] CrossRef
The impact of working night shifts on cardiac autonomic nervous regulation during the six-minute walk test in nurses
Taihe Zhan, Xiumei Wei, Ziying Zhang, Zhimin Shi, Hongyan Xie, Xiaotao Ma, Suyue Pan, Daogang Zha
BMC Nursing.2024;[Epub] CrossRef
D1S-Neuro Program: Frequency and Risk Factors for the Development of Diabetic Neuropathy in Pediatric Patients with Type 1 Diabetes Mellitus, a Single Center Study
Marco Piccoli, Joaquin Gutierrez de Rubalcava Doblas, Patrizia Furlan, Silvia Cocchio, Alessandro Zamberlan, Gloria Panzeri, Vincenzo Baldo, Carlo Moretti
Biomedicines.2024; 13(1): 19. CrossRef
Опитувальник «Композитна оцінка вегетативних симптомів 31» (COMPASS 31): валідація та можливості застосування в діагностиці вегетативної дисфункції у хворих на цукровий діабет 2-го типу
V.A. Serhiyenko, V.B. Sehin, A.A.
Endokrynologia.2024; 29(4): 338. CrossRef
Mortality risk factors in newly diagnosed diabetic cardiac autonomic neuropathy
Bruce A. Chase, Sylwia Pocica, Roberta Frigerio, Katerina Markopoulou, Demetrius M. Maraganore, Navamon Aunaetitrakul, Alexander Epshteyn, Alexandru C. Barboi
Clinical Autonomic Research.2023; 33(6): 903. CrossRef
Autonomic symptoms and associated factors in patients with chronic heart failure
Hellen Da Silva, Sofie Pardaens, Marc Vanderheyden, Johan De Sutter, Heleen Demeyer, Michel De Pauw, Laurent Demulier, Jan Stautemas, Patrick Calders
Acta Cardiologica.2023; 78(2): 203. CrossRef
Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
Jonathan Goldney, Jack A. Sargeant, Melanie J. Davies
Diabetologia.2023; 66(10): 1832. CrossRef
Functional and morphometric assessment of small-fibre damage in late-onset hereditary transthyretin amyloidosis with polyneuropathy: the controversial relation between small-fibre-related symptoms and diagnostic test findings
Eleonora Galosi, Luca Leonardi, Pietro Falco, Giuseppe Di Pietro, Alessandra Fasolino, Nicoletta Esposito, Caterina Leone, Giulia Di Stefano, Maurizio Inghilleri, Marco Luigetti, Antonini Giovanni, Andrea Truini
Amyloid.2023; 30(1): 59. CrossRef
In vivo molecular imaging of cardiac angiogenesis in persons with and without type 2 diabetes: A cross‐sectional 68 Ga‐RGD‐PET study
Jens Christian Laursen, Ida Kirstine Bull Rasmussen, Emilie Hein Zobel, Philip Hasbak, Lene Holmvang, Christian Stevns Hansen, Bernt Johan von Scholten, Marie Frimodt‐Møller, Peter Rossing, Tine Willum Hansen, Andreas Kjaer, Rasmus Sejersten Ripa
Diabetic Medicine.2023;[Epub] CrossRef
Cardiac innervations in diabetes mellitus—Anatomical evidence of neuropathy
Natalija Filipović, Maja Marinović Guić, Vana Košta, Katarina Vukojević
The Anatomical Record.2023; 306(9): 2345. CrossRef
Clinical Predictors of Pacing Device Implantation in Implantable Cardiac Monitor Recipients for Unexplained Syncope
Reina Tonegawa-Kuji, Yuko Y. Inoue, Michikazu Nakai, Koshiro Kanaoka, Yoko Sumita, Yuichiro Miyazaki, Akinori Wakamiya, Keiko Shimamoto, Nobuhiko Ueda, Kenzaburo Nakajima, Naoya Kataoka, Mitsuru Wada, Kenichiro Yamagata, Kohei Ishibashi, Koji Miyamoto, Sa
CJC Open.2023; 5(4): 259. CrossRef
Cardiovascular autonomic reflex tests using a handheld device in the diagnosis of cardiovascular autonomic neuropathy in patients with schizophrenia
Laura Blok-Husum, Milka Ane Rank Brcelic, Hanin Kawa Farman Kawal Bassi, Svend Eggert Jensen, Rene Ernst Nielsen, Kristian Kragholm, Jesper Fleischer, Esben Laugesen, Christoffer Polcwiartek
American Heart Journal Plus: Cardiology Research and Practice.2023; 26: 100252. CrossRef
Causal association between vitamin D and diabetic neuropathy: a Mendelian randomization analysis
Wei Huang, Lei Gu, Jingwen Wang, Yiqi Wang, Fangzheng Cao, Tianyu Jin, Yifan Cheng
Endocrine.2023; 80(2): 328. CrossRef
Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
Panagiotis Theofilis, Evangelos Oikonomou, Konstantinos Tsioufis, Dimitris Tousoulis
Life.2023; 13(2): 497. CrossRef
Sex differences and sex steroids influence on the presentation and severity of cardiovascular autonomic neuropathy of patients with type 1 diabetes
Lía Nattero-Chávez, María Insenser, Alejandra Quintero Tobar, Elena Fernández-Durán, Beatriz Dorado Avendaño, Tom Fiers, Jean-Marc Kaufman, Manuel Luque-Ramírez, Héctor F. Escobar-Morreale
Cardiovascular Diabetology.2023;[Epub] CrossRef
Early Gastrointestinal Neuropathy Assessed by Wireless Motility Capsules in Adolescents with Type 1 Diabetes
Vinni Faber Rasmussen, Mathilde Thrysøe, Páll Karlsson, Esben Thyssen Vestergaard, Kurt Kristensen, Ann-Margrethe Rønholt Christensen, Jens Randel Nyengaard, Astrid Juhl Terkelsen, Christina Brock, Klaus Krogh
Journal of Clinical Medicine.2023; 12(5): 1925. CrossRef
Heart rate variability in people with metabolic syndrome
Kostiantyn Apykhtin, Svitlana Drozdovska, Olha Hurenko, Anastasiia Nahorna, Anatoly Pisaruk, Yuliia Panchenko, Olena Andrieieva
Ageing and Longevity.2023; 4(1): 1. CrossRef
Heart rate variability in people with metabolic syndrome
Kostiantyn Apykhtin, Svitlana Drozdovska, Olha Hurenko, Anastasiia Nahorna, Anatoly Pisaruk, Yuliia Panchenko, Olena Andrieieva
JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE.2023; (1 2023): 1. CrossRef
Potential of electronic devices for detection of health problems in older adults at home: A systematic review and meta-analysis
Yu-ting Cao, Xin-xin Zhao, Yi-ting Yang, Shi-jie Zhu, Liang-dong Zheng, Ting Ying, Zhou Sha, Rui Zhu, Tao Wu
Geriatric Nursing.2023; 51: 54. CrossRef
Diabetes mellitus in der Akut- und Notfallmedizin
Leo Benning, Julian Krehl, Felix Patricius Hans
Notfallmedizin up2date.2023; 18(01): 45. CrossRef
Correlation between Heart rate recovery and Left Atrial phasic functions evaluated by 2D speckle-tracking Echocardiography after Acute Myocardial infarction
Behruz Mashayekhi, Reza Mohseni-Badalabadi, Ali Hosseinsabet, Tahereh Ahmadian
BMC Cardiovascular Disorders.2023;[Epub] CrossRef
Pancreatic sympathetic innervation disturbance in type 1 diabetes
Senlin Li, Huimin Yuan, Keshan Yang, Qing Li, Ming Xiang
Clinical Immunology.2023; 250: 109319. CrossRef
A Nonrandomized Trial of the Effects of Passive Simulated Jogging on Short-Term Heart Rate Variability in Type 2 Diabetic Subjects
Jose A. Adams, Jose R. Lopez, Veronica Banderas, Marvin A. Sackner, Mark Yorek
Journal of Diabetes Research.2023; 2023: 1. CrossRef
Evaluating treatment options for cardiovascular autonomic neuropathy in patients with diabetes mellitus: a systematic review
Jasmine KaiLi Goh, Leroy Koh
Diabetology International.2023; 14(3): 224. CrossRef
Autonomic neuropathic symptoms in patients with diabetes: practical tools for screening in daily routine
Ana Raquel Souza de Azevedo Vieira, Lara Benigno Porto-Dantas, Flaviene Alves do Prado Romani, Patrícia Souza Carvalho, Rodica Pop-Busui, Hermelinda Cordeiro Pedrosa
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
“Arterial stiffness is not associated with changes in the circadian pattern of blood pressure in patients with type 1 diabetes mellitus and cardiovascular autonomic dysfunction”
Lía Nattero-Chávez, Ane Bayona Cebada, Elena Fernández-Durán, Alejandra Quintero Tobar, Beatriz Dorado Avendaño, Héctor Escobar-Morreale, Manuel Luque-Ramírez
Diabetes and Vascular Disease Research.2023;[Epub] CrossRef
Frontiers in diagnostic and therapeutic approaches in diabetic sensorimotor neuropathy (DSPN)
Sanjeev Sharma, Gerry Rayman
Frontiers in Endocrinology.2023;[Epub] CrossRef
In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum
Jens Faber, Søren Ballegaard, Nanna Ørsted, Ebbe Eldrup, Benny Karpatschof, Finn Gyntelberg, Sofie Korsgaard Hecquet, Albert Gjedde
Frontiers in Neuroscience.2023;[Epub] CrossRef
Functional status associated with postural dizziness, but not postural hypotension, in older adults: a community-based study
Hsiang-Ju Cheng, Zih-Jie Sun, Feng-Hwa Lu, Yi-Ching Yang, Chih-Jen Chang, Jin-Shang Wu
BMC Geriatrics.2023;[Epub] CrossRef
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open‐label, crossover trial
Jens Christian Laursen, Viktor Rotbain Curovic, Marjolein Y. A. M. Kroonen, Niels Jongs, Emilie H. Zobel, Tine W. Hansen, Marie Frimodt‐Møller, Gozewijn D. Laverman, Adriaan Kooy, Frederik Persson, Hiddo J. L. Heerspink, Christian Stevns Hansen, Peter Ros
Diabetes, Obesity and Metabolism.2023; 25(10): 3064. CrossRef
The Retinal Nerve Fiber Layer Thickness Is Associated with Systemic Neurodegeneration in Long-Term Type 1 Diabetes
Christina Brock, Anne-Marie Wegeberg, Thomas Arendt Nielsen, Bassam Karout, Per M. Hellström, Asbjørn Mohr Drewes, Henrik Vorum
Translational Vision Science & Technology.2023; 12(6): 23. CrossRef
The Use of Empirical Mode Decomposition on Heart Rate Variability Signals to Assess Autonomic Neuropathy Progression in Type 2 Diabetes
Sandra Cossul, Felipe Rettore Andreis, Mateus Andre Favretto, Jefferson Luiz Brum Marques
Applied Sciences.2023; 13(13): 7824. CrossRef
Topical Capsaicin for the Management of Painful Diabetic Neuropathy: A Narrative Systematic Review
Brandon Goodwin, Maanas Chiplunkar, Ryan Salerno, Kylon Coombs, Umar Sannoh, Vrushank Shah, Nicholas Averell, Usmaan Al-Shebab, Deanna Janora
Pain Management.2023; 13(5): 309. CrossRef
Adynamic response to cold pain reflects dysautonomia in type 1 diabetes and polyneuropathy
Thomas Arendt Nielsen, Søren Lundbye-Christensen, Yoanna Krasimirova Dimitrova, Sam Riahi, Birgitte Brock, Asbjørn Mohr Drewes, Christina Brock
Scientific Reports.2023;[Epub] CrossRef
Autonomic Nerve Function Tests in Patients with Diabetes
Heung Yong Jin, Tae Sun Park
The Journal of Korean Diabetes.2023; 24(2): 71. CrossRef
Understanding the role of hyperglycemia and the molecular mechanism associated with diabetic neuropathy and possible therapeutic strategies
Mandeep Kaur, Sakshi Misra, Priyanka Swarnkar, Preeti Patel, Balak Das Kurmi, Ghanshyam Das Gupta, Amrita Singh
Biochemical Pharmacology.2023; 215: 115723. CrossRef
A three-month physical training program improves cardiovascular autonomic function in patients with metabolic syndrome with and without diabetes – a pilot study
Anna Vágvölgyi, Judit Erzsébet Ábrahám, Éva Máthéné Köteles, Andrea Korom, Mária Barnai, Mónika Szűcs, Andrea Orosz, Péter Kempler, Adrienn Menyhárt, Attila Nemes, Tamás Várkonyi, István Baczkó, István Kósa, Csaba Lengyel
Frontiers in Endocrinology.2023;[Epub] CrossRef
Cardiovascular autonomic neuropathy in patients with type 2 diabetes with and without sensorimotor polyneuropathy
Emil Peters, Mustapha Itani, Alexander G. Kristensen, Astrid Juhl Terkelsen, Thomas Krøigård, Hatice Tankisi, Troels S. Jensen, Nanna B. Finnerup, Sandra Sif Gylfadottir
Journal of the Peripheral Nervous System.2023; 28(3): 450. CrossRef
Cardiac Autonomic Neuropathy in Prediabetes: A Case-Control Study
Pavan Gujjar, Y. S. Ravikumar, Lakshmi Nagendra, Hiya Boro, Saptarshi Bhattacharya
Indian Journal of Endocrinology and Metabolism.2023; 27(4): 325. CrossRef
Diabetic Neuropathies
Melissa A. Elafros, Brian C. Callaghan
Continuum.2023; 29(5): 1401. CrossRef
Determinants of the heart rate variability in type 1 diabetes mellitus
Máté Hajdu, Konstandia Garmpis, Vivien Vértes, Noémi Vorobcsuk-Varga, Gergő Attila Molnár, László Hejjel, István Wittmann, Réka Faludi
Frontiers in Endocrinology.2023;[Epub] CrossRef
The Effect of Exercise on Cardiovascular Autonomic Nervous Function in Patients with Diabetes: A Systematic Review
Hidetaka Hamasaki
Healthcare.2023; 11(19): 2668. CrossRef
Influence of Fibrinogen/Albumin Ratio and Fibrinogen/Pre-Albumin Ratio on Cardiac Autonomic Neuropathy in Type 2 Diabetes
Subei Zhao, Zheng Yang, Meng Yu, Linyu Xiang, Yuhuan Lv, Chunyan Tian, Rong Li
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3249. CrossRef
In Ischemic Heart Disease, Reduced Sensitivity to Pressure at the Sternum Accompanies Lower Mortality after Five Years: Evidence from a Randomized Controlled Trial
Søren Ballegaard, Jens Faber, Christian Selmer, Finn Gyntelberg, Svend Kreiner, Benny Karpatschof, Tobias Wirenfeldt Klausen, Åke Hjalmarson, Albert Gjedde
Journal of Clinical Medicine.2023; 12(24): 7585. CrossRef
Assessment of the relationship of systemic vascular dysfunction and cardiac autonomic neuropathy (CAN) with diabetic retinopathy
KJ Hari Prakash, Sucheta Parija, Manisha Kar
Journal of Family Medicine and Primary Care.2023; 12(12): 3236. CrossRef
Autonomic Neuropathy in Ambulatory Type 2 Diabetes Mellitus Patients: A Single-arm Prospective, Observational Study
Kaustav Saha, Shatavisa Mukherjee, Animesh Maiti, Santanu Kumar Tripathi
Journal of the Practice of Cardiovascular Sciences.2023; 9(3): 178. CrossRef
Insomnia and type 2 diabetes: how to help the patient. Modern view of a neurologist
E. S. Akarachkova, O. V. Kotova, V. L. Klimov, D. I. Lebedeva
FOCUS. Endocrinology.2023; 4(4): 12. CrossRef
Carvedilol improves heart rate variability indices, biomarkers but not cardiac nerve density in streptozotocin-induced T2DM model of diabetic cardiac autonomic neuropathy
Olawale Mathias Akinlade, Bamidele Owoyele, Olufemi Ayodele Soladoye
Journal of Basic and Clinical Physiology and Pharmacology.2022; 33(2): 213. CrossRef
Cardiovascular autonomic responses during head-up tilt test in newly diagnosed type 2 diabetes
Esteban Jorge-Galarza, Margarita Torres-Tamayo, María del Rocío Martínez-Alvarado, Berenice Peña-Aparicio, Carmen González-Salazar, Juan Reyes-Barrera, Manuel Sierra-Beltrán, Erika Fajardo-Flores, Andrey Kostin, J. Antonio González-Hermosillo
Irish Journal of Medical Science (1971 -).2022; 191(5): 2077. CrossRef
Cardiovascular autonomic neuropathy and incident diabetic kidney disease in patients with type 2 diabetes
Ji Eun Jun, Min Sun Choi, Jae Hyeon Kim
Diabetes Research and Clinical Practice.2022; 184: 109181. CrossRef
Kardiovaskuläre Risiken in der 4.–6. Lebensdekade mit Diabetes mellitus Typ 1
Young Hee Lee-Barkey, Bernd Stratmann, Diethelm Tschöpe
Der Diabetologe.2022; 18(2): 131. CrossRef
Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants
Francesca Romana Prandi, Isabella Evangelista, Domenico Sergi, Alberto Palazzuoli, Francesco Romeo
Heart Failure Reviews.2022; 28(3): 597. CrossRef
Comparison of Risk Assessment Strategies for Patients with Diabetes Mellitus and Stable Chest Pain: A Coronary Computed Tomography Angiography Study
Jia Zhao, Shuo Wang, Pengyu Zhao, Yong Huo, Chunjie Li, Jia Zhou, Pawel Kleczynski
Journal of Diabetes Research.2022; 2022: 1. CrossRef
BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy
Gidon J Bönhof, Gundega Sipola, Alexander Strom, Christian Herder, Klaus Strassburger, Birgit Knebel, Claudia Reule, Jan-Christoph Wollmann, Andrea Icks, Hadi Al-Hasani, Michael Roden, Oliver Kuss, Dan Ziegler
BMJ Open.2022; 12(2): e057142. CrossRef
Pragmatic Clinic-Based Investigation of Glycemic Variability in Patients With Type 1 Diabetes in Routine Clinical Practice and Its Association With Cardiovascular Autonomic Neuropathy: A Pilot Study
Lucianne R.M. Tannus, Marilia B. Gomes
Endocrine Practice.2022; 28(5): 465. CrossRef
Longitudinal effects of one‐leg standing time on neuropathy outcomes in association with glycemic control in non‐elderly patients with type 2 diabetes
Kazuhiro Sugimoto, Takashi Sozu, Takehiko Hoshino, Yuko Watanabe, Akira Tamura, Toshiro Yamazaki, Setsu Ohta, Susumu Suzuki, Takuro Shimbo
Journal of Diabetes Investigation.2022; 13(6): 1039. CrossRef
Thermal quantitative sensory testing as a screening tool for cardiac autonomic neuropathy in patients with diabetes mellitus
Veronika Potockova, Sarka Mala, Lucie Hoskovcova, Vaclav Capek, Tomas Nedelka, Lucie Riedlbauchova, Daniel Baumgartner, Livie Mensova, Radim Mazanec
Brain and Behavior.2022;[Epub] CrossRef
Cardiovascular Autonomic Reflex Tests and 7 Heart Rate Variability Indices for Early Diagnosis of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes Individuals
Yeelen Ballesteros Atala, Mozânia Reis De Matos, Denise Engelbrecht Zantut-Wittmann, Alejandro Rosell Castillo, Daniele P Santos-Bezerra, Maria Lucia Correa-Giannella, Maria Cândida Ribeiro Parisi
Current Diabetes Reviews.2022;[Epub] CrossRef
Design, synthesis, in vitro and in silico studies of naproxen derivatives as dual lipoxygenase and α-glucosidase inhibitors
Asma Sardar, Obaid-ur-Rahman Abid, Saima Daud, M. Fakhar-e-Alam, Muhammad Hussnain Siddique, Muhammad Ashraf, Wardah Shahid, Syeda Abida Ejaz, M. Atif, Shafiq Ahmad, Sulman Shafeeq, Muhammad Afzal
Journal of Saudi Chemical Society.2022; 26(3): 101468. CrossRef
Clinical manifestations and evaluation of cardiac autonomic neuropathy in diabetes mellitus and metabolic syndrome
L. S. Moshkhoeva, A. N. Barinov
Neurology, Neuropsychiatry, Psychosomatics.2022; 14(2): 71. CrossRef
The relationship between vitamin B12 levels and electrocardiographic ventricular repolarization markers
Emre Yılmaz, Devrim Kurt, Aslı Vural, Ertan Aydın, Sencer Çamcı, Ercan Aydın
Nutrición Hospitalaria.2022;[Epub] CrossRef
The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double‐blinded, placebo‐controlled trial
Suvanjaa Sivalingam, Emilie Hein Zobel, Christian S. Hansen, Rasmus S. Ripa, Bernt J. von Scholten, Viktor Rotbain Curovic, Andreas Kjaer, Jacob K. Jensen, Tine W. Hansen, Peter Rossing
Diabetes, Obesity and Metabolism.2022; 24(8): 1638. CrossRef
Heart Rate Variability and Chronic Kidney Disease in Patients with Type 2 Diabetes
Wei Shi, Jing Zhang, Dan Chen, Xiaolei Chen, Wei Duan, Hongmei Zhang, Fahd Abd Algalil
Applied Bionics and Biomechanics.2022; 2022: 1. CrossRef
Spectrum of Cardiac Autonomic Neuropathy in Patients with Type 2 Diabetes Mellitus
Prativa Priyadarshani Sethi, Basavraj Jatteppanavar, Ravi Kant, Monika Pathania, Mukesh Chand Bairwa
Journal of Cardio-diabetes and Metabolic Disorders.2022; 2(1): 23. CrossRef
Cardiac Autonomic Dysfunction Is Associated With Risk of Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus
Haixia Zeng, Jianmo Liu, Zheng Chen, Peng Yu, Jianping Liu
Frontiers in Endocrinology.2022;[Epub] CrossRef
Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
Gidon J. Bönhof, Christian Herder, Dan Ziegler
Current Diabetes Reviews.2022;[Epub] CrossRef
Triglyceride glucose index is related with cardiac autonomic dysfunction in patients with metabolic syndrome
Akif Serhat Balcıoğlu, Ekrem Aksu, Ahmet Çağrı Aykan
Kardiologiia.2022; 62(6): 45. CrossRef
Pathogenesis of Distal Symmetrical Polyneuropathy in Diabetes
Sasha Smith, Pasha Normahani, Tristan Lane, David Hohenschurz-Schmidt, Nick Oliver, Alun Huw Davies
Life.2022; 12(7): 1074. CrossRef
Correlation between impaired hemodynamic response and cardiopulmonary fitness in middle-aged type 2 diabetes mellitus patients: a case–control study
Jinjin Xie, Lianhua Yin, Jia Huang, Ying Xu, Yannan Chen, Jiawei Qin, Zhizhen Liu, Jing Tao
European Journal of Applied Physiology.2022; 122(10): 2295. CrossRef
Higher frequency of cardiovascular autonomic neuropathy in youth with type 2 compared to type 1 diabetes: Role of cardiometabolic risk factors
Benjamin J. Varley, Megan L. Gow, Yoon Hi Cho, Paul Benitez‐Aguirre, Janine Cusumano, Alison Pryke, Albert Chan, Vallimayil Velayutham, Kim C. Donaghue, Maria E. Craig
Pediatric Diabetes.2022; 23(7): 1073. CrossRef
The role of protein kinase C in diabetic microvascular complications
Deng Pan, Lin Xu, Ming Guo
Frontiers in Endocrinology.2022;[Epub] CrossRef
Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Dimitrios Patoulias, Alexandra Katsimardou, Nikolaos Fragakis, Christodoulos Papadopoulos, Michael Doumas
Acta Diabetologica.2022; 60(1): 1. CrossRef
Association between blood glucose levels and autonomic symptoms in Peru
Gabriel Angeles-Zurita, Margorie Narro-Fuentes, Antonio Bernabe-Ortiz
Primary Care Diabetes.2022; 16(5): 709. CrossRef
Clinical scoring systems for the risk of cardiovascular autonomic neuropathy in type 1 and type 2 diabetes: A simple tool
Marika Menduni, Cinzia D'Amato, Martina Leoni, Valentina Izzo, Mariateresa Staltari, Carla Greco, Andrea Abbatepassero, Giuseppe Seminara, Ilenia D'Ippolito, Davide Lauro, Vincenza Spallone
Journal of the Peripheral Nervous System.2022; 27(4): 259. CrossRef
Vagus nerve stimulation as a novel treatment for systemic lupus erythematous: study protocol for a randomised, parallel-group, sham-controlled investigator-initiated clinical trial, the SLE-VNS study
Amanda Hempel Zinglersen, Ida Lynghøj Drange, Katrine Aagaard Myhr, Andreas Fuchs, Mogens Pfeiffer-Jensen, Christina Brock, Søren Jacobsen
BMJ Open.2022; 12(9): e064552. CrossRef
To the interpretation of frequency components of the heart rate variability
N. V. Kuzmenko, V. A. Tsyrlin, M. G. Pliss
Translational Medicine.2022; 9(3): 35. CrossRef
Protein pyrrole adducts are associated with elevated glucose indices and clinical features of diabetic diffuse neuropathies
Xiao Chen, Zhuyi Jiang, Lianjing Zhang, Wei Liu, Xiaohu Ren, Luling Nie, Desheng Wu, Zhiwei Guo, Weimin Liu, Xifei Yang, Yan Wu, Zhen Liang, Peter Spencer, Jianjun Liu
Journal of Diabetes.2022; 14(10): 646. CrossRef
Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
Scott Williams, Siddig Abdel Raheim, Muhammad Ilyas Khan, Umme Rubab, Prathap Kanagala, Sizheng Steven Zhao, Anne Marshall, Emily Brown, Uazman Alam
Clinical Therapeutics.2022; 44(10): 1394. CrossRef
Pathophysiological and clinical aspects of the circadian rhythm of arterial stiffness in diabetes mellitus: A minireview
Victoria A. Serhiyenko, Ludmila M. Serhiyenko, Volodymyr B. Sehin, Alexandr A. Serhiyenko
Endocrine Regulations.2022; 56(4): 284. CrossRef
Heart rate-corrected QT interval prolongation is associated with decreased heart rate variability in patients with type 2 diabetes
Seon-Ah Cha
Medicine.2022; 101(45): e31511. CrossRef
Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis
Carla Greco, Daniele Santi, Giulia Brigante, Chiara Pacchioni, Manuela Simoni
Diabetes & Metabolism Journal.2022; 46(6): 901. CrossRef
Diabetes-Induced Cardiac Autonomic Neuropathy: Impact on Heart Function and Prognosis
Susumu Z. Sudo, Tadeu L. Montagnoli, Bruna de S. Rocha, Aimeé D. Santos, Mauro P. L. de Sá, Gisele Zapata-Sudo
Biomedicines.2022; 10(12): 3258. CrossRef
The Relationship Between Orthostatic Hypotension and Vitamin D Deficiency in Patients with Uncontrolled Type 2 Diabetes Mellitus
Ece YİĞİT, Ridvan SİVRİTEPE, Dilay KARABULUT, Umut KARABULUT
Online Türk Sağlık Bilimleri Dergisi.2022; 7(2): 313. CrossRef
A study of heart rate variability in diabetic mellitus patients
Srinivasa Jayachandra, Satyanath Reddy Kodidala
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2022; 18(3): 153. CrossRef
Oxidative Damage and Anti-Inflammatory Activity of Myricetin from Berries in Streptozotocin-Induced Diabetic Rats
Shuling Wang, Jing Zhang
International Journal of Pharmacology.2022; 18(4): 753. CrossRef
Validation and Comparison of PROMISE and CONFIRM Model to Predict High-Risk Coronary Artery Disease in Symptomatic and Diabetes Mellitus Patients
Hantao Jiang, Jinping Feng, Chao Feng, Pei Ren, Kai Ren, Ying Jin, Jia Zhou
Reviews in Cardiovascular Medicine.2022;[Epub] CrossRef
The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review
Aikaterini Eleftheriadou, Scott Williams, Sarah Nevitt, Emily Brown, Rebecca Roylance, John P. H. Wilding, Daniel J. Cuthbertson, Uazman Alam
Diabetologia.2021; 64(2): 288. CrossRef
Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: A cross‐sectional study
Ernesto Maddaloni, Chiara Moretti, Rossella Del Toro, Sara Sterpetti, Maria Vittoria Ievolella, Gabriele Arnesano, Rocky Strollo, Silvia Irina Briganti, Luca D'Onofrio, Paolo Pozzilli, Raffaella Buzzetti
Diabetic Medicine.2021;[Epub] CrossRef
Effects of lunar cycle on fasting plasma glucose, heart rate and blood pressure in type 2 diabetic patients
Sutanu Dutta Chowdhury, Subhasish Pramanik, Koena Bhattacharjee, Lakshmi Kanta Mondal
Chronobiology International.2021; 38(2): 270. CrossRef
Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial
Yaling Tang, Hetal Shah, Carlos Roberto Bueno Junior, Xiuqin Sun, Joanna Mitri, Maria Sambataro, Luisa Sambado, Hertzel C. Gerstein, Vivian Fonseca, Alessandro Doria, Rodica Pop-Busui
Diabetes Care.2021; 44(1): 164. CrossRef
Decreased glomerular filtration rate and increased albuminuria for identification of cardiovascular autonomic neuropathy in subjects with and without diabetes
Ying-Chuen Lai, Hung-Yuan Li, Yi-Dier Jiang, Tien-Jyun Chang, Lee-Ming Chuang
Autonomic Neuroscience.2021; 230: 102757. CrossRef
Exposures influencing the developing central autonomic nervous system
Sarah D. Schlatterer, Adre J. du Plessis
Birth Defects Research.2021; 113(11): 845. CrossRef
Vitamin B12 Supplementation in Diabetic Neuropathy: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Trial
Triantafyllos Didangelos, Eleni Karlafti, Evangelia Kotzakioulafi, Eleni Margariti, Parthena Giannoulaki, Georgios Batanis, Solomon Tesfaye, Kοnstantinos Kantartzis
Nutrients.2021; 13(2): 395. CrossRef
The Association Between Continuous Glucose Monitoring-Derived Metrics and Cardiovascular Autonomic Neuropathy in Outpatients with Type 2 Diabetes
Min Young Kim, Gyuri Kim, Ji Yun Park, Min Sun Choi, Ji Eun Jun, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
Diabetes Technology & Therapeutics.2021; 23(6): 434. CrossRef
Insulin resistance is independently associated with cardiovascular autonomic neuropathy in type 2 diabetes
Yingshan Liu, Yu Peng, Jing Jin, Yanshan Chen, Chuna Chen, Zhenguo Chen, Haishan Huang, Lingling Xu
Journal of Diabetes Investigation.2021; 12(9): 1651. CrossRef
SGLT2 inhibitors and the autonomic nervous system in diabetes: A promising challenge to better understand multiple target improvement
Vincenza Spallone, Paul Valensi
Diabetes & Metabolism.2021; 47(4): 101224. CrossRef
Reduction of Pressure Pain Sensitivity as Novel Non-pharmacological Therapeutic Approach to Type 2 Diabetes: A Randomized Trial
Jens Faber, Ebbe Eldrup, Christian Selmer, Caroline Pichat, Sofie Korsgaard Hecquet, Torquil Watt, Svend Kreiner, Benny Karpatschof, Finn Gyntelberg, Søren Ballegaard, Albert Gjedde
Frontiers in Neuroscience.2021;[Epub] CrossRef
Relationship between cardiac autonomic neuropathy and cardio-metabolic risk profile in adults with type 1 diabetes
M. Serdarova, R. Dimova, N. Chakarova, G. Grozeva, A. Todorova, T. Tankova
Diabetes Research and Clinical Practice.2021; 174: 108721. CrossRef
Differences and Similarities in Neuropathy in Type 1 and 2 Diabetes: A Systematic Review
Mar Sempere-Bigorra, Iván Julián-Rochina, Omar Cauli
Journal of Personalized Medicine.2021; 11(3): 230. CrossRef
Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives
Ditte S. Kornum, Astrid J. Terkelsen, Davide Bertoli, Mette W. Klinge, Katrine L. Høyer, Huda H. A. Kufaishi, Per Borghammer, Asbjørn M. Drewes, Christina Brock, Klaus Krogh
Journal of Clinical Medicine.2021; 10(7): 1392. CrossRef
Diabetic heart disease: A clinical update
Jake Rajbhandari, Cornelius James Fernandez, Mayuri Agarwal, Beverly Xin Yi Yeap, Joseph M Pappachan
World Journal of Diabetes.2021; 12(4): 383. CrossRef
Novel and Emerging Electrophysiological Biomarkers of Diabetic Neuropathy and Painful Diabetic Neuropathy
Anne Marshall, Uazman Alam, Andreas Themistocleous, Nigel Calcutt, Andrew Marshall
Clinical Therapeutics.2021; 43(9): 1441. CrossRef
Cardiac Autonomic Neuropathy Is Not Reversed by Euglycemia Following Islet Transplantation
Tejas Deshmukh, Peter Emerson, Patricia Anderson, Eddy Kizana, Philip J. O’Connell, D. Jane Holmes-Walker, James J.H. Chong
Transplantation.2021; 105(5): 1125. CrossRef
Attenuation of Muscle Mass and Density Is Associated With Poor Outcomes Among Patients Undergoing Major Gynecologic Surgery: A Retrospective Cohort Study
Lu Che, Yan Zhang, Jiawen Yu, Li Xu, Yuguang Huang
Anesthesia & Analgesia.2021; 132(6): 1692. CrossRef
Association of Urinary N-Acetyl-β-D-Glucosaminidase with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Mellitus without Nephropathy
Min Sun Choi, Ji Eun Jun, Sung Woon Park, Jee Hee Yoo, Jiyeon Ahn, Gyuri Kim, Sang-Man Jin, Kyu Yeon Hur, Moon-Kyu Lee, Jae Hyeon Kim
Diabetes & Metabolism Journal.2021; 45(3): 349. CrossRef
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Gordon Sloan, Dinesh Selvarajah, Solomon Tesfaye
Nature Reviews Endocrinology.2021; 17(7): 400. CrossRef
Heart Rate Variability as a Potential Non-invasive Marker of Blood Glucose Level
L. R. Jarman, J. L. Elliott, T. Lees, R. Clifton-Bligh, A. M. Simpson, N. Nassif, S. Lal
Human Physiology.2021; 47(2): 209. CrossRef
Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications
Alice Duque, Mauro Felippe Felix Mediano, Andrea De Lorenzo, Luiz Fernando Rodrigues Jr
World Journal of Diabetes.2021; 12(6): 855. CrossRef
Gaussian process-based kernel as a diagnostic model for prediction of type 2 diabetes mellitus risk using non-linear heart rate variability features
R. Shashikant, Uttam Chaskar, Leena Phadke, Chetankumar Patil
Biomedical Engineering Letters.2021; 11(3): 273. CrossRef
Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
Vincenzo Maria Monda, Francesca Porcellati, Felice Strollo, Alessandro Fucili, Marcello Monesi, Ersilia Satta, Sandro Gentile
Advances in Therapy.2021; 38(8): 4195. CrossRef
Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus
Amanda Hempel Zinglersen, Katrine Kjær Iversen, Henrik Christian Bidstrup Leffers, Esben Laugesen, Jesper Fleischer, Søren Jacobsen
Lupus Science & Medicine.2021; 8(1): e000507. CrossRef
Impaired vagal adaptation to an exercise task in women with gestational diabetes mellitus versus women with uncomplicated pregnancies
Marieta P. Theodorakopoulou, Areti Triantafyllou, Andreas Zafeiridis, Afroditi Κ. Boutou, Iris Grigoriadou, Evangelia Kintiraki, Stella Douma, Dimitrios G. Goulis, Konstantina Dipla
Hormones.2021; 20(4): 753. CrossRef
Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis
Lucas Silva Sousa, Felipe de Araújo Nascimento, Juliano Rocha, Michelle Rocha-Parise
International Journal of Cardiovascular Sciences.2021;[Epub] CrossRef
Management of diabetic neuropathy
Simona Cernea, Itamar Raz
Metabolism.2021; 123: 154867. CrossRef
Large fibre, small fibre and autonomic neuropathy in adolescents with type 1 diabetes: A systematic review
Vinni Faber Rasmussen, Troels Staehelin Jensen, Hatice Tankisi, Páll Karlsson, Esben Thyssen Vestergaard, Kurt Kristensen, Jens Randel Nyengaard, Astrid Juhl Terkelsen
Journal of Diabetes and its Complications.2021; 35(11): 108027. CrossRef
Cardiovascular Risk Management in Type 1 Diabetes
I. H. Teoh, P. Elisaus, J. D. Schofield
Current Diabetes Reports.2021;[Epub] CrossRef
Disturbances in the intraventricular conduction system in teenagers with type 1 diabetes. A pilot study
Agnieszka Zubkiewicz-Kucharska, Anna Noczyńska, Małgorzata Sobieszczańska, Małgorzata Poręba, Joanna Chrzanowska, Rafał Poręba, Monika Seifert, Anna Janocha, Krystyna Laszki-Szcząchor
Journal of Diabetes and its Complications.2021; 35(11): 108043. CrossRef
Peripheral and Autonomic Neuropathy Status of Young Patients With Type 1 Diabetes Mellitus at the Time of Transition From Pediatric Care to Adult-Oriented Diabetes Care
Anna Vágvölgyi, Ágnes Maróti, Mónika Szűcs, Csongor Póczik, Dóra Urbán-Pap, István Baczkó, Attila Nemes, Éva Csajbók, Krisztián Sepp, Péter Kempler, Andrea Orosz, Tamás Várkonyi, Csaba Lengyel
Frontiers in Endocrinology.2021;[Epub] CrossRef
Pancreatic exocrine insufficiency in diabetes is associated with autonomic dysfunction
Dag André Sangnes, Elisabeth Sandvik Bergmann, Rose Marie Moss, Trond Engjom, Eirik Søfteland
Scandinavian Journal of Gastroenterology.2021; 56(10): 1222. CrossRef
Dependence of Heart Rate Variability Indices on the Mean Heart Rate in Women with Well-Controlled Type 2 Diabetes
Adriana Robles-Cabrera, José M. Torres-Arellano, Ruben Fossion, Claudia Lerma
Journal of Clinical Medicine.2021; 10(19): 4386. CrossRef
Normative data on cardiovascular autonomic function in Greenlandic Inuit
Marie Mathilde Bjerg Christensen, Christian Stevns Hansen, Jesper Fleischer, Dorte Vistisen, Stine Byberg, Trine Larsen, Jens Christian Laursen, Marit Eika Jørgensen
BMJ Open Diabetes Research & Care.2021; 9(1): e002121. CrossRef
What Is in the Field for Genetics and Epigenetics of Diabetic Neuropathy: The Role of MicroRNAs
V. Spallone, C. Ciccacci, A. Latini, P. Borgiani, Karim Gariani
Journal of Diabetes Research.2021; 2021: 1. CrossRef
Evaluation and treatment of peripheral nervous system dysfunction in patients with prediabetes
O. E. Zinovyeva, T. M. Ostroumova, M. V. Koniashova, N. A. Gorbachev
Neurology, Neuropsychiatry, Psychosomatics.2021; 13(5): 116. CrossRef
Manifestazioni cliniche della neuropatia autonomica diabetica: valutazione dei sintomi
Carla Greco, Chiara Pacchioni, Manuela Simoni
L'Endocrinologo.2021; 22(6): 514. CrossRef
Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review
Xiaochun Zhang, Xue Yang, Bao Sun, Chunsheng Zhu
Communications Biology.2021;[Epub] CrossRef
The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls
Jens Christian Laursen, Ida Kirstine B. Rasmussen, Emilie H. Zobel, Philip Hasbak, Bernt Johan von Scholten, Lene Holmvang, Rasmus S. Ripa, Christian S. Hansen, Marie Frimodt-Moeller, Andreas Kjaer, Peter Rossing, Tine W. Hansen
Frontiers in Endocrinology.2021;[Epub] CrossRef
Dependence of heart rate variability on indicators of type 1 diabetes mellitus control.
N. O. Pertseva, O. V. Gurzhiy, K. I. Moshenets
Medicni perspektivi (Medical perspectives).2020; 25(1): 88. CrossRef
Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active‐controlled, randomized, double‐blind study with open‐label extension (the EVERGREEN study)
Gyuri Kim, Soo Lim, Hyuk‐Sang Kwon, Ie B. Park, Kyu J. Ahn, Cheol‐Young Park, Su K. Kwon, Hye S. Kim, Seok W. Park, Sin G. Kim, Min K. Moon, Eun S. Kim, Choon H. Chung, Kang S. Park, Mikyung Kim, Dong J. Chung, Chang B. Lee, Tae H. Kim, Moon‐Kyu Lee
Diabetes, Obesity and Metabolism.2020; 22(9): 1527. CrossRef
Diabetes mellitus and comorbidities: A bad romance
Niki Katsiki, Dimitrios Tousoulis
Hellenic Journal of Cardiology.2020; 61(1): 23. CrossRef
Features of the glucose influence on the heart activity and the changes in the potentials of the stomach and the intestines at the heart insufficiency conditions
V. V. Soltanov, L. M. Komarovskaya
Doklady of the National Academy of Sciences of Belarus.2020; 63(6): 736. CrossRef
Living Day to Day
Gerald Kayingo, Virginia McCoy Hass
Physician Assistant Clinics.2020; 5(2): 213. CrossRef
Source specific PM2.5 associated with heart rate variability in the elderly with coronary heart disease: A community-based panel study
Xi Chen, Bing Qiu, Qinpei Zou, Tian Qiu, Runkui Li, Ashley Truong, Yanmin Qi, Tao Liu, Limin Han, Tiebing Liu, Junrui Chang, Qi Sun, Ying Zhu, Dongqun Xu
Chemosphere.2020; 260: 127399. CrossRef
The Association of Autonomic Nervous System Function With Ischemic Stroke, and Treatment Strategies
Mengxi Zhao, Ling Guan, Yilong Wang
Frontiers in Neurology.2020;[Epub] CrossRef
Cardiac diabetic autonomic neuropathy
L. T. Akhmedzhanova, T. A. Belyakova, Yu. A. Podkovko, Yu. M. Shor
Medical Council.2020; (21): 94. CrossRef
Diabetes, and its treatment, as an effector of autonomic nervous system circuits and its functions
Liliana Espinoza, Carie R Boychuk
Current Opinion in Pharmacology.2020; 54: 18. CrossRef
Morning blood pressure surge is associated with autonomic neuropathy and peripheral vascular disease in patients with diabetes
Federica Di Gennaro, Cinzia D’Amato, Roberto Morganti, Carla Greco, Susanna Longo, Diana Corradini, Davide Lauro, Vincenza Spallone
Journal of Human Hypertension.2020; 34(7): 495. CrossRef
The Compound Expression of HSP90 and INOS in the Testis of Diabetic Rats as Cellular and Pathologic Adverse Effects of Diabetes
Ali Alsarhan, Kawther Faisal Amawi, Inas Saleh Al-Mazari, Hashem Abu Hurirah, Ahed J. Alkhatib
Analytical Cellular Pathology.2020; 2020: 1. CrossRef
Heart rate variability features from nonlinear cardiac dynamics in identification of diabetes using artificial neural network and support vector machine
Yogender Aggarwal, Joyani Das, Papiya Mitra Mazumder, Rohit Kumar, Rakesh Kumar Sinha
Biocybernetics and Biomedical Engineering.2020; 40(3): 1002. CrossRef
Distal Symmetric and Cardiovascular Autonomic Neuropathies in Brazilian Individuals with Type 2 Diabetes Followed in a Primary Health Care Unit: A Cross-Sectional Study
Mozania Reis de Matos, Daniele Pereira Santos-Bezerra, Cristiane das Graças Dias Cavalcante, Jacira Xavier de Carvalho, Juliana Leite, Jose Antonio Januario Neves, Sharon Nina Admoni, Marisa Passarelli, Maria Candida Parisi, Maria Lucia Correa-Giannella
International Journal of Environmental Research and Public Health.2020; 17(9): 3232. CrossRef
Awareness of hypoglycemia and spectral analysis of heart rate variability in type 1 diabetes
Ticiana Paes, L. Clemente Rolim, Celso Sallum Filho, João Roberto de Sa, Sérgio A. Dib
Journal of Diabetes and its Complications.2020; 34(8): 107617. CrossRef
Is there cardiac autonomic neuropathy in prediabetes?
Lindsay A. Zilliox, James W. Russell
Autonomic Neuroscience.2020; 229: 102722. CrossRef
Chronic Microvascular Complications in Prediabetic States—An Overview
Angelika Baranowska-Jurkun, Wojciech Matuszewski, Elżbieta Bandurska-Stankiewicz
Journal of Clinical Medicine.2020; 9(10): 3289. CrossRef
Cardiac vagal tone as a novel screening tool to recognize asymptomatic cardiovascular autonomic neuropathy: Aspects of utility in type 1 diabetes
Anne-Marie Wegeberg, Elin D Lunde, Sam Riahi, Niels Ejskjaer, Asbjørn M Drewes, Birgitte Brock, Rodica Pop-Busui, Christina Brock
Diabetes Research and Clinical Practice.2020; 170: 108517. CrossRef
Assessment of baroreceptor reflex sensitivity in young obese Saudi males at rest and in response to physiological challenges
Abdullah N. AlShahrani, Lubna I. Al‐Asoom, Ahmed A. Alsunni, Nabil S. Elbahai, Talay Yar
Physiological Reports.2020;[Epub] CrossRef
The relationship between QT interval indices with cardiac autonomic neuropathy in diabetic patients: a case control study
Maryam Vasheghani, Farzaneh Sarvghadi, Mohammad Reza Beyranvand, Habib Emami
Diabetology & Metabolic Syndrome.2020;[Epub] CrossRef
Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options
Péter Bencsik, Kamilla Gömöri, Tamara Szabados, Péter Sántha, Zsuzsanna Helyes, Gábor Jancsó, Péter Ferdinandy, Anikó Görbe
British Journal of Pharmacology.2020; 177(23): 5336. CrossRef
Biological Activity of c-Peptide in Microvascular Complications of Type 1 Diabetes—Time for Translational Studies or Back to the Basics?
Aleksandra Ryk, Aleksandra Łosiewicz, Arkadiusz Michalak, Wojciech Fendler
International Journal of Molecular Sciences.2020; 21(24): 9723. CrossRef
Diabetes and cardiovascular disease: inter-relation of risk factors and treatment
Aman Sharma, Shweta Mittal, Rohan Aggarwal, Meenakshi K. Chauhan
Future Journal of Pharmaceutical Sciences.2020;[Epub] CrossRef
Diabetic Autonomic Neuropathy: A Clinical Update
Jugal Kishor Sharma, Anshu Rohatgi, Dinesh Sharma
Journal of the Royal College of Physicians of Edinburgh.2020; 50(3): 269. CrossRef
Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus
Niki Katsiki, Panagiotis Anagnostis, Kalliopi Kotsa, Dimitrios G. Goulis, Dimitri P. Mikhailidis
Current Pharmaceutical Design.2019; 25(18): 2051. CrossRef
Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review
Scott M. Williams, Aikaterini Eleftheriadou, Uazman Alam, Daniel J. Cuthbertson, John P. H. Wilding
Diabetes Therapy.2019; 10(6): 1995. CrossRef

First
Prev
Page of 1
Next
Last

Search